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Design and Synthesis of Core Structural Intermediates for Novel HIV-1 Protease 
Inhibitors & Synthesis, Biological Activity and Molecular Modeling of 20S 
Proteasome Inhibitors 
 
Kiran Kumar Venkata Raja Avancha 
 
ABSTRACT 
 HIV-1 protease binds to its peptide/protein substrates in extended conformations. 
Therefore protease inhibitors that are constrained to form extended conformations are 
likely to produce very active protease inhibitors. This is because they are pre-organized to 
form favorable interactions with the enzyme environment immediately surrounding the 
active site. With this hypothesis in mind, we designed a family of structurally related 
molecules, which contain dipeptide analogs constrained to adopt the extended 
conformation. Core structural intermediates that are required for the total synthesis of the 
novel class of HIV-1 protease inhibitors are outlined in Chapter One. Chapter Two 
discusses the enantioselective synthesis of 2-alkyl-3-nitropropionates (NPA’s) that is the 
part A of the cyclic urea molecule 8, and can also be used as the building block for the 
synthesis of unnatural β-amino acids. In conclusion on this project, we were able to 
successfully achieve the novel enantioselective route for the synthesis of NPA’s and also 
obtain the absolute stereochemistry of one of the NPA’s by solving the crystal structure.  
Various routes were explored for the synthesis of the substituted orthogonally protected 
geminal diamino acids (OPGDA’s) and these were discussed in Chapter Three. Chapter 
Three also discusses the synthesis of a versatile N-Boc transfer reagent and the 
 xv
applications of it in the synthesis of α-helix mimics. The outcomes of this project were 
the efficient synthesis of oxaziridine (104) and the methods that show how we cannot 
make the “substituted OPGDA’s” which can serve as the guidance for future research 
on them.  
 The proteasome is cellular machinery that is responsible for the breakdown of the 
complex proteins that are not required by a living cell. The inhibition of its activity in 
cancerous cells can promote apoptosis. Chapter Four discusses the synthesis of a new 
class of 20S proteasome inhibitors, their biological testing and lead optimization by 
molecular modeling, library synthesis and biological evaluation. In short this project 
achieves our goal for the synthesis of a novel class of 20S proteasome inhibitors that have 
a potential to act as drug molecules in the future. 
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CHAPTER ONE 
HIV PROTEASE INHIBITORS: INTRODUCTION 
1.1 Global epidemic: AIDS  
 Acquired Immunodeficiency Syndrome (AIDS) is an epidemic, which forced the 
21st century human population into the grip of constant fear. Among the top ten global 
health issues of 2005 published by the World Health Organization (WHO), HIV/AIDS 
was next only to the avian influenza. It was also ranked number two among the top 10 
neglected global health issues of the year 2005. The etiological agent that causes AIDS 
was previously determined to be a retrovirus, Human Immunodeficiency Virus (HIV). 
According to the statistics released by WHO, in the year 2005 alone, five million people 
were newly infected with HIV and more than three million died of HIV/AIDS related 
issues, among them more than half a million were children. AIDS has killed more than 25 
million people since it was first defined in the year 1982 as the manifestation of a 
deficiency in the human immune system. It is one of the most destructive epidemics in 
recorded history.1  
1.2 HIV-1 Protease: Reason for its inhibition 
 HIV is a retrovirus with ribonucleic acid (RNA) as the core genetic material. 
Hence it is also classified under RNA viruses. Since it cannot replicate by itself it has to 
find a living host cell for its survival. HIV infects the CD4+ lymphocytes, macrophages 
and dendritic cells. HIV viral replication requires deoxyribonucleic acid (DNA) synthesis 
and viral protein synthesis. The major enzyme in HIV responsible for making the DNA 
copy of the viral RNA is reverse transcriptase. This DNA copy is then incorporated into 
the host genome, which is subsequently transcribed into both genomic RNA and mRNA, 
which are translated into viral proteins. The release of the viral particles results in the 
manifestation of AIDS. In general, host mRNAs code directly for functional proteins, but 
in HIV, the RNA is translated into biochemically inert polyproteins. A virus-specific 
protease then converts these polyproteins into various structural and functional proteins 
by cleaving at specific sites. HIV-1 Protease is a virus specific protease that binds to the 
peptide substrates in extended conformations. It is responsible for the maturation of HIV 
into infectious particles. Because of the absence of this protease in the host cells, HIV 
protease inhibitor design and synthesis gained tremendous importance over the last 
decade. The life cycle of the HIV virus and the stage at which HIV protease inhibitors 
act, is depicted in Figure 1.1. 
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Figure 1.1:- Replicative cycle of HIV-1, and the site of action of HIV-1 protease 
inhibitors 
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1.3 HIV-1 Protease structure and function 
 The first structure of HIV-1 protease was reported by Navia et al. in 1989.2 After 
a decade, more than two hundred crystal structures of various genetic strains of HIV-1 
protease and complexes with various enzyme inhibitors and mutant enzymes were 
deposited in the Protein Data Bank (PDB). HIV-1 protease is a C2 symmetric homodimer, 
which consists of two monomers with 99 amino acids in each.  Both the monomers are of 
similar configuration. Each monomer contributes an aspartic acid to form the catalytic 
site.3 The preferred cleavage site of the protease enzyme is the N- terminal side of the 
proline residues, especially between phenylalanine and proline. There are also other 
general cleavage sites like Tyr/Pro, Leu/Ala, Met/Met, Phe/Tyr, Phe/Leu, and Leu/Phe, 
which were mentioned in the literature. 4, 5   
 The design and development of the HIV-1 protease inhibitors became possible 
because of the X-ray crystal structure of the HIV-1 protease enzyme (Figure 1.2). 
 
   
 
 
 
Figure 1.2:- Three-dimensional structure of aspartyl protease from HIV-14
 The two monomeric chains assemble in such a fashion to form a long tunnel, 
which is covered by two flexible protein “flaps”. The flaps open up and the enzyme 
wraps around the protein chain or the substrate (Figure 1.3). This results in holding the 
substrate tightly in the tunnel for the cleavage. There is a water molecule in the center of 
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the tunnel, which is responsible for breaking the protein chain/substrate. This is the active 
site of the HIV-1 protease. There is no crystal structure of the protein chain bound to the 
active form of HIV-1 protease because the chain would be cleaved before the crystal 
structure was solved. 
 The aspartyl residues located in the active site are generally in a tripeptide 
sequence, Asp-Thr-Gly, which is covered over by two β-hairpin structures or flaps. These 
glycine rich flaps are highly flexible and undergo conformational changes that are 
localized, so that the substrate and inhibitors can be bound and released.6 The active site 
triad is located within the loop that is stabilized by a network of hydrogen bonds formed 
with the corresponding loop of the other monomer.7  
 
(a)       (b) 
Figure 1.3:- HIV-1 Protease enzyme (a) tunnel view (b) “Flaps” in action 
 The proposed catalytic mechanism and the transition state intermediate of the 
amide hydrolysis by an aspartic protease (Figure 1.4) clearly shows that the two aspartic 
residues participate in general-acid general-base catalysis of the addition of oxygen of 
water at the carbonyl of the scissile amide.8
 4
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Figure 1.4:- Enzyme reaction mechanism of HIV protease/Aspartyl protease 
 According to Schechter and Berger,9 the standard nomenclature of any peptide 
substrate complexed with aspartic protease like HIV-1 protease, the active site of the 
enzyme is designated with “subsites” S1, S2,.......Sn and S1’, S2’,…..Sn’ located on both 
sides of the scissile bond. Where as the amino acid residues of the substrate or the 
inhibitor are termed P1, P2,.......Pn and P1’, P2’,.........Pn’ and counted from the point of 
cleavage and have the same numbering as the enzyme subsites they occupy (Figure 1.5). 
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Figure 1.5:- Standard nomenclature of peptide substrate of aspartic proteases 
S1, S2.....Sn subunits binding specificity for the HIV-1 protease inhibitors is one of the 
most important features that are needed to be taken in to consideration during the design 
of the potent inhibitors with less toxic profiles. 
1.4 HIV Protease inhibitors approved by FDA 
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Figure 1.6:- FDA approved HIV protease inhibitors10-16 and their brand names 
 There are currently six HIV protease inhibitors that are approved by the FDA. 
They all act by a similar mechanism. By binding reversibly to the active site of the HIV-1 
Protease enzyme, thus resulting in the prevention of cleavage of the viral precursor 
proteins/polypeptides.  All six HIV protease inhibitors currently available in the market 
are shown in the Figure 1.6. All of the HIV protease inhibitors that have been approved 
and the ones that are in development are peptidomimetics with non-hydrolysable 
transition-state mimetics. The cleavage site at the peptide linkage is replaced by 
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transition-state isosteres, such as hydroxyethylamine, which is found in all of the 
currently approved drugs. The side chains in the inhibitors can protrude in to the well-
defined binding pockets, or subsites, in the active region of the enzyme, and thus result in 
the tight binding interactions. 
1.5 HIV-1 Protease Inhibitors with Extended Conformations 
 Since HIV-1 protease binds to their peptide/protein substrates in extended 
conformations, protease inhibitors constrained to form extended conformations are likely 
to produce very active protease inhibitors because they are pre-organized to form 
favorable interactions with the enzyme environment immediately surrounding its active 
environment. We wish to test this hypothesis, by synthesizing a family of structurally 
related molecules, which contain dipeptide analogs constrained to adopt the extended 
conformation. We also planned to use our dipeptide-like units as a central core and attach 
peripheral groups to the N- and C- termini that are selected by structural analogy with the 
most successful currently available HIV-1 protease inhibitors. Due to the synthetic 
difficulties, the currently approved hydroxyethylamines and analogs are generally acyclic 
and therefore are not pre-organized to form the extended conformation. The constrained 
dipeptide units (DPUs) we have designed, structurally mimic natural peptides in extended 
conformation. There are only a handful of reported compounds that are pre-organized to 
adopt the extended conformation before binding and one of these is a 5 pM Ki inhibitor 
cyclic urea 7 (Figure 1.7)17, which is about 1000 times more active than the approved 
drugs discussed above. The acyclic flexible hydroxyethylamine-based drugs strongly 
bind to the HIV-1 protease due to a favorable combination of specific electrostatic and 
hydrophobic interactions between the enzyme and the inhibitors. But, these flexible 
inhibitors must lose conformational entropy when they bind, whereas, inhibitors that have 
the same specific electrostatic and hydrophobic interactions and that are pre-organized to 
adopt the favorable extended conformation can bind with much greater affinity and be 
much more potent inhibitors.18 Compound 7 is constrained to adopt an extended-like 
conformation at the active site of the enzyme and it also has a carbonyl oxygen that 
replaces the water number 301 found in the crystal structures of the protease structures 
bound with other flexible HIV-1 protease inhibitors. It is believed that water number 301 
plays a key role by helping to stabilize the extended conformation of flexible inhibitors 
by bridging a hydrogen-bonding network between the amide hydrogens at Ile 50 and Ile 
150 and the carbonyl oxygens of the flexible inhibitors.18
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Figure 1.7:- Constrained cyclic urea 7, with reported picomolar activity 
 There are five peptide backbone bonds in a dipeptide unit. Figure 1.8 illustrates 
our definition of the peptide backbone bonds of dipeptide unit and two constrained 
dipeptide units that we have designed. In Figure 1.8, structure A is a canonical dipeptide 
unit shown in context of a larger peptide. The peptide backbone bonds are shown in bold 
and these bonds are labeled DP1 – DP5. The double bond character of the DP3 bond 
ensures that either a trans or cis conformation is adopted at that bond; the trans 
conformation is strongly favored in most peptides. The dipeptide units that we have 
designed are the Friedinger lactam derivatives DPU (DiPeptide Unit) and the novel ADP 
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(Aza – DiPeptide unit) that are shown below. The unnatural six-membered lactam of 
DPU constrains the DP2 and DP3 bonds to adopt the extended conformation while 
maintaining a natural extended strand-like structure on the lower surface. The unnatural 
six-membered succinylhydrazide ring of ADP constrains the DP2 and DP3 bonds to 
adopt the extended conformation and the intramolecular hydrogen bond built into ADP 
restrains the DP4 and DP5 bonds to adopt the extended conformation while maintaining 
a natural extended strand-like structure on the lower surface.  
O
N
N
O
N
H O H H
R1
R2
DP2 DP3
O
N
N
N O
N
H O H H
R1
R2
O
H
DP2 DP3 DP4 DP5DPU ADP
O
N
R1
N
H O
N
H O
R2H
H
DP1 DP2 DP3 DP4 DP5
H
A
 
Figure 1.8:- (A) Dipeptide bonds in a dipeptide unit; Constrained DPU- DiPeptide 
Unit; ADP-Novel Aza – DiPeptide unit 
1.5.1 Design Considerations 
 We advance our design strategy further by mimicking the hydroxyethylamine 
derivative drugs that still comprise constraints on dipeptide bonds, and that are similar to 
that of the most active inhibitor like cyclic urea 7. The design we considered should also 
conserve the extended conformation by constraining the DP1 bond as well because of the 
intramolecular hydrogen bonding built into the cyclic urea 8 (Figure 1.9). This cyclic 
urea 8 is also similar to hydroxyethylamine derivative where the partially reduced amide 
bond is a result from the ketone derivative of the ADP.  
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Figure 1.9:- Novel cyclic urea 8 with all the dipeptide bonds constrained 
 The proposed target molecule 8 (Figure 1.9) is worthy of investigating because it 
is constrained to adopt the backbone conformation that HIV-1 protease binds, but also 
enables the design and testing of the partially reduced amide bond derivative as a 
completely novel HIV-1 protease inhibitor. The partially reduced amide bond derivative 
will be little more flexible than when compared to ADP and may better mimic the 
tetrahedral proteolysis intermediate like the hydroxyethylamine derivatives. Even the 
carbonyl oxygen for our urea 8, is similarly oriented as that of the carbonyl oxygen of the 
urea 7, which was important in the replacement of the water number 301 in the protease 
binding pocket. 
 We also hypothesize that our constrained cyclic urea 8 with side chains that 
optimize the binding to the S1 and S1’ HIV-1 protease binding sites and peripheral groups 
that optimize binding with the S3, S2 and S2’, S3’ HIV-1 protease binding sites 
respectively, will probably produce the most active HIV-1 protease inhibitors ever 
prepared. This can also be achieved by attaching the readily available flexible 
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hydroxyethylamine cores to the cyclic urea 8 that we planned to synthesize. This 
contributes to optimized binding of our novel HIV-1 protease inhibitors into S3, S2 and 
S2’, S3’ HIV-1 protease binding sites. 
1.5.2 Retrosynthetic analysis of cyclic urea 8 
 The Retrosynthetic analysis of the cyclic urea 8, which is depicted in figure 1.10, 
clearly indicates that it can be generated via a nitroaldol condensation (Henry reaction) of 
the 2-subsituted 3-nitropropionate (NPA) A with the aldehyde version of the 
orthogonally protected geminal diamino compound (OPGDA’s) B. The resulting nitro 
alcohol is subjected to tandem reduction of nitro group and hydrogenolytic cleavage of 
the Cbz protecting group of B, followed by ring closure should form the proposed six-
membered cyclic urea 8. 
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Figure 1.10:- Retrosynthesis of cyclic urea 8 
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 Chapter-2 discusses the synthesis of various NPA’s and Chapter-3 discusses the 
efforts towards the synthesis of the substituted OPGDA’s, which are the precursors for 
the novel HIV-1 protease inhibitor 8. 
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CHAPTER TWO 
SYNTHESIS OF 2-SUBSTITUTED 3-NITROPROPIONATES: PART-A OF 
CYCLIC UREA 8 
2.1 Introduction 
 
 During the last few years, the preparation of β-amino acids that are 1,3-
difunctionalized have attracted significant attention since they turned out to be 
components of an array of natural products, such as taxols,1 the dolastatins,2 and also act 
as antihyperglycemic/antiobesity compound building blocks.3 Recently they have also 
emerged as a class of unnatural biopolymers that offer interesting secondary structures 
with high potency. Furthermore, a number of open-chain4 or cyclized5 β-amino acids 
exhibit interesting pharmacological properties and act as precursors for stabilized helical 
peptides with enhanced resistance to enzymatic degradation.6 Often the substitution of α-
amino acids with β-isomers in biologically active peptides increases the activity and 
enzymatic stability of the resulting peptide.7 Several β-amino acids are 
pharmacologically active and are also the key structural components of biologically 
active terpenes, alkaloids, macrolides and β-lactam antibiotics.8 (Figure 2.1)  
 One more reason for the increased development of β-amino acid chemistry is the 
consequence of their ample role in numerous aspects of synthetic organic chemistry, 
namely their utility as chiral auxiliaries, chiral ligands, chiral building blocks and 
intermediates in the synthesis of β-lactams.9   
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Figure 2.1:- β-amino acid as the component of bioactive compounds 
 Although many methods for synthesizing enantiomerically pure β-amino acids 
have been reported, great effort continues to be devoted towards more efficient 
enantioselective methods. Cardillo10 and Konopelski11 used substituted 
perhydropyrimidin-4-ones, for stereoselective alkylation and subsequent hydrolysis to 
afford the desired substituted β-amino acids. Juaristi and Seebach12 showed the 
usefulness of chiral derivatives of 3-aminopropionic acids in order to synthesize α-
branched β-amino acids. The syntheses described in the literature using Oppolzer’s 
sultam,13 the Evans chiral auxiliary,14 or Seebach and Juaristi’s15 chiral pyrimidinone 
methodology appeared to give highly scalemic α-substituted β-amino acids. Myers16 has 
shown (1R,2R)-(-)-pseudoephedrine to be an efficient and inexpensive chiral auxiliary in 
the stereoselective synthesis of unnatural α-amino acids. This methodology has also been 
extended for the synthesis of chiral β-hydroxy acids17 and chiral α-substituted acids.18 
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Further, Nagula and co-workers19 have shown the successful use of the Myers chiral 
auxiliary for the stereoselective synthesis of α-substituted β-amino acids. 
 Seebach et al.20 employed methyl 3-nitropropionates for the synthesis of 2-alkyl-
3-nitropropionates in their racemic form via α, β-doubly deprotonated species (Figure 
2.2).  
 
 
 
Figure 2.2:- Seebach’s racemic synthesis of 3-NPA 
 Recently, a few reports were published on the enantioselective synthesis of α-
substituted-β-nitropropionates using nitroacrylates and dialkylzinc or trialkyl aluminium 
reagents in the presence of a chiral catalyst (Figure 2.3).21 These methods have some 
inherent limitations, as the yields and enantiocontrol are dependent on the nature of alkyl 
zinc or aluminum used as well as the ester alkyl group of the nitro acrylate. In addition, 
these methods are only providing e.e.’s in the range of 5 to 87%, the later being achieved 
by several optimizations of reaction conditions. 
 
 
 
 
 
Figure 2.3:- Rimkus et al. and Eilitz et al.’s enantiomeric route for 3-NPA synthesis 
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 Thus, there is a need for more robust and versatile enantioselective routes for the 
synthesis of biologically important α-substituted-β-nitropropionates. We report here a 
synthetic strategy for the preparation of enantiomerically pure α-alkyl-β-nitropropionates 
starting from inexpensive alkyl malonates. These compounds are very interesting from a 
synthetic point of view; because of the ease with which they form carbon-carbon bonds in 
reactions such as Henry and Michael additions.22 The β-amino acids can be obtained 
easily by catalytic hydrogenation of the β-nitro acids, which was not the primary focus of 
this project. In addition, the -NO2 functionality can be transformed into an aldehyde or a 
carboxylic acid.23 Our asymmetric route for the synthesis of potential α-alkyl-β-nitro 
propionates is novel, highly applicable, and can be useful for the generation of array of 
nitro propionates by varying the alkyl group at the α-carbon.  
 A highly enantioselective synthesis of 2-substituted 3-nitropropionates is reported 
using Pseudomonas cepacia lipase (Amano PS-30)-mediated desymmetrization of the 
prochiral 2-alkyl-1,3-propanediol as the key reaction step and subsequent transformation 
of optically pure monoacetates into methyl 2-alkyl-3-nitropropionates by functional 
group interconversions. 
2.2 Results & Discussion 
 A retrosynthetic analysis of target compounds (17a-d) prompted us to investigate 
the lipase-catalyzed desymmetrization of the prochiral 1,3-diol intermediate (Refer to 
scheme in figure 2.4). The most striking aspect of this desymmetrization reaction is the 
enantiocontrol exhibited by the biocatalyst Amano PS-30 Lipase. These prochiral 1,3-
diols were successfully converted to compounds 11a-d in high yields with incorporation 
of the stereocenter. Our methodology for using this desymmetrization reaction is a very 
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useful strategy because of the high yields and the ease with which enantiomerically pure 
compounds (11a-d) were made. This pivotal lipase reaction is a well known type, indeed, 
compound 11a was prepared previously in a near identical manner by Itoh et al. and 
recently by Duhamel and Duhamel, albeit with a different Psedomonas lipase.24 This 
route also enabled us to achieve stereocenter early in synthetic route and maintain it till 
the end. The key factor involved in these biocatlysis reactions is the correct choice of the 
lipases for the desymmetrization of the prochiral 1,3-diols. But that was successfully 
achieved because the lipase we selected Amano PS-30 lipase had the ability to undergo 
various conformational changes in order to accommodate substrates of different sizes.25 
This was proved further by the variety of the subsrates selected in this synthetic route. 
Our synthesis of methyl 2-alkyl-3-nitropropionates began with the reduction of the 
substituted diethyl malonates 9a-d into the 2-substituted-1,3-propanediols 10a-d in yields 
of 70-90% (Step 2 in Figure 2.4).26  
 The transesterification of resulting diol using lipase from Pseudomonas cepacia 
(Amano lipase PS-30) and vinyl acetate in THF afforded racemic monoacetates. 
However, when the diol was treated with neat vinyl acetate in the presence of the lipase, 
an excellent yield of pure monoacetate 11a was obtained that proved to be of high 
enantiomeric excess. This modified reaction condition was successfully applied for 
making compounds 11b-d in high enantiomeric excess and good yields. The 
enantiopurity of these monoacetates was estimated from their 1H NMR spectra acquired 
in the presence of (+)-Eu(hfc)3 (Figure 2.5). 
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Figure 2.4:- General scheme for the synthesis of 2-alkyl-3-nitropropionates 
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Figure 2.5:- 1H NMR’s for the optically pure and racemic monoacetates and 
monoalcohols with and without Eu(hfc)3 
(A) 1H NMR of optically pure 11a with Eu(hfc)3. (B) 1H NMR of racemic 11a* with 
Eu(hfc)3. (C) 1H NMR of optically pure 12b with Eu(hfc)3. (D) 1H NMR of racemic 12b* 
with Eu(hfc)3. (E) 1H NMR of optically pure 12c with Eu(hfc)3. (F) 1H NMR of racemic 
12c* with Eu(hfc)3. (G) 1H NMR of optically pure 11d with Eu(hfc)3. (H) 1H NMR of 
racemic 11d* with Eu(hfc)3. 
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Figure 2.6: - NMR Determination of Enantiomeric Purity Using Eu(hfc)3 
  
 As a control, we checked the effect of the chiral shift reagent on the racemate 
methyl protons (in 11a* and 11d* prepared by treating the diols with acetic 
anhydride/DMAP in THF)27 and the tosylate methyl (in 12b* and 12c* prepared by 
tosylation of the corresponding racemic monoacetates 11b* and 11c*).  The appropriate 
methyl peaks split into two signals of equal intensity for the racemates in the presence of 
(+)-Eu(hfc)3 (Figures 2.5 & 2.6). The product monoacetates 11a and 11d obtained by 
lipase catalyzed desymmetrization showed a single singlet for methyl protons in the 
presence of (+)-Eu(hfc)3, while tosylates 12b and 12c show a single singlet for the 
tosylate methyl proton (Figure 2.6).28 The rationale behind the synthesis and use of 12b* 
and 12c* for chiral shift NMR experiments is that the racemic monoacetates 11b* and 
11c* in the presence of (+)-Eu(hfc)3 even at 1:7 ratio failed to split into two equal 
intensity signals.   The enantiomeric excess is reported in the table in figure 2.7. 
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Figure 2.7:- Lipase PS-30 catalyzed transesterification of substrates 10a-d (Results in 
tabular form). 
Substrate Product R Time (h) Yield % e.e.a % Config. 
10a 
10b 
10c 
10d 
11a 
11b 
11c 
11d 
-CH2C6H5 
-CH2C6H11 
-CH2CH(CH3)2 
-CH2CH2CH2CH3 
6 
5 
12 
8 
98 
90 
88 
92 
>99 
>99 
>97 
>80 
b 
b 
R 
b 
 
a Determined from 1H NMR spectra in the presence of Eu(hfc)3, by integration of either 
CH3C=O (11a and 11d) or tosylate CH3 (12b and 12c). 
b No X-ray diffraction quality crystals were obtained for the salts of acids 16a, 16b, and 
16d with (1R,2R)-(-)-pseudoephedrine. 
 The enantiomerically enriched monoacetates were successfully converted to their 
respective tosyl derivatives 12a, 12c, and 12d upon treatment with tosyl chloride, triethyl 
amine, and DMAP in DCM in excellent yields. The similar reaction condition did not 
work for making compound 12b, instead replacement of triethyl amine and DMAP by 
pyridine yielded 12b in good yield. Direct replacement of tosyl group with nitro function 
by using NaNO2 or AgNO2 failed to furnish the desired products in acceptable yields. 
The formation of a silver-halide complex is an important driving force for the reaction of 
alkyl halides with silver nitrite.29 Hence, we decided to convert tosyl function into an 
iodide before treating with AgNO2. The SN2 displacement of the tosylate by treatment 
with sodium iodide in refluxing acetone afforded the corresponding iodides 13a-d in 
quantitative yields. Displacement of the iodide with NaNO2 in DMF did not afford the 
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desired product in acceptable yield. However, AgNO2 provided the desired nitro product 
in <50% yield. The reaction of silver nitrite with alkyl halides is considered as a “pull-
push” process, where the pull of silver on the halogen and the push of the NO2- are both 
crucial in the transition state. Interestingly, AgNO2 in the presence of 0.5 to 1.5 
equivalents of nitrite scavenger phloroglucinol in DMF gave the desired nitro products 
14a-d in 45-75% yields. An iodide replacement by nitrite anion usually gives 40-70% 
yields of nitro compounds as NO2- is an ambident anion, both the nitrogen atom and 
oxygen atom can act as the nucleophilic site of reaction, leading to the desired nitro 
compound (RNO2) and the undesired nitrite (RONO), respectively.30 
 The nitro acetates 14a-d were hydrolyzed by treatment with potassium carbonate 
in MeOH-water to give the corresponding nitro alcohols 15a-d in 35-54% yields. The 
compounds 14b-d were hydrolyzed to afford 15b-d in poor yields without isolation of 
any side products. This might be due to the polar nature of these intermediates as even 
after saturating with brine, these β-nitroalcohols were difficult to isolate. The resulting 
nitro alcohols were subjected to Jones oxidation to afford corresponding carboxylic acids 
16a-d in good to excellent yields. In order to measure the absolute configuration, the 
resulting carboxylic acids were mixed with equimolar amounts of (1R,2R)-(-)-
pseudoephedrine 18 in a minimum amount of DCM and the solvent was allowed to 
evaporate at room temperature to obtain crystalline samples of the corresponding salts. 
The results of the representative structure determination study of the salt 19, of 2-
isobutyl-3-nitropropionic acid (16c) with (1R,2R)-(-)-pseudoephedrine (18) confirmed the 
(R)-enantiomer is produced as shown in Figure 2.8 (The detailed crystal structure is 
reported in Appendix B). 
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Figure 2.8: - Structure of the salt 19, of 2-isobutyl-3-nitropropionic acid (16c) with 
(1R,2R)-(-)-pseudoephedrine (18) determined by X-ray structural analysis. 
  Unfortunately, we were unable to obtain high quality crystals for the salts of 
carboxylic acids 16a, 16b, and 16d. Our attempts to make diastereomeric amides of these 
acids with optically pure R(+)-α-methylbenzylamine by standard peptide coupling 
method resulted in poor quality crystals (data not shown). We hypothesize that 
compounds 16a, 16b, and 16d also have the (R) absolute stereochemistry at the chiral 
center. Our hypothesis is further supported by the analogy between the side chains in 
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terms of bulk and branching associated with substrates 10a, 10b, and 10d to that of 
isobutyl side chain in substrate 10c and all of these substrates should assume a similar 
docking orientation onto the lipase. In addition, transesterification of 2-benzyl-1,3-
propanediol catalyzed by Pseudomonas fluorecens lipase in the presence of vinyl acetate 
as acyl donor afforded (R)-3-acetoxy-2-benzyl-1-propanol with enantiomeric excess 
>94%.31 Finally, esterification of the carboxylic acids 16a-d using methyl iodide and 
potassium carbonate in DMF led to the target compounds 17a-d in good to excellent 
yields. 
2.3 Conclusion 
 In conclusion, we came up with a novel and efficient synthetic route for the 
enantioselective synthesis of NPA’s. This route can be followed for the large scale 
synthesis of the NPA’s, which can further be used for the synthesis of the β-amino acids. 
Also, we were able to obtain the absolute stereochemistry of the substituted 
nitropropionic acids due to the solving of the crystal structure of the isobutyl substituted 
nitropropionic acid. 
2.4 Experimental Data 
2.4.1 Materials and Methods: 
 Organic and inorganic reagents (ACS grade) were obtained from commercial 
sources and used without further purification, unless otherwise noted. Pseudomonas 
cepacia lipase (Amano PS-30) was obtained from Amano Pharmaceuticals. Thin layer 
chromatography (TLC) was performed on glass plates (Whatman) coated with 0.25 mm 
thickness of silica gel 60 Å with fluorescent indicator. Column chromatographic 
purification was performed using silica gel 60 Å (#70-230 mesh, Selecto Scientific). 
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Melting points (uncorrected) were determined using Mel-Temp II®, Laboratory Devices, 
MA, USA. All 1H and 13C NMR spectra were recorded on a Bruker 250 MHz or Varian 
INOVA 400 MHz spectrometer in CDCl3 or unless otherwise specified and chemical 
shifts are reported in ppm (δ) relative to internal tetramethylsilane (TMS). Infrared 
spectra of samples dissolved in DCM were acquired on a Avatar FT IR 320 spectrometer. 
Gas Chromatography Mass Spectra (LRMS) were recorded using a Shimadzu GC-17A 
GCMS-QP5000. High resolution mass spectra were obtained on an Agilent LC-MSD-
TOF. 
Preparation of the starting esters (9a-d) 
 
 
 
Starting esters 9a, 9c, and 9d were obtained from commercial sources. While ester 9b 
was prepared according to the following procedure: 60% sodium hydride/mineral oil 
(0.15 g, 3.75 mmol) was washed under argon flow with hexane (3 x 10 mL). The 
resulting free flowing powder of sodium hydride was suspended in DMF (5 mL) and was 
treated with diethyl malonate (0.5 g, 3.12 mmol) drop wise. The resulting reaction 
mixture was stirred for 1h at room temperature and treated with cyclohexylmethyl 
bromide (0.67 g, 3.8 mmol) slowly. The reaction was allowed to stir at room temperature 
for 12 h. The reaction mixture was quenched with water (50 mL), the aqueous phase was 
extracted with EtOAc (2 x 50 mL), combined organic layers were washed with brine (3 x 
25 mL), dried over anhydrous Na2SO4, and evaporated under vacuo to afford the crude 
product. The crude residue was purified by column chromatography (3:7 EtOAc/hexane) 
OEt
O
OEt
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to afford compound 9b (0.68 g, 85%); a pale yellow oil; Rf = 0.78 (3:7 EtOAc/Hexane); 
IR (cm-1) 1752; 1H NMR (CDCl3, 400 MHz) δ  0.88-0.94 (m, 2H), 1.14-1.28 (m, 10H), 
1.62-1.73 (m, 5H), 1.77-1.81 (t, J=7.2 Hz, 2H), 3.42-3.45 (t, J = 7.6 Hz, 1H), 4.16- 4.21 
(q, J = 6.8 Hz, 4H); 13C NMR (CDCl3, 62.5 MHz) 13.9, 25.9, 26.2, 32.7, 35.4, 35.9, 49.5, 
61.1, 169.7 ppm; MS (GC/MS) m/z 256, 210, 182, 109, 95, 67, 55. 
A General Procedure for the Preparation of the 2-alkylpropane-1,3-diols (10a-d) 
The diols 10a-d were prepared according to the literature method25 from their 
corresponding diesters 9a-d.  
 
 
 
Ethyl 2-benzylmalonate (10 g, 40 mmol), LiAlH4 (6.1 g, 160 mmol), THF (75 mL) gave 
compound 10a (5.94 g, 90%); a white powder; mp 65-67 0C (lit. mp 66-68); Rf = 0.18 
(1:1 EtOAc/hexane); IR (cm-1) 3350; 1H NMR (CDCl3, 400 MHz) δ 1.97-2.06 (m, 1H), 
2.57-2.59 (d, J = 7.6 Hz, 2H), 2.97 (s, 2H), 3.59-3.64 (d, J = 9.6 Hz, 2H), 3.73-3.76 (d, J 
= 10 Hz, 2H), 7.15-7.20 (m, 3H), 7.25-7.29 (m, 2H); 13C NMR (CDCl3, 100 MHz) 
δ 34.4, 44.0, 65.4, 126.3, 128.6, 129.2, 140.0 ppm; MS (GC/MS) m/z 148, 130, 117, 91. 
 
 
 
2-Cyclohexylmethylpropane-1,3-diol (10b). 
9b (6.21 g, 24.3 mmol), LiAlH4 (2.30 g, 60.6 mmol), gave compound 10b (3.09 g, 75%); 
as a white powder; mp 64-66 0C; Rf = 0.29 (1:1 EtOAc/hexane); IR (cm-1) 3292, 1275; 1H 
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NMR (CDCl3, 250 MHz) δ  0.79-0.92 (m, 2H), 1.03-1.08 (t, J = 7.0 Hz, 2H), 1.15-1.31 
(m, 4H), 1.68-1.73 (m, 5H), 1.87-1.96 (m, 1H), 2.71 (br s, 2H), 3.57-3.64 (dd, J = 10.4 
Hz, 7.5 Hz, 2H), 3.77-3.82 (dd, J = 10.5 Hz, 3.4 Hz, 2H); 13C NMR (CDCl3, 62.5 MHz) 
26.2, 26.5, 33.5, 34.8, 35.2, 38.6, 67.0 ppm; MS (GC/MS) m/z 136, 121, 107, 96, 81, 67, 
55. 
 
 
 
2-Isobutylpropane-1,3-diol (10c). 
9c (25.2 g, 112.2 mmol), LiAlH4 (10.6 g, 280.6 mmol), gave compound 10c (14 g, 94%); 
a colorless oil; Rf = 0.45 (1:1 EtOAc/hexane); IR (cm-1) 3395, 1262; 1H NMR (CDCl3, 
250 MHz) δ 0.83-0.86 (d, J = 6.5 Hz, 6H), 0.98-1.04 (t, J = 7.0 Hz, 2H), 1.54-1.59 (m, 
1H), 1.74-1.80 (m, 1H), 3.48-3.55 (dd, J = 10.7 Hz, 7.9 Hz,  2H), 3.66-3.72 (dd, J = 10.7 
Hz, 3.7 Hz 2H), 4.13 (br s, 2H); 13C NMR (CDCl3, 62.5 MHz) 22.6, 25.1, 36.7, 39.3, 
65.5 ppm; MS (GC/MS) m/z 114, 96, 84, 70, 56. 
 
 
 
2-Butylpropane-1,3-diol (10d). 
9d (5 g, 23.1 mmol), LiAlH4 (2.2 g, 57.8 mmol), yielded compound 10d (2.2 g, 72%); a 
colorless oil; Rf = 0.16 (1:4 EtOAc/hexane); IR (cm-1) 3368; 1H NMR (CDCl3, 250 MHz) 
δ 0.78-0.83 (t, J = 6.2 Hz, 3H), 1.12-1.22 (m, 6H), 1.63-1.66 (m, 1H), 3.47-3.54 (dd, J = 
10.7 Hz, 7.8 Hz, 2H), 3.64-3.70 (dd, J = 10.8 Hz, 4.0 Hz, 2H), 4.77 (br s, 2H); 13C NMR 
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(CDCl3, 62.5 MHz) 13.9, 22.8, 23.8, 27.3, 29.2, 41.8, 65.2 ppm. MS (GC/MS) m/z 114, 
96, 84, 71, 57. 
A General procedure for the preparation of optically pure 3-Acetoxy-2-alkyl-1-
propanol (11a-d) 
 
 
 
To a mixture of Lipase PS-30 (1 g) and 10a (5 g, 30.12 mmol) was added vinyl acetate 
(50 mL) and reaction was stirred at room temperature for the time shown in Figure 2.7 
and filtered through a Celite pad and washed with ethyl acetate (50 mL). The filtrate was 
concentrated in vacuo to give 11a (6.25 g, 99%) as a colorless oil: Rf = 0.49 (1:1 
EtOAc/hexane); IR (cm-1) 3447, 1729; 1H NMR (CDCl3, 400 MHz) δ 2.0 (s, 1H), 2.08 (s, 
3H), 2.12-2.17 (m, 1H), 2.59-2.72 (m, 2H), 3.48-3.53 (dd, J = 11.2 Hz, 6 Hz, 1H), 3.58-
3.62 (dd, J = 11.6 Hz, 4.8 Hz, 1H) 4.05-4.12 (dd, J = 11.2 Hz, 6.4 Hz, 1H), 4.16-4.20 (dd, 
J = 11.2 Hz, 4.8 Hz, 1H), 7.17-7-22 (m, 3H), 7.26-7.31 (m, 2H); 13C NMR (CDCl3, 100 
MHz) 21.1, 34.5, 42.6, 62.2, 64.2, 126.4, 128.6, 129.2, 139.5, 171.9 ppm; MS (GC/MS) 
m/z 190, 148, 130, 117, 104, 91.Remaining monoacetates 11b-d were prepared similarly 
with the following results. The isolated yield and the optical purity of the products are 
listed in table in figure 2.7. 
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3-Acetoxy-2-cyclohexylmethyl-1-propanol (11b) 
10b (5.71 g, 33.2 mmol), lipase (2.9 g), vinyl acetate (50 mL), yielded compound 11b 
(6.43 g, 90%); a colorless oil; Rf = 0.43 (3:7 EtOAc/hexane); No spectral data for 11b as 
it was immediately converted to 12b. 
 
 
 
3-Acetoxy-2-isobutyl-1-propanol (11c). 
10c (14.0 g, 106.0 mmol), lipase (7.0 g), vinyl acetate (50 mL), yielded compound 11c 
(13.4 g, 73%); a colorless oil; Rf = 0.49 (3:7 EtOAc/hexane); IR (cm-1) 3474, 1736; 1H 
NMR (CDCl3, 400 MHz) δ  0.90-0.91 (d, J = 6.4 Hz, 6H), 1.12-1.21 (m, 2H), 1.60-1.68 
(m, 2H), 1.88-1.91 (m, 1H), 1.98 (br s, 1H), 2.08 (s, 3H), 3.46-3.51 (dd, J = 11.2 Hz, 6.4 
Hz, 1H), 3.57-3.61 (dd, J = 11.2 Hz, 3.6 Hz, 1H), 4.03-4.08 (dd, J = 11.2 Hz, 6.8 Hz, 
1H), 4.19-4.23 (dd, J = 11.2 Hz, 4.4 Hz, 1H); No 13C NMR and mass spectral data for 
11c as it was immediately converted to 12c. 
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3-Acetoxy-2-butyl-1-propanol (11d) 
10d (1.0 g, 7.57 mmol), lipase (0.25 g), vinyl acetate (10 mL), yielded compound 11d  
(0.66 g, 50%); a colorless oil; Rf = 0.45 (2:5 EtOAc/hexane); IR (cm-1) 3466, 1736; 1H 
NMR (CDCl3, 250 MHz) δ 0.87-0.91 (t, J = 6.25 Hz, 3H), 1.15-1.30 (m, 6H), 1.73-1.83 
(m, 1H), 2.70 (s, 3H), 3.46-3.63 (dd, J = 16.2 Hz, 6.3 Hz 2H), 4.03-4.10 (dd, J = 11.2 Hz, 
6.7 Hz, 1H), 4.17-4.23 (dd, J = 11.2 Hz, 4.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz) 14.1, 
21.1, 23.0, 27.7, 29.3, 40.6, 62.8, 64.9, 171.9 ppm; MS (GC/MS) m/z 114, 96, 84, 69, 55. 
A General Procedure for the preparation of 3-Acetoxy-2-alkyl-1-(4-
methylbenzenesulfonyloxy)propane (12a-d) 
 
 
 
To a solution of 11a (6.25 g, 30 mmol), triethyl amine (4.55 g, 45 mmol), DMAP (0.37 g, 
3 mmol) in DCM (60 mL) was added tosyl chloride (6.3 g, 33 mmol) at 0 0C and stirred 
at room temperature for 12 h. Reaction mixture was quenched with saturated NH4Cl 
solution (100 mL). The organic layer was separated, and the aqueous phase was extracted 
with DCM (2 x 50 mL). The combined organic layers were washed with brine (2 x 50 
mL), dried over Na2SO4, and evaporated to give the product 12a (10.42 g, 95%) as a 
white powder. Mp 52-54 0C; Rf = 0.67 (1:1 EtOAc/hexane); IR (cm-1) 1731, 1359, 1171; 
1H NMR (CDCl3, 400 MHz) δ 1.95 (s, 3H), 2.25-2.28 (m, 1H), 2.45 (s, 3H), 2.62-2.65 
(dd,  J = 7.2 Hz, 4.4 Hz, 2H), 3.90-4.04 (m, 4H), 7.04-7.06 (d, J = 7.6 Hz, 2H), 7.17-7.25 
(m, 3H), 7.32-7.34 (d, J = 8 Hz, 2H), 7.75-7.77 (d, J = 8 Hz, 2H); 13C NMR (CDCl3, 100 
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MHz) δ 20.8, 21.8, 34.0, 39.6, 63.2, 69.1, 126.7, 128.2, 128.7, 128.9, 129.8, 132.9, 138.1, 
145.1, 170.8 ppm; MS (GC/MS) m/z 148, 130, 117, 104, 91. 
The remaining acetoxy tosylates 12b-d were prepared similarly, with the following 
results. 
 
 
 
3-Acetoxy-2-cyclohexylmethyl-1-(4-methylbenzenesulfonyloxy)propane (12b) 
11b (3.11 g, 14.5 mmol), tosyl chloride (3.0 g, 16.0 mmol), pyridine (5.7 g, 72.5 mmol), 
yielded compound 12b (2.27 g, 43%); a colorless oil; Rf = 0.61 (3:7 EtOAc/hexane); IR 
(cm-1) 1733, 1237; 1H NMR (CDCl3, 250 MHz) δ  0.77-0.81 (m, 2H), 1.06-1.19 (m, 6H), 
1.55-1.67 (m, 5H), 1.93 (s, 3H), 2.04-2.07 (m, 1H), 2.44 (s, 3H), 3.83-4.05 (m, 4H), 7.34-
7.37 (d, J = 8.1 Hz, 2H), 7.78-7.81 (d, J = 6.6 Hz, 2H); 13C NMR (CDCl3, 62.5 MHz) 
20.7, 21.6, 26.1, 26.4, 33.2, 33.2, 34.3, 34.4, 35.0, 63.6, 69.8, 127.9, 129.8, 132.8, 144.8, 
170.7 ppm. MS (GC/MS) m/z 213, 155, 136, 124, 96, 67, 55. 
 
 
 
3-Acetoxy-2-isobutyl-1-(4-methylbenzenesulfonyloxy)propane (12c) 
11c (13.4 g, 77.4 mmol), tosyl chloride (16.2 g, 85.2 mmol), pyridine (30.6 g, 387.3 
mmol), yielded compound 12c (16.7 g, 66%); a colorless oil; Rf = 0.60 (3:7 
EtOAc/hexane); IR (cm-1) 1732, 1265; 1H NMR (CDCl3, 250 MHz) δ 0.83-0.86 (d, J = 
6.5 Hz, 6H), 1.11-1.18 (m, 2H), 1.52-1.59 (m, 2H), 1.94 (s, 3H), 2.46 (s, 3H), 3.85-4.05 
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(m, 4H), 7.34-7.37 (d, J = 8.0 Hz, 2H), 7.77-7.81 (d, J = 8.2 Hz, 2H); 13C NMR (CDCl3, 
100 MHz) 20.9, 21.8, 22.7, 25.1, 35.4, 36.7, 63.7, 70.0, 128.1, 130.0, 145.0, 171.0 ppm. 
MS (GC/MS) m/z 155, 96, 84, 56. 
 
 
 
3-Acetoxy-2-butyl-1-(4-methylbenzenesulfonyloxy)propane (12d)  
11d (0.3 g, 1.72 mmol), tosyl chloride (0.66 g, 3.44 mmol), DMAP (0.02 g, 0.17 mmol), 
triethyl amine (0.5 mL, 3.44 mmol), yielded compound 12d (0.52 g, 89%); a pale yellow 
oil; Rf = 0.36 (1:5 EtOAc/hexane); IR (cm-1) 1732, 1176; 1H NMR (CDCl3, 250 MHz) δ 
0.70-0.75 (t, J = 6.9 Hz, 3H), 1.11-1.22 (m, 6H), 1.82 (s, 3H), 2.33 (s, 3H), 3.76-4.00 (m, 
4H), 7.23-7.26 (d, J = 8.0 Hz, 2H), 7.65-7.68 (d, J = 8.2 Hz, 2H); 13C NMR (CDCl3, 62.5 
MHz) 13.7, 20.5, 21.4, 22.4, 26.9, 28.5, 37.2, 63.1, 69.5, 127.8, 129.7, 132.5, 144.7, 
170.5 ppm. MS (GC/MS) m/z 155, 96, 84, 55. 
General Procedure for the preparation of 3-Acetoxy-2-alkyl-1-iodopropane (13a-d) 
 
 
 
To a solution of tosylate 12a (5 g, 13.8 mmol) in acetone (100 mL) was added sodium 
iodide (4.5 g, 30 mmol) at room temperature. Then the reaction mixture was refluxed for 
19 h. Solvent was evaporated and residue was treated with aqueous saturated NH4Cl 
solution. The resulting mixture was extracted with diethyl ether (3 x 100 mL). The 
combined organic layers were washed with brine (2 x 50 mL), dried over anhydrous 
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Na2SO4 and evaporated to afford the product 13a (4.3 g, 98%) as a yellow oil: Rf = 0.69 
(1:4 EtOAc/hexane); IR (cm-1) 1731; 1H NMR (CDCl3, 250 MHz) δ 1.88-1.95 (m, 1H), 
2.0 (s, 3H), 2.59-2.75 (dd, J = 13.0 Hz, 5.8 Hz, 2H), 3.11-3.17 (dd, J = 10.0 Hz, 5.0 Hz  
1H), 3.25-3.31 (dd, J = 10.0 Hz, 4.6 Hz, 1H), 3.92-3.95 (dd, J = 11.1 Hz, 7.2 Hz, 1H), 
4.09-4.15 (dd, J = 11.0 Hz, 4.8 Hz, 1H), 7.19-7.33 (m, 5H); 13C NMR (CDCl3, 100 MHz) 
10.3, 20.9, 37.1, 40.4, 66.4, 126.6, 128.6, 129.0, 138.3, 170.8 ppm; MS (GC/MS) m/z 
191, 131, 117, 91, 65; ESI-TOF Calcd for [M+NH4]+ is 336.04550, Found: 336.04528 
The remaining iodides 13b-d were prepared similarly, with the following results. 
 
 
 
 
3-Acetoxy-2-cyclohexylmethyl-1-iodopropane (13b) 
12b (2.27 g, 6.17 mmol), sodium iodide (2.78 g, 18.51 mmol), yielded compound 13b 
(1.88 g, 94%); a brown oil; Rf = 0.81 (3:7 EtOAc/hexane); IR (cm-1) 1737, 1268; 1H 
NMR (CDCl3, 250 MHz) δ 0.82-0.96 (m, 2H), 1.11-1.30 (m, 6H), 1.60-1.72 (m, 6H), 
2.06 (s, 3H), 3.21-3.35 (m, 2H), 3.84-3.91 (dd, J = 11.2 Hz, 7.5 Hz, 1H), 4.06-4.12 (dd, J 
= 11.2 Hz, 4.6 Hz, 1H); 13C NMR (CDCl3, 62.5 MHz) 11.8, 20.9, 26.1, 26.2, 26.4, 33.2, 
33.5, 34.3, 35.3, 39.0, 66.9, 170.8 ppm; MS (GC/MS) m/z 197, 155, 137, 109, 95, 81, 67, 
55. 
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3-Acetoxy-2-isobutyl-1-iodopropane (13c) 
12c (16.6 g, 50.76 mmol), sodium iodide (22.84 g, 152.29 mmol), yielded compound 13c 
(12.22 g, 85%); a brown oil; Rf = 0.81 (3:7 EtOAc/hexane); IR (cm-1) 1728, 1262; 1H 
NMR (CDCl3, 250 MHz) δ 0.81-0.86 (t, J = 6.3 Hz, 6H), 1.08-1.18 (m, 2H), 1.52-1.60 
(m, 2H), 2.00 (s, 3H), 3.14-3.20 (dd, J = 10.0 Hz, 5.1 Hz, 1H), 3.23-3.29 (dd, J = 10.0 
Hz, 4.2 Hz, 1H), 3.76-3.84 (dd, J = 11.1 Hz, 7.6 Hz, 1H), 3.99-4.05 (dd, J = 11.1 Hz, 4.5 
Hz, 1H); 13C NMR (CDCl3, 62.5 MHz) 11.6, 20.8, 22.2, 22.7, 24.7, 35.8, 40.2, 66.7, 
170.7 ppm. MS (GC/MS) m/z 157, 115, 97, 81, 69, 55. 
 
 
 
3-Acetoxy-2-butyl-1-iodopropane (13d)  
12d (0.32 g, 0.94 mmol), Sodium iodide (0.74 g, 4.92 mmol), yielded compound 13d 
(0.25 g, 93%); a brown oil; Rf = 0.45 (1:10 EtOAc/hexane); IR (cm-1) 1732; 1H NMR 
(CDCl3, 250 MHz) δ 0.78-0.84 (t, J = 6.6 Hz, 3H), 1.21-1.32 (m, 6H), 1.45-1.55 (m, 1H), 
1.99 (s, 3H), 3.16-3.27 (m, 2H), 3.79-3.86 (dd, J = 11.1 Hz, 7.5 Hz, 1H), 3.99-4.06 (dd, J 
= 11.1 Hz, 4.7 Hz, 1H); 13C NMR (CDCl3, 62.5 MHz) 11.2, 13.9, 20.8, 22.5, 28.5, 30.8, 
38.2, 66.5, 170.7 ppm. MS (GC/MS) m/z 157, 115, 97, 81, 69, 55. 
General Procedure for the preparation of 3-Acetoxy-2-alkyl-1-nitropropane (14a-d) 
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To a solution of iodide 13a (6.22 g, 19.6 mmol) in dry DMF (20 mL) were added 
phloroglucinol (1.23 g, 9.8 mmol) and AgNO2 (6.0 g, 39.2 mmol) under an argon 
atmosphere at room temperature and allowed to stir for 24 h. Reaction mixture was 
diluted with ethyl acetate and filtered through a pad of celite. The filtrate was washed 
with brine (3 x 25 mL), dried with anhydrous Na2SO4 and evaporated in vacuo. The 
crude product was purified by column chromatography (1:4 EtOAc/hexane) to give pure 
14a (3.5 g, 75%) as a colorless oil: Rf = 0.46 (1:4 EtOAc/Hexane); IR (cm-1) 1728, 1551, 
1175; 1H NMR (CDCl3, 400 MHz) δ 2.06 (d, J = 2.8 Hz, 3H), 2.32-2.38 (m, 1H), 2.70-
2.75 (dd, J = 13.2 Hz, 7.2 Hz, 2H), 4.0-4.20 (m, 3H), 4.33-4.46 (ddd, J = 13.2 Hz, 6.4 
Hz, 1H), 7.15-7.34 (m, 5H); 13C NMR (CDCl3, 100 MHz) 21.0, 34.6, 39.2, 63.2, 63.7, 
76.4, 126.7, 128.8, 129.2, 138.6, 171.1 ppm; MS (GC/MS) m/z 190, 130, 117, 104, 91, 
65; ESI-TOF Calcd for [M+NH4]+ is 255.13393, Found: 255.13405 
The remaining nitro acetates 14b-d were prepared similarly, with the following results. 
 
 
 
3-Acetoxy-2-cyclohexylmethyl-1-nitropropane (14b) 
13b (2.5 g, 7.71 mmol), phloroglucinol (0.97 g, 7.71 mmol), silver nitrite (4.14 g, 26.98 
mmol), yielded compound 14b (1.88 g, 48%); a colorless oil; Rf = 0.70 (3:7 
EtOAc/hexane); IR (cm-1) 1733, 1548, 1370; 1H NMR (CDCl3, 250 MHz) δ 0.80-0.88 
(m, 2H), 1.05-1.27 (m, 6H), 1.62-1.66 (m, 5H), 1.99 (s, 3H), 2.65-2.69 (m, 1H), 3.93-
4.14 (m, 3H), 4.29-4.37 (ddd, J = 15.2 Hz, 6.0 Hz, 1H); 13C NMR (CDCl3, 62.5 MHz) 
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20.7, 26.4,32.8, 33.3, 33.4, 35.7, 36.1, 64.2, 76.6, 170.6 ppm; MS (GC/MS) m/z 197, 182, 
166; ESI-TOF Calcd for [M+NH4]+ is 261.18088, Found: 261.18063 
 
 
 
3-Acetoxy-2-isobutyl-1-nitropropane (14c) 
13c (1.1 g, 3.87 mmol), phloroglucinol (0.73 g, 5.8 mmol), silver nitrite (1.2 g, 7.74 
mmol), yielded compound 14c (0.44 g, 56%); a colorless oil; Rf = 0.66 (3:7 
EtOAc/hexane); IR (cm-1) 1739, 1549, 1366; 1H NMR (CDCl3, 250 MHz) δ 0.86-0.91 (t, 
J =  6.5 Hz, 6H), 1.15-1.27 (m, 2H), 1.60-1.63 (m, 1H), 2.02 (s, 3H), 2.60-2.70 (m, 1H), 
3.92-4.15 (m, 3H), 4.32-4.40 (ddd, J = 13.6 Hz, 6 Hz, 1H); 13C NMR (CDCl3, 62.5 MHz) 
20.5, 21.9, 22.6, 24.9, 34.8, 37.5, 64.1, 77.3, 170.5 ppm; MS (GC/MS) m/z 160, 114, 95, 
81, 69, 55. 
 
 
3-Acetoxy-2-butyl-1-nitropropane (14d)  
13d (3.55 g, 12.5 mmol), silver nitrite (5.77 g, 37.5 mmol), phloroglucinol (0.8 g, 6.25 
mmol), yielded compound 14d (1.34 g, 54%); a colorless oil; Rf = 0.39 (1:10 
EtOAc/hexane); IR (cm-1) 1735, 1552; 1H NMR (CDCl3, 250 MHz) δ 0.85-0.90 (t, J = 
6.6 Hz, 3H), 1.26-1.36 (m, 6H), 2.03 (s, 3H), 2.50-2.55 (m, 1H), 3.96-4.18 (m, 2H), 4.32-
4.44 (m, 2H); 13C NMR (CDCl3, 62.5 MHz) δ 13.7, 20.6, 22.6, 28.2, 28.4, 36.9, 64.0, 
77.1, 160.9 ppm; MS (GC/MS) m/z 159, 114, 96, 81, 71, 55; ESI-TOF Calcd for 
[M+NH4]+ is 221.14958, Found: 221.14914 
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General Procedure for the preparation of 3-nitro-2-alkyl-1-propanol (15a-d) 
 
 
 
To a solution of nitro acetate 14a (2.0 g, 8.44 mmol) in MeOH (180 mL) was added a 
solution of K2CO3 (3.5 g, 25.3 mmol) in H2O (20 mL) at room temperature. The resulting 
milky white reaction mixture was stirred at the same temperature for 2 h. the majority of 
the organic solvent was evaporated and residue was extracted with EtOAc (3 x 25 mL). 
Combined organic layers were washed with brine (2 x 25 mL), dried over anhydrous 
Na2SO4 and evaporated. The crude residue was purified by column chromatography (1:1 
EtOAc/hexane) to give the compound 15a (0.74 g, 45%) as a colorless oil plus undesired 
white solid (which did not undergo Jones oxidation) (0.54 g, 33%): Rf = 0.64 (1:1 
EtOAc/Hexane); IR (cm-1) 3583, 3409, 1544; 1H NMR (CDCl3, 400 MHz) δ 1.58 (s, 1H), 
2.64-2.79 (m, 3H), 3.58-3.62 (dd, J = 10.8 Hz, 4.8 Hz, 1H), 3.70-3.74 (dd, J = 10.8 Hz, 
3.2 Hz, 1H), 4.37-4.41 (dd, J = 12.4 Hz, 5.2 Hz, 1H), 3.52-3.57 (dd, J = 12.4 Hz, 6.4 Hz, 
1H), 7.19-7.34 (m, 5H); 13C NMR (CDCl3, 100 MHz) 34.9, 41.8, 62.1, 76.4, 127.0, 
128.9, 129.2, 138.0 ppm; MS (GC/MS) m/z 131, 117, 91, 65.  
The remaining nitro alcohols 15b-d were prepared similarly, with the following results. 
 
 
 
 
 
HO NO2
HO NO2
 40
3-nitro-2-cyclohexylmethyl-1-propanol (15b) 
14b (1.31 g, 5.4 mmol), potassium carbonate (2.24 g, 16.2 mmol), yielded compound 15b 
(0.55 g, 51%); A colorless oil; Rf = 0.5 (3:7 EtOAc/Hexane); IR (cm-1) 3440, 1544, 1381; 
1H NMR (CDCl3, 250 MHz) δ 0.83-0.90 (m, 2H), 1.07-1.32 (m, 6H), 1.65-1.70 (m, 5H), 
2.38-2.51 (m, 2H), 3.47-3.54 (dd, J = 11.2 Hz, 6.8 Hz, 1H), 3.64-3.70 (dd, J = 11.2 Hz, 
4.2 Hz, 1H), 4.30-4.37 (dd, J = 12.0 Hz, 5.9 Hz, 1H), 4.46-4.54 (dd, J = 12.1 Hz, 7.0 Hz, 
1H); 13C NMR (CDCl3, 62.5 MHz) 25.9, 26.0, 26.2, 32.3, 32.9, 34.4, 35.8, 36.9, 62.5, 
77.2 ppm; MS (GC/MS) m/z 182, 135, 107, 95, 81, 67, 55. 
 
 
 
3-nitro-2-isobutyl-1-propanol (15c) 
14c (0.44 g, 2.17 mmol), potassium carbonate (0.9 g, 6.51 mmol), yielded compound 15c 
(0.15 g, 43%); a colorless oil; Rf = 0.47 (3:7 EtOAc/hexane); IR (cm-1) 3403, 1549; 1H 
NMR (CDCl3, 250 MHz) δ 0.92-0.95 (dd, J = 6.5 Hz, 1.7 Hz, 6H), 1.15-1.34 (m, 2H), 
1.62-1.73 (m, 2H), 2.45-2.47 (m, 1H), 3.55-3.62 (dd, J = 11.1 Hz, 6.6 Hz, 1H), 3.72-3.78 
(dd, J = 11.1 Hz, 4.2 Hz, 1H), 4.37-4.44 (dd, J = 12.1 Hz, 5.8 Hz, 1H), 4.52-4.59 (dd, J = 
12.1 Hz, 7.1 Hz, 1H); 13C NMR (CDCl3, 62.5 MHz) 22.2, 22.6, 25.0, 37.4, 37.7, 62.5, 
77.2 ppm; MS (GC/MS) m/z 115, 97, 84, 69, 55. 
 
 
 
 
HO NO2
HO NO2
 41
3-nitro-2-butyl-1-propanol (15d)  
14d (1.34 g, 6.6 mmol), potassium carbonate (1.37 g, 9.9 mmol), yielded compound 15d 
(0.36 g, 34%); a colorless oil; Rf = 0.61 (2:5 EtOAc/hexane); IR (cm-1) 3410, 1549; 1H 
NMR (CDCl3, 250 MHz) δ 0.86-0.93 (t, J = 2.5 Hz, 3H), 1.28-1.38 (m, 6H), 2.33-
2.37(m, 1H), 3.51-3.58 (dd, J = 11.1 Hz, 6.7 Hz, 1H), 3.66-3.72 (dd, J = 11.1 Hz, 4.3 Hz, 
1H), 4.33-4.40 (dd, J = 12.1 Hz, 6.1 Hz, 1H), 4.48-4.55 (dd, J = 12.1 Hz, 7.0 Hz, 1H); 
13C NMR (CDCl3, 62.5 MHz) 11.2, 13.9, 20.8, 22.5, 28.5, 30.8, 38.2, 66.5, 170.7 ppm; 
MS (GC/MS) m/z 97, 84, 69, 55.  
General Procedure for the preparation of 3-nitro-2-alkylpropionic acids (16a-d) 
 
 
 
Jones reagent (2 mL) was added to a solution of nitro alcohol 15a (1.0 g, 5.13 mmol) in 
acetone (3 mL) at 0 0C. The reaction mixture was stirred for 2 h at same temperature, and 
then quenched with i-PrOH until the color of the reaction mixture turned to green. After 
dilution with water and extraction with EtOAc (3 x 25 mL), the combined organic layers 
were washed with brine (2 x 25 mL), dried over Na2SO4 and the solvent was evaporated 
under vacuo. The crude product was purified by column chromatography (1:1 
EtOAc/hexane) to give the carboxylic acid 16a (0.75 g, 70%) as colorless oil. Rf = 0.13 
(1:1 EtOAc/hexane); IR (cm-1) 3027, 1714, 1551; 1H NMR (CDCl3, 400 MHz) δ 2.83-
2.89 (dd, J = 14.4 Hz, 9.2 Hz, 1H), 3.21-3.26 (dd, J = 14.4 Hz, 5.6 Hz, 1H), 3.48-3.55 (m, 
1H), 4.35-4.39 (dd, J = 14.8 Hz, 4.4 Hz, 1H), 4.61-4.67 (dd, J = 14.8 Hz, 8.8 Hz, 1H), 
7.17-7.19 (d, J = 6.8 Hz, 2H), 7.26-7.36 (m, 3H); 13C NMR (CDCl3, 100 MHz) 35.0, 
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44.3, 73.7, 127.7, 129.0, 129.3, 136.2, 177.2 ppm; MS (GC/MS) m/z 191, 162, 147, 131, 
117, 91, 65; ESI-TOF Calcd for [C10H10O4N]- is 208.06153, Found: 208.06120 
Remaining nitro acids 16b-d were prepared similarly, with the following results. 
 
 
 
3-nitro-2-cyclohexylmethylpropionic acid (16b)  
15b (0.55 g, 2.74 mmol), Jones reagent (5.5 mL), yielded compound 16b (0.39 g, 67%); a 
white solid; mp 96-98 0C; Rf = 0.57 (1:1 EtOAc/hexane); IR (cm-1) 1722, 1536, 1381; 1H 
NMR (CDCl3, 400 MHz) δ 0.89-0.95 (m, 2H), 1.16-1.40 (m, 5H), 1.65-1.81 (m, 6H), 
3.32-3.33 (m, 1H), 4.39-4.44 (dd, J = 14.4 Hz, 4.0 Hz, 1H), 4.67-4.73 (dd, J = 14.4 Hz, 
9.6 Hz 1H); 13C NMR (CDCl3, 62.5 MHz) 25.8, 26.1, 32.7, 34.7, 36.3, 40.1, 74.8, 178.9 
ppm; MS (GC/MS) m/z 168, 121, 107, 95, 81, 67, 55; ESI-TOF Calcd for[C10H16O4N]- is 
214.10848, Found: 214.10826 
 
 
3-nitro-2-isobutylpropionic acid (16c) 
15c (0.96 g, 5.96 mmol), Jones reagent (4.5 mL), yielded compound 16c (0.98 g, 95%); a 
white powder; mp 58-61 0C; Rf = 0.59 (1:1 EtOAc/hexane); IR (cm-1) 1713, 1545, 1373; 
1H NMR (CDCl3, 250 MHz) δ 0.94-0.99 (dd, J = 14.6 Hz, 8.8 Hz, 6H), 1.25-1.44 (m, 
2H), 1.62-1.73 (m, 2H), 3.25-3.33 (m, 1H), 4.39-4.46 (dd, J = 14.6 Hz, 4.3 Hz, 1H), 4.66-
4.76 (dd, J = 14.6 Hz, 9.4 Hz, 1H); 13C NMR (CDCl3, 62.5 MHz) 21.9, 22.2, 25.5, 37.8, 
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40.9, 74.9, 178.7 ppm; MS (GC/MS) m/z 129, 83, 69, 55; ESI-TOF Calcd for 
[C7H12O4N]- is 174.07718, Found: 174.07698 
 
 
 
3-nitro-2-butylpropionic acid (16d)  
15d (0.1 g, 0.62 mmol), Jones reagent (1 mL), yielded compound 16d (0.1 g, 93%); a 
colorless oil; Rf = 0.64 (9:1 EtOAc/hexane); IR (cm-1) 3750, 1713, 1556; 1H NMR 
(CDCl3, 250 MHz) δ 0.89 (s, 3H), 1.29-1.39 (m, 6H), 3.20-3.23 (m, 1H), 4.39-4.45 (d, J 
= 14.6 Hz, 1H), 4.66-4.76 (dd, J = 13.8 Hz, 9.2 Hz, 1H); 13C NMR (CDCl3, 62.5 MHz) 
13.6, 22.3, 28.6, 42.6, 74.5, 178.8 ppm; MS (GC/MS) m/z 129, 83, 73, 55; ESI-TOF 
Calcd for [C7H12O4N]- is 174.07718, Found: 174.07703 
General Procedure for the Preparation of Methyl, 3-nitro-2-alkylpropionate (17a-d) 
 
 
 
To a solution of acid 16a (0.1 g, 0.48 mmol) in dry DMF (3 mL) at –5 0C was added 
anhydrous K2CO3 (0.066 g, 0.48 mmol) with stirring under an argon atmosphere. After 
stirring for 10 min., methyl iodide (0.075 g, 0.53 mmol) was added and reaction mixture 
was stirred for another 2 h at same temperature. The reaction mixture was diluted with 20 
mL of saturated aqueous NaHCO3 solution and extracted with EtOAc (2 x 25 mL). 
Combined organic layers were washed once with saturated aqueous NaHCO3 solution, 
then with brine (2 x 25 mL), dried over anhydrous Na2SO4, and evaporated under vacuo 
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to afford the pure 17a (0.08 g, 75%) as a light yellow oil: Rf = 0.47 (1:4 EtOAc/hexane); 
IR (cm-1) 1736, 1551; 1H NMR (CDCl3, 400 MHz) δ 2.71-2.77 (dd, J = 14.0 Hz, 9.2 Hz, 
1H), 3.03-3.08 (dd, J = 14.0 Hz, 6.0 Hz, 1H), 3.34-3.42 (m, 1H), 3.68 (s, 3H), 4.25-4.30 
(dd, J = 14.8 Hz, 4.4 Hz, 1H), 4.55-4.60 (dd, J = 14.4 Hz, 9.2 Hz, 1H), 7.05-7.07 (d, J = 
7.2 Hz, 2H), 7.18-7.26 (m, 3H); 13C NMR (CDCl3, 100 MHz) 35.3, 44.7, 52.7, 74.2, 
127.5, 129.0, 136.6, 172.2 ppm; MS (GC/MS) m/z 178, 117, 105, 91, 65; ESI-TOF Calcd 
for [M+NH4]+ is 241.11828, Found: 241.11779 
The remaining nitro esters 17b-d were prepared similarly, with the following results. 
 
 
 
Methyl, 3-nitro-2-cyclohexylmethylpropionate (17b) 
16b (0.05 g, 0.23 mmol), potassium carbonate (0.037 g, 0.28 mmol), methyl iodide (0.08 
g, 0.56 mmol), yielded compound 17b (0.046 g, 87%); a colorless oil; Rf = 0.80 (3:7 
EtOAc/hexane); IR (cm-1) 1739, 1553, 1378; 1H NMR (CDCl3, 400 MHz) δ  0.86-0.93 
(m, 2H), 1.15-1.37 (m, 5H), 1.57-1.79 (m, 6H), 3.28-3.30 (m, 1H), 3.74 (s, 3H), 4.37-
4.42 (dd, J = 14.0 Hz, 4.4 Hz, 1H), 4.67-4.73 (dd, J = 14.4 Hz, 9.6 Hz, 1H); 13C NMR 
(CDCl3, 100 MHz) 26.1, 26.4, 33.0, 33.2, 35.2, 36.9, 40.6, 52.5, 75.7, 173.3 ppm; MS 
(GC/MS) m/z 183, 151, 121, 107, 95, 81, 67, 55; ESI-TOF Calcd for [M+NH4]+ is 
247.16523, Found: 247.16470 
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Methyl, 3-nitro-2-isobutylpropionate (17c) 
16c (0.05 g, 0.29 mmol), potassium carbonate (0.048 g, 0.35 mmol), Methyl iodide (0.05 
g, 0.35 mmol), yielded compound 17c (0.05 g, 93%); a colorless oil; Rf = 0.75 (3:7 
EtOAc/hexane); IR (cm-1) 1735, 1560, 1370; 1H NMR (CDCl3, 250 MHz) δ 0.91-0.96 
(dd, J = 11.9 Hz, 6.0 Hz, 6H), 1.29-1.34 (m, 1H), 1.55-1.65 (m, 3H), 3.22-3.28 (m, 1H), 
3.74 (s, 3H), 4.35-4.43 (dd, J = 14.3 Hz, 4.5 Hz, 1H), 4.66-4.75 (dd, J = 14.3 Hz, 9.5 Hz, 
1H); 13C NMR (CDCl3, 62.5 MHz) 21.9, 22.3, 25.6, 38.1, 41.1, 52.2, 75.4, 173.0 ppm; 
MS (GC/MS) m/z 158, 111, 69, 55; ESI-TOF Calcd for [M+NH4]+ is 207.13393, Found: 
207.13390 
 
 
Methyl, 3-nitro-2-butylpropionate (17d)  
16d (0.1 g, 0.57 mmol), methyl iodide (0.12 mL, 2.0 mmol), yielded compound 17d 
(0.50 g, 47%); a pale yellow oil; Rf = 0.58 (1:5 EtOAc/hexane); IR (cm-1) 1735, 1549; 1H 
NMR (CDCl3, 250 MHz) δ 0.85-0.90 (t, J = 6.7 Hz, 3H), 1.22-1.32 (m, 4H), 1.50-1.71 
(m, 2H), 3.12-3.23 (m, 1H), 3.72 (s, 3H), 4.36-4.44 (dd, J = 14.3 Hz, 4.8 Hz, 1H), 4.67-
4.76 (dd, J = 14.3 Hz, 9.4 Hz, 1H); 13C NMR (CDCl3, 62.5 MHz) δ 13.7, 22.3, 28.6, 
28.9, 42.7, 52.3, 75.1, 172.8 ppm; MS (GC/MS) m/z 158, 111, 69, 55; ESI-TOF Calcd for 
[M+NH4]+ is 207.13393, Found: 207.13389 
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CHAPTER THREE 
EFFORT TOWARDS THE SYNTHESIS OF “SUBSTITUTED” 
ORTHOGONALLY PROTECTED GEMINAL DIAMINO ACIDS (OPGDA’S) & 
CYCLIC UREA 8 
3.1 Introduction 
 Unnatural amino acids and amino acid mimics have become increasingly 
important in the discovery of pharmacologically active peptides and peptidomimetics. 
Several monomeric building blocks that mimic the peptide backbone have been proposed 
and include peptoids,1 azoles,2 2-isoxazolines,3 oligocarbamates, oligosulfones and 
oligosulfoxides,4 pyrolinones,5 vinylogous backbones,6 β-methyl amino acids7, β-amino 
acids,8 and most recently betidamino acids.9,10,11 Biopolymers generated using these 
unnatural scaffolds, have been found to have physicochemical, chemical, structural, 
biological, metabolic, absorptive properties that differ from those of the parent peptides. 
The amino acid mimics received considerable attention due to their important role in the 
design of conformationally restricted peptides with enhanced properties, such as 
resistance to hydrolysis and enzyme cleavage processes. A number of methods have been 
devised to stabilize biologically active peptides against metabolic degradation and to 
study their structure – activity relationships. Among these methods is the preparation of 
partially modified retro-inverso peptide structures (Figure 3.1).12-15 A general definition 
of a retro-isomer of a linear peptide would be the one that is obtained through formal 
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reversal of all the peptide bonds in the backbone, thus conserving the side chain topology. 
An absolute retro-isomer can be defined as the one that incorporates amino acids of the 
opposite chirality while preserving the same residues at the N-terminal and C-terminal of 
the peptide. Synthesis of the absolute linear retro-isomer has an “end-group” problem,16 
which requires the conservation of the C-terminal end group and N-terminal end group. 
The C-terminal end group problem can be solved by the replacement of the C-terminal 
amino acid with an α- substituted malonic acid.   
 Goodman, Cherov and Willson, the pioneers in the field of synthesis of the retro – 
inverso peptides realized that the “end-group problem” can be solved by incorporating 
differentially protected α, α-diamino residues.17  
 
 
 
 
Figure 3.1:- Retro-inverso peptide and its similarity to a normal peptide 
gem-Diamino compounds also received considerable attention throughout the literature 
because they are the basic components in the betidamino acids (Figure 3.2). 
 
 
 
Figure 3.2:- Representative structure of betidamino acids. (* indicates a chiral center) 
Betidamino acids are the novel versatile and constrained scaffolds for the drug discovery, 
that were utilized in the synthesis of the bioactive gonadotropin-releasing hormone 
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(GnRH) analogs.10 “Betidamino” is a term generated from the contraction of “beta” 
position with “peptide” or “amide”. According to Rivier et al.,10 they are N’-
monoacylated (optionally, N’-monoacylated and N-mono- or N,N’-dialkylated) 
aminoglycine derivatives in which each N’-acyl/alkyl group may mimic naturally 
occurring amino acid side chains or introduce novel functionalities. The use of the gem-
diamino compounds for the synthesis of linear peptides, retro-isomers as well as our 
Part-B of the cyclic urea 8 requires two different protecting groups (orthogonal 
protection), which could be removed selectively, so that the two nitrogen atoms can be 
utilized in different ways. This requirement proved to be a synthetic challenge for us. 
3.2 Literature Reported Syntheses And Applications Of Geminal Diamino 
Compounds 
 There were few literature reported procedures for the synthesis of the gem-
diamino compounds, but their applications were enormous as stated earlier in the 
introductory section. Bergmann and Zervas18 reported the first method for the stepwise 
degradation of polypeptides. In their paper they mentioned gem-diamino compounds for 
the first time. The first reported synthesis of the geminal diamino acid by Shemin and 
Herbest19,20 included the synthesis of α,α-diacetamino derivative 22, which was made 
from condensing the α-acetamino acrylic acid 20 with acetamide 21 (Figure 3.3).Their 
synthesis was based on the findings by Zervas et al. 
 
 
Figure 3.3:- Condensation of α-acetamino acrylic acid 20 with acetamide 21 
C
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The resulting diacetamino compound 22 is a gem-diamino compound, but it lacks the 
different protecting groups on the geminal amines. The next reported synthesis of the 
gem-diamino is by Greenstein et al.,21,22 where they synthesized the α,α-
Di(glycylamino)propionic acid hydrochloride by amination of the α,α-
Di(chloroacetamino)propionic acid. Brenner et al.23 further synthesized the substituted 
versions of the acid and also reported Cbz protecting groups on the amines (Figure 3.4).  
 
 
 
Figure 3.4:- gem-Diamino compounds synthesized by Brenner et al. 
 A series of reports were published by Goodman et al. on the synthesis of 
orthogonally protected gem-diamino compounds by Curtius- or Hoffmann type 
rearrangements of protected amino acid derivatives.12,24-26 They used a modified Curtius 
reaction on the general structure 23, by employing a saturated solution of nitrosoyl 
chloride in dry THF. The azide that formed was allowed to rearrange to the 
corresponding isocyanate by heating in toluene at 80 oC. Addition of either tert-butyl 
alcohol or benzyl alcohol to the reaction mixture yielded N,N’-diprotected gem-diamino 
compound with the general formula 24 (Figure 3.5). 
 
 
  
Figure 3.5:- General scheme for the synthesis of orthogonally protected gem-
diamino compounds via modified Curtius reaction. 
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They used their orthogonally protected gem-diamino compounds in the synthesis of 
partially modified retro-inverso-enkephalinamide 25 that was proved to be long-acting 
analog both in vitro and in vivo (Figure 3.6).24 Their synthesis of novel class of 
enkephalin analogs was based on the reversal of one or more of the peptide bond 
residues, thus avoiding the proteolytic degradation. All the modified structures of the 
enkephalin analogs they made contain gem-diamino alkyl residues.24 
 
 
 
 
 
Figure 3.6:- Enkephalinamide 25 synthesized by Goodman et al. 
 Another report by Goodman et al. came in 1980, where they synthesized the gem-
diamino compounds by the similar route they reported earlier, but this time with a 
variation in the usage of the starting material 26 (Figure 3.7).25  
 
 
 
 
 
Figure 3.7:- gem-Diamino compounds synthesized by Goodman et al. 
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 These gem-diamines were used for the synthesis of the peptide sweeteners, and 
also to find their effect of modifying the peptide bond on the sweet taste of L-Aspartyl-L-
phenylalanine methyl ester and their analogs. Goodman’s group was unsuccessful in their 
attempts to come up with the analogs that are sweeter than L-Aspartyl-L-phenylalanine 
methyl ester 31 in this attempt (Figure 3.8). 
 
 
 
 
Figure 3.8:- Retro-inverso peptide analog of L-Aspartyl-L-phenylalanine (31)  
Their relentless efforts towards synthesis of peptide sweeteners were successful finally, 
when they synthesized N-(L-aspartyl)-1,1-diaminoalkane-based sweeteners that are up to 
1000 times sweeter than sucrose (Figure 3.9).26 
  
  
 
 
 
 
Figure 3.9:- Retro-inverso peptide analogs of N-(L-aspartyl)-1,1-diaminoalkane 
 Since diamino methane is not a sufficiently stable compound in the mono- or 
unprotonated form to survive the conditions required to use it as a reagent, orthogonally 
protected diaminomethane was first synthesized by Loudon et al.27,28, where they 
H3N N
O O
H
O
O O
gem-diamino
31
H2N
HOOC
H
N
O
H
N R'
O
R' =
1000 times     700 times
gem-diamino
 57
converted the Boc-Glycine 32 to its acyl azide 33 by using bis(p-nitrophenyl)-phosphoryl 
azide, and the resulting material 33 was rearranged via a modified Curtius reaction in the 
presence of benzyl alcohol to give the diprotected methylenediamine derivative 34.  
 
 
Figure 3.10:- Synthesis of orthogonally protected dichloromethane 34 
 Additional interest in the synthesis of α,α-diamino compounds was supported, 
when their possible application as the peptide carrier systems designed for transporting 
therapeutically useful compounds into microbial cells was reported.29 Kingsbury et al.29 
described a versatile peptide delivery system in which the toxophoric agent was attached 
to the α-carbon of a glycine residue within a peptide chain. Intracellular cleavage of the 
peptide by cytoplasmic peptidases results in the formation of an unstable intermediate 
that decomposes with release of the attached toxophoric group. 
 Bock et al.30 reported an efficient synthesis of α-aminoglycine in protected form 37, 
which complements the existing methodology developed by Goodman’s group (Refer to 
Figure 3.11). 
 
 
 
 
 
Figure 3.11:- Synthesis of orthogonally protected α,α-geminal diaminoglycine 37 
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 “gem-peptides” are the peptides containing gem-diamino units in the terminal 
position of a retro-inverso peptide and this terminology was introduced by Katritzky et 
al.31 They reported a convenient and versatile method for the preparation of various 
simple α-substituted monoacyl aminals and also a novel synthetic route to “gem-
peptides”. Their synthesis involved Mannich condensation of various amides, aldehydes, 
and benzotriazole to give adducts of type R1CONH-CH(R2)Bt, which upon reaction with 
NH3 result in versatile monoacyl aminal structures (R1CONH-CH(R2)NH2 and using 
protected amino acid amides as the amide component leads to “gem-peptides” (Refer to 
figure 3.12). 
 
Figure 3.12:- Katritzkey et al.’s scheme for the synthesis of “gem-peptides” subunit 
3.2.1 Cushman et al.’s synthesis of gem-diamino compounds 
Cushman et al.32 reported the synthesis of end group modified retro-inverso Bombesin C-
terminal nonapeptide. Bombesin (GlpGlnArgLeuGlyAsnGlnTrpAlaValGlyHisLeuMet-
NH2) and structurally related peptides display a wide spectrum of biological activity. 
Cushman et al. followed the approach proposed by Goodman et al.14 for the synthesis of 
the retro-inverso peptide analog 38 by incorporating the gem-diamino in the termini of 
Bombesin (Figure 3.13). Their synthesis of the amino terminus analogue was not smooth; 
they basically had to abandon a couple of schemes before they made their gem-diamino 
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compound. Their schemes will be discussed below in detail, as they closely resemble the 
approach that we followed in our efforts towards the syntheses of substituted OPGDA’s. 
 
 
 
 
 
 
Figure 3.13:- Retro-inverso peptide analog 38 of Bombesin 
 Their original plan was to construct the geminal amino amide unit at the end of the chain 
in the above mentioned retro-inverso peptide analog 38 of bombesin, by performing a 
Curtius rearrangement on a peptide containing an asparagine residue. Attempts to 
rearrange the acyl azide derivative of Z-L-asparagine in TFA or reaction of Z-L-
asparagine with diphenyl phosphorazidate (an azide transfer reagent) gave disappointing 
results. They concluded that the side chain amide group of asparagine was interfering 
with the reaction at the isocyanate stage. They further described some model studies for 
making orthogonally protected gem-diamino compounds by selecting an amino acid 
derivative lacking a reactive side chain. They chose Z-L-leucine to conduct their studies, 
which are outlined in Figures 3.14 & 3.15. 
 
 
 
Figure 3.14:- Failed attempt to synthesize gem-diamino analog of leucine 
H
NH2N
O
N
H
O H
N
O
N
H
O H
N
O
N
H
O H
N
O
N
H
O
NH2
O
H
O
H2N
O NH2
H
HN
H
H
H
NH
N
H
H
H
SCH3
gem-diamino
CbzHN
H OH
O
i) diphenyl phosphorazidate, TEA
ii) Benzene, t-BuOH, reflux
CbzHN NHBoc
HX
39 40
 60
The reaction of Z-L-leucine 39 with diphenyl phosphorazidate and triethylamine 
followed by heating at a reflux in benzene containing tert-butyl alcohol also did not lead 
them to the desired gem-diamino compound 40. They were able to make acyl azide 41 by 
mixed anhydride method, and were able to achieve the formation of isocyanate 42 via 
rearrangement. But when this isocyanate 42 was reacted with tert-butyl alcohol in 
refluxing benzene, it took 15 h before the complete decomposition of the starting 
material, and they couldn’t get the desired product 43. In contrast to tert-butyl alcohol, 
benzyl alcohol reacted readily with the isocyanate 42 to give 44 as the major product 
(Figure 3.15). 
Figure 3.15:- Failed attempt via mixed anhydride route 
They concluded that the Curtius rearrangement was not possible if the amino acid has i) a 
Leucine side chain ii) an amide group like in asparagine. They came up with a new 
strategy for the construction of the geminal amino unit of the retro-inverso peptide analog 
38 of Bombesin (Figure 3.16), where they masked the amide group on the asparagine side 
chain as a nitrile (-CN), and carried out the Curtius rearrangement. They were successful 
in achieving the gem-diamino compound 49 in moderate yields. 
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Figure 3.16:- Cushman et al.’s successful attempt to synthesize gem-diamino 
compound 49 via masked amide of 45 
3.2.2 Reports on orthogonally protected geminal diamino acids (OPGDA’s) 
 Kohn et al.33 reported gem-diamino compounds that showed excellent 
anticonvulsant activity. In their paper they reported the synthesis of some of those active 
compounds by a much simpler scheme depicted in figure 3.17.   
 
Figure 3.17:- Kohn’s synthesis of gem-diamino compound 52 
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section) involved the solid phase peptide synthesis by selectively acylating one of the two 
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chain either prior to or after the elongation of the main chain. They used racemic 
orthogonally protected geminal diaminoglycine as the template for the introduction of 
BocHN COOH
H2NOC
DCC/Pyridine
BocHN COOH
NC
BocHN CON3
NC
BocHN NHCbz
NC
BocHN NHCbz
H2NOC
mixed
anhydride method
Curtius 
rearrangement
benzyl
alcohol
reflux
basic
H2O2
in acetone
45 46 47
4849
NHAcEtOOC
Br2, CCl4
NHAcEtOOC
Br
Liq. NH3
NHAcEtOOC
NH2
50 51 52
 62
betidamino acids in Acyline, which is a potent gonadotropin-releasing hormone 
antagonist. They followed an earlier synthesis of racemic α-Fmoc-α’-Boc-aminoglycine 
by Qasmi et al.34 (Figure 3.18).  
 
 
 
 
 
 
Figure 3.18:- Synthesis of α-Fmoc-α’-Boc-aminoglycine analogs 
Davies et al.35 in their paper reported that they had explored all the literature precedent 
reports for the synthesis of gem-diamino alkyl units, but only two published methods 
proved fruitful in their hands. The synthetic route based on the work of Bock et al.30 
(Figure 3.11) and synthesis via their adaptation of a procedure by Waki et al.36 (Figure 
3.19) were the only synthetic sequences to give significant yields of OPGDA. 
 
 
 
 
Figure 3.19:- Synthesis of glycine OPGDA by Davies et al. 
 Sypniewski et al.11 introduced the first enantiospecific synthesis of (R)-Boc-
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strategy took advantage of the carboxylic acid moiety of 56 to introduce the second 
amino functionality through carboxylic acid interconversion to a carbamino group via the 
acyl azide – isocyanate pathway. The hydroxymethyl group was then oxidized to 
carboxyl functionality (Refer to figure 3.20).  
 
 
 
 
 
Figure 3.20:- Enantiospecific synthesis of OPGDA’s 
 More recently it was Cantel et al.37 who reported the synthesis of gem-diamino 
derivatives on solid support. They anchored α-aminoacid amide residue by its amine 
function to a carbamate resin followed by primary amide Hofmann rearrangement to 
yield gem-diamino residues linked to the resin. Later they acylated the primary amine 
generated in the previous step, with various carboxylic compounds thus to offer a large 
variety of molecules. Their novel solid-phase strategy was feasible to synthesize gem-
diamino monomeric residues that could not be easily obtained in solution phase due to 
the limited stability of monocarbamate-protected gem-diaminoalkyl derivatives. Their 
synthetic scheme was outlined below in the figure 3.21. 
 
 
 
Figure 3.21:- Solid-phase peptide synthesis of gem-diamino derivatives 
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 The most recent of the reports on the synthesis of chiral gem-diamino compounds 
came in 2005 by Antilla et al.38 They synthesized chiral gem-diamino compounds via 
Brønsted Acid-catalyzed imine amidation (Refer to figure 3.22). 
 
 
 
 
Figure 3.22:- Antilla et al.’s synthesis of N,N-aminals 
3.2.3 Our efforts towards the synthesis of orthogonally protected α-substituted α,α-
diamino acids  
Scores of reports were seen from literature so far on the syntheses of compounds of 
general class-A (Figure 3.23) that are normal OPGDA’s, but none in the class-B. Our 
efforts that are represented in this chapter, are towards the synthesis of class-B 
compounds that we coined as “Substituted OPGDA’s”. These are the building blocks 
for our designed novel HIV-1 protease inhibitors (Refer to Chapter-1). 
 
 
 
 
 
 
Figure 3.23:- Difference between normal “OPGDA’s” and “Substituted OPGDA’s”  
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3.3 Results & Discussion 
 Before I started working on this synthesis of substituted OPGDA’s, Dr. Talele a 
post-doctoral fellow in our lab had already pursued various routes towards their 
synthesis. The results and routes explored by Dr. Talele are not mentioned here, but only 
the ones on which Dr. Talele and I worked or the ones that I worked independently are 
discussed in this chapter. Our first attempt towards the synthesis of substituted 
OPGDA’s was in similar lines with that of Goodman’s first synthesis12 of gem-diamino 
compounds, except that we employed porcine liver esterase (PLE) for the 
desymmetrization of the 2-Azido-2-methyl-malonic acid diethyl ester 62 to provide us 
the enantiomeric excess (Figure 3.24). Our enantioselective route started with the 
commercially available 2-methyl-malonic acid diethyl ester 61. Azido transfer was 
accomplished successfully by the use of NaH to pull the methine proton of 61, and trisyl 
azide as the azide transfer reagent. This reaction was also tried with tosyl azide but the 
yields of methyl azido diethylmalonate 62 were poor (23% – 30%). Synthesis of Trisyl 
azide 68 was carried out by reacting trisyl chloride 67 with sodium azide in aqueous 
ethanol, according to the standard literature reported procedure (Refer to figure 3.25). 
Desymmetrization of the prochiral methyl azido diethyl malonate 62 was accomplished 
by selective hydrolysis with PLE according to the literature reported procedures. We 
were able to achieve 84% yield of 2-Azido-2-methyl-malonic acid monoethyl ester 63, 
which was then converted to 2-Azido-2-azidocarbonyl-propionic acid ethyl ester 64 via 
the mixed-anhydride method. We tried Curtius rearrangement several times on this acyl 
azide 64 by refluxing in t-BuOH, but we failed to achieve the 2-Azido-2-tert-
butoxycarbonylamino-propionic acid ethyl ester 65. Every time we ended up in a product 
 66
with the loss of the azide group. We used Rh2(OAc)4 in catalytic amount and refluxed in 
t-BuOH and this time we were able to achieve 65 in very low yield (28%).This reaction 
had its own draw back of reproducibility. With the compound 65 available in hand, we 
tried to reduce the azide to amine and follow it by a Cbz protection. But our attempt to 
reduce the azide with PtO2, EtOH/H2 was unsuccessful. We tried this reaction several 
times with H2 (balloon) and on hydrogenation apparatus at 25 psi, but in all the cases we 
failed to synthesize the free amine, instead we observed decomposition. We also tried in 
situ Cbz protection with PtO2 as the catalyst and H2 (balloon) but we ended up with 
streak of spots on the TLC, suggesting the possible decomposition of the starting material 
or the intermediate or the product.  
 
Figure 3.24:- Failed attempt for the enantioselective synthesis of substituted 
OPGDA’s 
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Even the reduction of azide with SnCl2, dioxane/water and in situ Cbz protection with 
Cbz-Cl/pyridine did not yield us the desired product 2-Benzyloxycarbonylamino-2-tert-
butoxycarbonylamino-propionic acid 66 and we had to abandon this route. 
 
 
 
 
Figure 3.25:- Synthesis of 2,4,6-Triiospropyl-benzenesulfonyl azide  
 Desymmetrization of methyl azido diethylmalonate 62 with PLE yielded 
monoacid 63. In order to find out the enantiomeric excess we derivatized the chiral 
monoacid 63 with a known chiral amine (R)-(+)-1-phenylethylamine 69, and checked for 
the formation of diasteriomers of 2-Azido-2methyl-(R)-(+)-N-(1-phenyl-ethyl)-
malonamic acid ethyl ester 70 (Figure 3.26). But we were able to see only one spot on the 
TLC and also one set of peaks on the 1H NMR spectrum of the derivative, indicating that 
there is only one diasteriomer (either R,S or R,R) and the enantiomeric excess was 
determined to be >99% (e.e). We did not determine the absolute stereochemistry of the 
acid 63, since our aim was to confirm whether we have only a single enantiomer or not at 
this stage.  
 
 
 
 
Figure 3.26:- Determination of enantiomeric excess of monoacid 63 
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  Then we moved on to synthesize substituted OPGDA’s via a racemic route and 
came up with a scheme along similar lines with the synthesis of OPGDA’s by 
Sypniewski et al.11 Our racemic route shown in figure 3.27, started with a very old 
literature reported procedure39 for the synthesis of 2,2-Bis-benzyloxycarbonylamino-
propionic acid 73. Pyruvic acid 71 was reacted with phenyl carbamate 72 on a rotavap at 
95 oC and under vacuum to pull the water formed during the reaction and thus push the 
reaction forward for the formation of gem-diamino acid 73 in 80% yield. Compound 73 
was activated by making a 2,2-Bis-benzyloxycarbonylamino-propionic acid 2,5-dioxo-
pyrrolidin-1-yl ester 74 in 90% yield. Ester 74 was reduced to (1-
Benzyloxycarbonylamino-2-hydroxy-1-methyl-ethyl)-carbamic acid benzyl ester 75 by 
NaBH4 at 0 oC (70% yield). (4-Methyl-2-oxo-oxazolidin-4-yl)-carbamic acid benzyl ester 
76 was obtained from alcohol 75 by the elimination of benzyl alcohol, and subsequent 
ring closure. We were able to achieve this in two different ways i) using potassium tert-
butoxide in THF at -78 oC  or ii) by sodium hydride/THF at -78 oC. Using NaH yielded 
87% of oxazolidine 76, which is more when compared to 70% produced by KOtBu. 
Oxazolidine 76 was subjected to Boc protection by using (Boc)2O, DMAP (catalytic 
amount) and TEA to give 4-Benzyloxycarbonylamino-4-methyl-2-oxo-oxazolidine-3-
carboxylic acid tert-butyl ester 77 over 90% yield. We were able to achieve till this step 
very smoothly with good to moderate yields. But we were unsuccessful in opening the 
Boc-protected oxazolidine 77 to yield the orthogonally protected (1-tert-
Butoxycarbonylamino-2-hydroxy-1-methyl-ethyl)-carbamic acid benzyl ester 78. When 
oxazolidine 77 was treated with BTAH (phase transfer catalyst) in THF at -78 oC 
according to the literature reported procedure,11 we ended up in getting the undesired 
 69
product (4-Methyl-2-oxo-oxazolidin-4-yl)-carbamic acid tert-butyl ester 79 due to the 
elimination of benzyl alcohol. We tried doing this reaction at different conditions i) by 
decreasing the amount of the BTAH used ii) by changing the solvent from THF to 
toluene iii) by changing the temperature conditions (from -78 oC to -40 oC and to room 
temperature), but still we ended up with the undesired product 79. A possible mechanism 
for this ring flipping and elimination of the benzyl alcohol was deduced and was shown 
in figure 3.28. We concluded that the oxide intermediate during this reaction might be a 
strong enough nucleophile to attack the carbonyl carbon of the Cbz group and eliminate 
benzyl alcohol, and thus result in the flipping of the ring. 
Figure 3.27:- Failed attempt to synthesize racemic substituted OPGDA 
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Figure 3.28:-Possible mechanism for the ring flipping and elimination of benzyl 
alcohol 
 Our observation led us to believe that if we reverse the order of the protecting 
groups on the oxazolidine ring amine with Cbz and the amine geminal to it with a Boc; 
we might be able to eliminate the ring flipping. With that intention we tried to deprotect 
the Cbz from oxazolidine 76 by standard hydrogenation procedure by H2/Pd/C in MeOH. 
After 3 hr the starting material disappeared on TLC plate, but we did not isolate the free 
amine. The supposed crude free amine was subjected to Boc protection; we were not 
successful in obtaining the compound 79. TLC suggested decomposition of the product. 
We tried to do the in situ Cbz deprotection followed by Boc protection but the reaction 
failed again to achieve the compound 79 (Figure 3.29). 
 
 
 
 
Figure 3.29:- Failed attempt to synthesize oxazolidine 79 from Oxazolidine 76 
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So we changed our plan to open the ring of oxazolidine 79 by a known literature 
procedure40 using cesium carbonate in MeOH at 0 oC to give the free amine 80. The 
reaction for ring opening did not yield the free amine 80, but instead the starting material 
remained unreacted. We increased the temperature but this was not of any help because 
we ended up with multiple spots on TLC suggesting possible decomposition (Figure 
3.30). 
 
 
 
Figure 3.30:-Failed attempt for ring opening of compound 79 
We changed our approach to tackle this problem of ring flipping by using a milder base 
that can form an adduct with the oxide during the intermediate stage i.e. as soon as it is 
formed. We proposed a mechanism for ring opening of oxazolidine 77 with a milder base 
like trimethylsilanolate. The possible reaction mechanism was depicted in figure 3.31. 
 
Figure 3.31:- Proposed mechanism for the ring opening with trimethylsilanolate 
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The reaction mechanism seemed to be reasonable for the fact that by protecting the 
hydroxy group with a trimethylsilanolate reduces the reactivity of the oxide intermediate. 
This in turn prevents the subsequent attack of the urethane by the less reactive oxide 
adduct and prevents elimination of Cbz. We tried the reaction that we discussed above by 
treating oxazolidine 77 with potassium trimethylsilanolate in THF at 0 oC. But the 
reaction did not occur leaving the starting material intact. We wanted to push the reaction 
by refluxing in THF, but this did not help us in achieving the desired product 81. Next we 
used catalytic amount of 18Crown-6 and performed the reaction by refluxing in THF. This 
time we did push the reaction far enough that we ended up with the undesired product 79. 
This is formed due to the unavoidable ring flipping and we had to abandon this route. We 
assumed that our proposed mechanism to avoid ring flipping might be wrong. Instead of 
breaking the C-N bond if C-O bond breaks in the intermediate, then ring flipping is quite 
possible (Refer to figure 3.32). 
 
 
 
 
 
 
 
 
 
Figure 3.32:- Failed reactions for ring opening of oxazolidine 77  
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3.3.1 Effort towards the synthesis of cyclic urea 8 
 Our intention of making the substituted OPGDA’s was to differentiate the two 
geminal amines in terms of their reactivity so that we can achieve the synthesis of the 
cyclic urea moiety 8. We asked ourselves a question “Can we make cyclic urea 8 with out 
OPGDA’s?” To answer that question we wanted to synthesize an aldehyde from the gem-
diamino acid 73 which can undergo a Henry type reaction with our synthesized part-A 
i.e. substituted nitropropionates (NPA’s) discussed in chapter 2. The subsequent 
reduction of the nitro alcohol to an amino alcohol, followed by ring closure potentially 
can lead us to our desired cyclic urea 8. With that intention we synthesized 2,2-Bis-
benzyloxycarbonylamino-propionic acid methyl ester 82 from our previously synthesized 
gem-diamino acid 73 by standard methylation procedure in 90% yield. We were able to 
get a decent crystal structure for this compound 82. There were two patterns of 
crystallization for this molecule and the relationship of one pattern to the other in the 
formation of crystal lattice was reported in Appendix B along with the individual crystal 
structures of these two patterns.  Compound 82 was subjected to reduction with DIBAL 
in THF at -78 oC to yield the (1-Benzyloxycarbonylamino-1-methyl-2-oxo-ethyl)-
carbamic acid benzyl ester 83 in 70% yield (Figure 3.33). 
 
Figure 3.33:- Synthesis of gem-diamino aldehyde 83 
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 We were able to synthesize the aldehyde 83 also from oxidizing the alcohol 75 
with Dess-Martin periodinane according to the literature reported procedure.41 These 
yields were good when compared to the DIBAL reduction of the ester 82.We did a model 
Henry reaction on this aldehyde 83 with nitromethane and DBU as the base to 
deprotonate the nitromethane to generate the carbanion, which in turn attacks the 
carbonyl carbon of the aldehyde resulting (1-Benzyloxycarbonylamino-2-hydroxy-1-
methyl-3-nitro-propyl)-carbamic acid benzyl ester 84 in 70% yield (Figure 3.34). 
Figure 3.34:- Model Henry reaction on 83 with nitromethane 
We failed to reduce this nitro-alcohol 84 to (3-Amino-1-benzyloxycarbonylamino-2-
hydroxy-1-methyl-propyl)-carbamic acid benzyl ester 85 by hydrogenation in the 
presence of catalytic amount of PtO2. Instead the reduction of the nitro group was 
achieved by using 5eq of freshly activated Zinc in acetic acid/THF solvent system at 
room temperature. We obtained the amino-alcohol 85 in 70% yield (Figure 3.35).  
 
 
 
 
 
 
 
 
 
 
Figure 3.35:- Synthesis of amino-alcohol 85 
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 We tried to synthesize the six-membered ring 86, which will be the simplest of 
our novel HIV-1 protease inhibitor building block. We could theoretically achieve the 
cyclic urea 86 by eliminating benzyl alcohol from compound 85 and subsequent ring 
closure to potentially form (5-Hydroxy-4-methyl-2-oxo-hexahydro-pyrimidin-4-yl)-
carbamic acid benzyl ester 86 (Figure 3.36). Several attempts were made in this direction, 
various solvents like 1,4-Dioxane, 1,2-DME, THF and acetone were used at their 
respective reflux temperatures and we were not able to achieve the desired cyclic urea 86. 
In almost all the cases thermal decomposition was observed by noting multiple spots on 
the TLC after the workup or during the reaction itself.  These reactions were closely 
monitored by checking TLC at various time intervals and still we were able to observe 
the decomposition of the starting material. We tried an in situ nitro reduction and 
cyclization by treating the nitro compound 84 with Zn/CH3COOH and immediately 
followed with reflux in 1,4-dioxane. This time also we observed multiple spots on TLC 
after 1 hr and these failed attempts forced us to abandon this route from any further 
exploration. 
 
 
 
 
 
Figure 3.36:- Failed attempts for cyclization 
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this could prevent the subsequent ring closure. We wanted to replace the Cbz protecting 
group on the gem-diamino with a common protecting group like Boc and try our previous 
scheme for the ring closure. We were trying to compare the ease of ring closure with the 
changes in the protecting groups. The proposed scheme for the synthesis of the cyclic 
urea 93 was depicted in figure 3.37 and this is in similar lines with the failed attempt to 
synthesize cyclic urea 86. We hoped that this slight modification may generate the 
desired compound, which was not uncommon in literature where certain reactions work 
better with a change of the protecting group. 
 
 
Figure 3.37:- Proposed scheme for the synthesis of cyclic urea 93  
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So our next step was towards the synthesis of the 2,2-Bis-tert-butoxycarbonylamino-
propionic acid 87 which is exactly similar to that of the gem-diamino compound 73 
except that 87 is a di-Boc version of 73. We tried the rotavap reaction (described 
previously) with t-butyl carbamate 94 and pyruvic acid 71 at 70 oC but we failed to obtain 
the desired product 87 (Figure 3.38). The starting material t-butyl carbamate remained as 
the major impurity along with several other unidentified products. 
 
 
Scheme 3.38:- Failed rotavap reaction for the synthesis of the 87 
 We proposed another strategy for the synthesis of 93 that is shown in figure 3.39. 
This avoids using of the di-Boc compound 87 which could not be synthesized previously. 
Instead we wanted to start with the di-Cbz compound 75 from the previous scheme.  
 
 
 
 
 
 
 
 
Figure 3.39:- Proposed scheme via selective Boc protection  
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According to the new strategy, we wanted to selectively perform a Boc protection on one 
of the Cbz protected amines on the gem-diamino compound 75. This way we could 
achieve the reduction of the nitro and elimination of Cbz group by the standard 
hydrogenation procedures. This will not touch the Boc protected amine. We were not 
able to do this kind of one pot reduction till now because of the potential problem of 
deprotecting both Cbz groups (Refer to figure 3.35). This would have resulted in the 
collapse of the molecule. Even though this strategy seemed reasonable we couldn’t go 
much far in the proposed scheme. We tried to selectively protect one of the Cbz protected 
amines of compound 75 by using 0.5eq of (Boc)2O, 0.5eq of TEA and catalytic amount of 
DMAP. But we ended up in a compound confirmed by NMR to be the Boc- protected 
alcohol. We could not explore this route any further. 
 Since we had an availability of a variety of nitropropionates (from chapter-2), we 
attempted to perform Henry reaction with the gem-diamino aldehyde 83. We attempted 
the nitroaldol condensation several times using the isobutyl nitropropionic acid 16c and 
isobutyl nitropropionate 17c with aldehyde 83 in presence of DBU as the base and THF 
as the solvent. Various reaction conditions were tried without any success to achieve the 
desired nitro-alcohol 99 or 100 and we concluded that it might be due to steric effects 
(Fig 3.40)  
 
 
 
 
Figure 3.40:- Failed attempts of nitroaldol condensation 
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3.3.2 Electrophilic Amination with Oxaziridines 
 We realized that all the routes that we had visited so far were almost in similar 
lines, either the Curtius rearrangement or the racemic route via oxazolidine ring opening.  
But still the task for achieving the substituted OPGDA’s remained at large. We wanted to 
approach this problem from a view that is different from that of the literature reported 
approaches for gem-diamino compounds syntheses. We tried to make a new C-N bond 
that is geminal to an amine or protected amine via electrophilic amination. Electrophilic 
amination is an important synthetic reaction in which electron-poor nitrogen carried by 
the reagent is transferred to a nucleophilic center of the substrate to form a Nu-N bond in 
the product. There were several literature reports on electrophilic amination with 
oxaziridines.42-49 But the one that specifically caught our attention was N-Boc-3-
trichloromethyloxaziridine 104 which was reported for the first time by Vidal et al.50 as a 
versatile and powerful reagent for electrophilic amination. We synthesized 104 following 
their procedures (Figure 3.41). We started with t-Butyl carbazate 101 and reacted it with 
NaNO2 in acetic acid and water at 0 oC for 30 min. The resulting t-butyl azide was 
immediately reacted with triphenylphosphine to yield N-Boc iminophosphorane 102 in 
more than 80% yield. We were able to obtain nice crystals of the compound 102 and the 
crystal structure was reported in the Appendix B.  Compound 102 was treated with 
chloral (a prescription drug in United States), under the reflux conditions of toluene via 
an Aza-Wittig reaction type to yield imine 103 in 95% yield after a vacuum distillation in 
a Kugelrohr apparatus.  The final compound oxaziridine 104 was obtained by oxone 
oxidation of the imine 103. This was very laborious process where the aqueous phase 
along with the consumed oxone® /K2CO3  in the reaction mixture had to be replaced after 
 80
every hour. Apparently there was no visualization technique to monitor if this change was 
really helping or not. We thought if we can make a change in this step, the whole 
synthesis can become more efficient and less time consuming. As mentioned earlier the 
real challenge in monitoring this reaction is lack of visualization technique since neither 
the imine nor the oxaziridine show up on the TLC. We changed various TLC developing 
agents like PMA, iodine, phenol/sulfuric acid, ninhydrin etc but none of them worked. 
We tried to do a model reaction with triflurobenzaldehyde 106 so that we can make an 
imine 107 that can be monitored on TLC for the oxidation with oxone, but the reaction 
between aldehyde 106 and iminophospharane 102 failed (Figure 3.42).  
 
 
 
 
 
 
 
 
 
Figure 3.41:- Scheme for the synthesis of Oxaziridine 104 
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104. If they were left at room temperature unsealed we obtained the hydrolysis product 
105, which was confirmed by comparing with the literature reported melting point. We 
were able to obtain a good crystal structure of this molecule, which was reported in 
Appendix B. This hydrolysis problem was further avoided by storing the oxaziridine 104 
in the freezer at -4 oC  and in a tightly sealed container. 
    
 
 
Figure 3.42:- Failed attempt to synthesize imine 69 
 Our aim behind the synthesis of this oxaziridine was able to use it as an N-Boc 
transfer reagent on α-carbon in an amino acid, so that we can generate the gem-diamino 
compound. Figure 3.43 outlines our proposed synthesis of the substituted OPGDA’s and 
the subsequent ring closure to form the cyclic urea 114. 
 
Figure 3.43:- Proposed synthesis of substituted OPGDA’s via oxaziridine 104 
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base derivative of phenyl alanine methyl ester 110 in 60% yield. The imine derivative 
110 was treated with the oxaziridine 104 in order to transfer the N-Boc on α-carbon to 
that of the imine, but our attempt failed to synthesize the compound 111. We tried to see 
if we can make N-Cbz version of the oxaziridine and use that for the electrophilic 
amination (Figure 3.44). But our efforts towards the synthesis of compound 116 were 
futile. We concluded that the intermediate free amine 115 might be highly unstable and 
not isolable because of its polar nature. We tried in situ Boc deprotection and Cbz 
protection according to literature procedures, but that was not of much help. We 
abandoned the idea of making substituted OPGDA’s via electrophilic amination using 
oxaziridine 104. 
 
Figure 3.44:- Failed attempt to make Cbz version of the oxaziridine 104 
3.3.3 Application of Oxaziridine 104 in α-helix mimics synthesis 
 With an improved synthesis of oxaziridine 104 in terms of overall yield as well as 
efficiency in purification (by Vacuum distillation of the crude product instead of the 
expensive silica gel chromatography done by Vidal et al.), we were able to perform a 
multigram scale synthesis of 104. We did a model study on the effect of solvents on the 
electrophilic amination of diethyl iminodiacetate 117 to synthesize (N'-tert-
Butoxycarbonyl-N-ethoxycarbonylmethyl-hydrazino)-acetic acid ethyl ester 118 and the 
results were tabulated in the figure 3.45. 
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Entry Solvent  Time Temp. % Yield % unreacted
1) CH2Cl2 (5 mL) 12 h -78 oC to r.t. 80% 20% 
2) THF (5 mL) 12 h -78 oC to r.t. 87% 10% 
3) MeOH (5 mL) 12 h -78 oC to r.t. 94% not cal. 
4) CH3CN (5 mL) 12 h -40 oC to r.t. >99% not cal. 
5) EtOAc (5 mL) 12 h -78 oC to r.t. 70% 30% 
6) 5% MeOH in DCM  12 h -78 oC to r.t. 50% 50% 
Figure 3.45:- Solvent effects on the N-Boc transfer on the secondary amine  
 Having this data from this model study had helped us in achieving a crucial step 
in the synthesis of α-helix mimics, which was another project (currently in progress) in 
our lab. Dr. McLaughlin designed α-helix mimics that have drug-like properties and can 
be used in preventing certain protein-protein interactions in a cancerous cell and in turn 
promotes apoptosis. Details regarding this project were discussed elsewhere (refer to 
Stephanie Weiss’s dissertation work).53 The designed “McLaughlin helix”, a 3-
substituted piperazine-2,6-dione repeat units and the retro synthetic analysis of this 
molecule were depicted in Figure 3.46. This helix was built in similar fashion as that of 
“Hamilton helix”54 but a significant consideration was given to answer the aqueous 
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solubility and physiological compatibility issues. Some molecular modeling data was also 
generated in order to support our idea for mimicking the α-helix. 
 
 
 
 
 
 
 
Figure 3.46:- “McLaughlin Helix” and retrosynthetic analysis of 3-substituted 
piperazine-2,6-dione repeat units 
The proposed route for the synthesis of An moiety i.e. hydrazine diacid is shown in figure 
3.47 (details of the scheme are not discussed here). We wanted to use the oxaziridine 104 
as an N-Boc transfer reagent on the secondary amine, which is a key and crucial step for 
the synthesis of the hydrazino diacid. 
Figure 3.47:- Use of Oxaziridine 104 in the key step for the synthesis of the An 
subunit 
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With the intention stated above we tried our synthesis on phenylalanine methylester 119 
as one of the substituents for the An moiety. We took compound 119 and treated with 
DIEA and ethylbromoacetate to yield the N-alkylated product 120, which was further 
treated with the oxaziridine 104 to yield the desired hydrazine 121 in more than 80% 
yield. This was done in order to prove that oxaziridine works as an excellent N-Boc 
transfer reagent in our key step and also to standardize the reaction conditions (Figure 
3.48). 
 
 
 
 
 
 
 
 
Figure 3.48:- Synthesis of Phe-N-Boc-hydrazine in two steps using oxaziridine 104 
3.3.4 Design considerations in the core structural unit of HIV-1 protease inhibitors 
synthesis and Future direction 
 We revised our task to synthesize a much simpler DPU (DiPeptide Unit) subunit 
126 compared to that of the much complex cyclic urea 8. The only difference in this 
change of design is that we don’t need the substituted OPGDA’s as one of our building 
blocks, instead we can use an aldehyde derived from N-Boc aspartic acid β- benzyl ester 
122 (Figure 3.49). We activated the acid 122 with NMM and isobutyl chloroformate to 
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form the ester intermediate and subsequently reduced the intermediate with NaBH4 to 
give the primary alcohol 123 in 80% yield. The primary alcohol 123 was subjected to 
Swern oxidation to yield the required aldehyde 124 in 70% yield. We did a model Henry 
reaction on this aldehyde with nitromethane and DBU as the base to yield the nitro-
alcohol 125 in 50% yield. The future plan would be to reduce the nitro and deprotect the 
Cbz group from the β carboxylic acid in one pot by hydrogenolysis using Pd as the 
catalyst. This would yield the intermediate δ aminoacid. Subsequent ring closure with 
CDI could potentially yield the DPU compound 126. 
 
Figure 3.49:- Synthesis of DPU 126 as the building block for the HIV-1 protease 
inhibitors Library 
3.4 Conclusion 
 In conclusion we can state that various routes for the synthesis of substituted 
OPGDA’s were explored. Some of them are similar to those reported in the literature and 
some that we specifically designed to tailor our needs. Unfortunately none of them have 
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yielded our desired subunit (part-B of cyclic urea 8 moiety) substituted OPGDA’s. But 
all these routes serve as a guideline for the future synthesis of the substituted OPGDA’s 
by others. The decent outcome of this project is the efficient synthesis of versatile N-Boc 
transfer reagent oxaziridine 104, which has a potential application in the synthesis of α-
helix mimics designed by Dr. McLaughlin. 
3.5 Experimental 
 
 
 
Synthesis of 2,4,6-Triisopropyl-benzenesulfonyl azide (68) :- 
To suspension of sodium azide (7.0 g, 109 mmol) in absolute EtOH (60 mL), distilled 
water (~ 50 mL) was added until a clear solution is seen. 2,4,6-Triisopropyl 
benzenesulfonyl chloride 67 (10 g, 33 mmol), dissolved in absolute EtOH (150 mL) was 
added to the above sodium azide solution while stirring. The cloudiness of the reaction 
mixture was cleared by the addition of aqueous EtOH (80%). The reaction mixture was 
stirred for 24 h at room temperature. After that, EtOH was evaporated, and the aqueous 
layer was extracted with Et2O (50 mL). The organic layer was separated and washed with 
brine (30 mL), dried over anhydrous Mg2SO4 (3 g) and evaporated in vacuo to afford a 
pure product 68 as a white solid; Rf = 0.42 (hexane) and mp 42-43 oC (lit. mp 40-42 oC) 
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Synthesis of 2-Azido-2-methyl-malonic acid diethyl ester (62):- 
60% NaH in mineral oil (0.25 g, 6.32 mmol) was washed under argon flow with hexane 
(3 x 5 mL). The resulting free flowing powder of NaH was suspended in 1,2-DME (8 
mL) and was treated with 2-methyl-malonic acid diethyl ester 61 (1 g, 5.75 mmol) drop 
wise. The reaction mixture was heated at 50 oC for 1 h, and a solution of 2,4,6-
Triisopropyl-benzenesulfonyl azide 68 (1.96 g, 6.32 mmol) in minimum amount of 1,2- 
DME was added in portions. The whole reaction mixture was brought to reflux and 
stirred for 12 h. After 12 h starting material was not seen on the TLC plate. The reaction 
mixture was filtered and the filtrate was subjected to evaporation. The residue was 
distributed between H2O (20 mL) and EtOAc (30 mL), and the organic layer was 
subjected to further washing with brine (2 x 10 mL), dried over anhydrous MgSO4 and 
evaporated in vacuo to yield the crude product. This crude residue was subjected to 
column chromatography (1:3 EtOAc/hexane) to give the compound 2-Azido-2-methyl-
malonic acid diethyl ester 62 (0.72 g, 60%) as a pale yellow oil; Rf = 0.62 (1:1 
EtOAc/Hexane); 1H NMR (CDCl3, 250 MHz) δ 1.23-1.29 (t, J =7.5 Hz, 6H), 1.50 (s, 
3H), 4.20-4.29 (q, J = 7.5 Hz, 4H); 13C NMR (CDCl3, 100 MHz) 17.9, 24.3, 66.6, 72.1, 
171.7 ppm; ESI-TOF Calcd for [M+H]+ is 216.09788, Found: 216.09786 
 
 
 
Synthesis of 2-Azido-2-methyl-malonic acid monoethyl ester (63):- 
Commercially available Porcine Liver Esterase (Aldrich) (0.89 g, 17,814 units) was 
weighed and placed immediately in a reaction vessel containing a solution of 2-Azido-2-
N3 COOH
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methyl-malonic acid diethyl ester 62 (3.8 g, 17.8 mmol) in phosphate buffer (158 mL) 
and CH3CN (18 mL) at a pH of 7.5. The reaction mixture was stirred at room temperature 
for 24 h, and then acidified by adding 1N HCl until the pH was equal to 3.0. EtOAc (100 
mL) was added to the reaction mixture and filtered through celite. The organic layer was 
separated from the filtrate and the aqueous layer was extracted with EtOAc (2 x 100 mL). 
Combined organic layers were washed with brine (300 mL), dried on anhydrous Na2SO4 
and evaporated in vacuo to yield the crude compound. The crude product was subjected 
to column chromatography to yield 2-Azido-2-methyl-malonic acid monoethyl ester 63 
(2.7 g, 84%) as a pale yellow oil; Rf = 0.21 (1:3 EtOAc/hexane); 1H NMR (CDCl3, 250 
MHz) δ 1.25-1.32 (t, J = 7.5 Hz, 3H), 1.58 (s, 3H), 4.22-4.35 (q, J = 7.5 Hz, 2H); 13C 
NMR (CDCl3, 62.5 MHz) 13.8, 20.3, 63.1, 68.0, 167.3, 172.9 ppm 
 
 
 
Synthesis of 2-Azido-2-azidocarbonyl-propionic acid ethyl ester (64): - 
To a solution of 2-Azido-2-methyl-malonic acid monoethyl ester 63 (1.1 g, 5.9 mmol) in 
anhydrous THF (20 mL) at -20 oC, was added NMM (0.6 g, 5.9 mmol) followed by 
isobutylchloroformate (0.8 g, 5.9 mmol). The reaction mixture was stirred at -20 oC for 2 
h, until the starting material disappeared on the TLC. After which it was filtered through 
celite, and the filtrate was brought to -20 oC and NaN3 (0.96 g, 14.7 mmol) was added 
while stirring. After 3 h, brine (50 mL) was added to the reaction mixture and the organic 
layer was separated and extracted again with EtOAc (50 mL). The combined organic 
layers were subjected to drying on anhydrous Na2SO4 and evaporated in vacuo until 
N3 COOEt
H3C CON3
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minimum amount of solvent was left.a A minimum amount of this product was taken for 
the characterization and the rest of the material was forwarded to the next step. Rf = 0.65 
(1:4 EtOAc/hexane); 1H NMR (CDCl3, 250 MHz) δ 1.24-1.30 (t, J= 7.5 Hz, 3H), 1.49 (s, 
3H), 4.21-4.29 (q, J= 7.5 Hz, 2H); 13C NMR (CDCl3, 62.5 MHz) 14.2, 20.7, 63.5, 69.6, 
167.3, 175.3 ppm aNOTE: - Complete evaporation of solvent is not recommended 
because of the highly unstable and explosive nature of acylazides.  
 
 
 
Synthesis of 2-Azido-2-tert-butoxycarbonylamino-propionic acid ethyl ester (65):-  
To a solution of 2-Azido-2-azidocarbonyl-propionic acid ethyl ester 64 (0.6 g, 2.83 
mmol) in t-BuOH (10 mL) catalytic amount of Rh2(OAc)4 (3.0 mg) was added and was 
refluxed at 80 oC. After 1 h, t-BuOH was evaporated and EtOAc (10 mL) was added to 
the residue and filtered. The filtrate was evaporated in vacuo while the rotavap 
temperature was maintained at 30 oC. The product obtained was characterized without 
any further purification. Obtained a colorless oil; Rf = 0.32 (1:4 EtOAc/hexane); 1H NMR 
(CDCl3, 250 MHz) 1.27-1.32 (t, J= 7.0 Hz, 3H), 1.42 (s, 9H), 1.63 (s, 3H), 4.25-4.30 (m, 
2H), 5.72 (br s, 1H); 13C NMR (CDCl3, 62.5 MHz) 14.4, 21.4, 28.4, 60.8, 63.1, 74.1, 
154.2, 169.5 ppm 
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Synthesis of 2-Azido-2methyl-(R)-(+)-N-(1-phenyl-ethyl)-malonamic acid ethyl ester 
(70):- 
 To a solution of HOBT (0.04 g, 0.30 mmol), HATU (0.12 g, 0.30 mmol), DIEA (47 µL, 
0.30 mmol) in 5 mL of DCM / DMF solvent system (2:1), was added 2-Azido-2-methyl-
malonic acid monoethyl ester 63 (0.05 g, 0.27 mmol) and the chiral amine (R)-(+)-1-
phenylethylamine 69 (62 µL, 0.30 mmol) and stirred at room temperature for 12 h. 
EtOAc (5 mL) was added to the reaction mixture and washed with brine (2 x 5 mL) to 
remove DMF. The organic layer was separated, dried on anhydrous Na2SO4 and 
evaporated in vacuo to yield the pure compound 2-Azido-2methyl-(R)-(+)-N-(1-phenyl-
ethyl)-malonamic acid ethyl ester 70 (0.055 g, 77%) as a pale yellow oil; Rf = 0.61 (1:4 
EtOAc/hexane); 1H NMR (CDCl3, 250 MHz) δ 1.20-1.26 (t, J = 7.5 Hz, 3H), 1.50-1.53 
(d, J = 7.5 Hz, 3H), 1.78 (s, 3H), 4.18- 4.26 (q, J =7.5 Hz, 2H), 5.03- 5.15 (p, J = 7.5 Hz, 
1H), 7.30-7.37 (m, 5H); 13C NMR (CDCl3, 62.5 MHz) 14.3, 20.3, 22.0, 49.5, 63.2, 69.2, 
126.4, 127.8, 129.0, 129.2, 142.8, 166.2 ppm; ESI-TOF Calcd for [M+H]+ is 291.14517, 
Found: 291.14518 
 
 
Synthesis of 2,2-Bis-benzyloxycarbonylamino-propionic acid (73) :- 
To a round bottom flask add benzyl carbamate 72 (15.5 g, 102 mmol) and pyruvic acid 
71 (3.9 mL, 56.8 mmol) and rotavap the reaction mixture. The temperature of the water 
bath was maintained at 70 oC for 2 h, and then dissolved the reaction mixture in excess 
ethyl acetate (200 mL). Organic layer was washed with cold distilled H2O (2 x 100 mL) 
in order to get rid of unreacted pyruvic acid. Hexane was added slowly to the organic 
NHCbzCbzHN
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layer until a clean white precipitate was obtained. Filtered the suspension to obtain 2,2-
Bis-benzyloxycarbonylamino-propionic acid 73 (16.8 g, 80%) as a white solid; Rf = 0.4 
(1:1 EtOAc/hexane); mp 137-139 oC (lit. mp 139 oC); 1H NMR (CD3OD, 250 MHz) δ 
1.78 (s, 3H), 5.04 (s, 4H), 7.30-7.35 (m, 10H); 13C NMR (CD3OD, 100 MHz) 21.1, 64.6, 
65.7, 125.9, 126.2, 126.6, 135.2, 153.6, 171.0 ppm; ESI-TOF Calcd for [M+Na]+ is 
395.12136, Found: 395.12112 
 
 
 
Synthesis of 2,2-Bis-benzyloxycarbonylamino-propionic acid 2,5-dioxo-pyrrolidin-1-
yl ester (74) : - 
To a solution of acid 73 (4.23 g, 11.4 mmol) in dry DCM (30 mL) were added N-hydroxy 
succinamide (1.30 g, 11.4 mmol) and EDCl (2.17 g, 11.4 mmol) while stirring at 0 oC and 
maintained at 0 oC for 1 h. After which the reaction mixture was brought to room 
temperature and further stirred for 5 h, and the washed with H2O (2 x 25 mL). DCM layer 
was separated, washed with brine (3 x 50 mL), dried over anhydrous MgSO4 and was 
evaporated in vacuo to give pale yellow oil. The crude product was subjected to column 
chromatography (1:1 EtOAc/hexane) to give the compound 74 (4.9 g, 92%) as a pale 
yellow oil; Rf = 0.54; 1H NMR (CDCl3, 250 MHz) δ 1.91 (s, 3H), 2.71 (s, 4H), 5.00 (s, 
4H), 6.39 (br s, 2H), 7.23-7.39 (m, 10H); 13C NMR (CDCl3, 100 MHz) 20.9, 21.2, 25.5, 
60.7, 67.4, 128.4, 128.5, 128.7, 128.8, 136.1, 158.1, 172.8, 176.0, 176.5 ppm; ESI-TOF 
Calcd for [M+Na]+ is 492.13774, Found: 492.13719 
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Synthesis of (1-Benzyloxycarbonylamino-2-hydroxy-1-methyl-ethyl)-carbamic acid 
benzyl ester (75): -  
To a solution of N-hydroxy succinamide derivative 74 (4.9 g, 10.5 mmol) in anhydrous 
THF (25 mL), NaBH4 (0.8 g, 21 mmol) was added while stirring at 0 oC. The reaction 
mixture was stirred for 1 h at 0 oC and then brought to room temperature and further 
stirred for 24 h, after which it was quenched with 10% KHSO4 solution (20 mL). THF 
was evaporated and the aqueous layer was extracted with DCM (3 x 100 mL), and the 
combined organic layers were washed with brine (2 x 100 mL), dried over anhydrous 
MgSO4 and evaporated in vacuo to yield a pale yellow solid product. The crude product 
was recrystallised from DCM/hexane to yield pure compound 75 (2.63 g, 71%) as a white 
solid; Rf = 0.70 (1:1 EtOAc/hexane); mp 102-105 oC; 1H NMR (CDCl3, 400 MHz) δ 1.57 
(s, 3H), 3.73 (s, 2H), 5.04 (s, 4H), 5.17 (br s, 1H), 6.29 (br s, 2H), 7.32-7.36 (m, 10H); 
13C NMR (CDCl3, 100 MHz) 25.3, 67.0, 67.3, 68.8, 128.2, 128.4, 128.7, 136.2, 155.8 
ppm; ESI-TOF Calcd for [M+Na]+ is 381.14209, Found: 381.14198 
 
 
 
Synthesis of (4-Methyl-2-oxo-oxazolidin-4-yl)-carbamic acid benzyl ester (76):- 
Alcohol 75 (2.63 g, 7.35 mmol) from the previous step was dissolved in anhydrous THF 
(30 mL) and was cooled to -78 oC while stirring under argon atmosphere. To the above 
solution, KOtBu solution (9.0 mL from stock 1M 50 mL THF, 8.97 mmol) was added in 
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one portion and was allowed to stirred for 10 min after which the reaction was warmed to 
room temperature and stirred for 1 h. Reaction was quenched with 10% NH4Cl solution 
(10 mL), THF was evaporated and the aqueous layer was extracted with DCM (3 x 30 
mL). The combined organic layers were washed with 0.1N HCl (2 x 10 mL), followed by 
brine wash (2 x 50 mL), dried over anhydrous MgSO4 and evaporated in vacuo to yield 
the crude product as yellow oil. Recrystallization in DCM/hexane yielded pure compound 
76 (1.38 g, 75%) as a white solid; Rf = 0.21 (1:1 EtOAc/hexane); mp 125-128 oC; 1H 
NMR (CDCl3, 400 MHz) δ 1.64 (s, 3H), 4.16-4.19 (d, J = 9.6 Hz, 1H), 4.51-4.54 (d, 9.2 
Hz, 1H), 5.09 (s, 2H), 7.30-7.36 (m, 5H); 13C NMR (CDCl3, 100 MHz) 26.0, 66.9, 69.3, 
75.4, 128.2, 128.3, 128.6, 135.9, 154.9, 158.6 ppm; ESI-TOF Calcd for [M+H]+ is 
251.10263, Found: 251.10272 
 
 
 
4-Benzyloxycarbonylamino-4-methyl-2-oxo-oxazolidine-3-carboxylic acid tert-butyl 
ester (77):- 
Oxazolidine 76 (1.36 g, 5.44 mmol), DMAP (0.013 g, 0.10 mmol), TEA (0.9 mL, 6.53 
mmol) were dissolved in anhydrous THF (20 mL) and was cooled down to 0 oC. A 
solution of tert-butyl chloroformate (1.25 g, 5.71 mmol) in anhydrous THF (5 mL) was 
added to the above mixture under argon atmosphere, while stirring over a period of 15 
min. The reaction temperature was maintained between 5 oC to 10 oC for 3 h and then the 
reaction mixture was quenched with 0.001 mmol solution of KHSO4 (5 mL). THF was 
evaporated to leave a white suspension which was dissolved in EtOAc (100 mL) and was 
O
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washed with 10% KHSO4 solution (20 mL), dried over anhydrous Na2SO4 and 
evaporated in vacuo to yield Boc protected oxazolidine 77 (1.9 g, 99%) as pure white 
solid; Rf = 0.82 (4:1 EtOAc/hexane); mp 131 – 134 oC; 1H NMR (CDCl3, 400 MHz) δ 
1.50 (s, 9H), 1.77 (s, 3H), 4.11-4.14 (d, J = 9.6 Hz, 1H), 4.67-4.69 (d, J = 8.8 Hz, 1H), 
5.09-5.12 (d, J = 10.8 Hz, 2H), 5.69 (br s, 1H), 7.32-7.36 (m, 5H); 13C NMR (CDCl3, 100 
MHz) 27.9, 67.1, 71.6, 71.9, 84.5, 128.3, 128.4, 128.5, 128.6, 135.6, 149.1, 151.1, 154.2 
ppm; ESI-TOF Calcd for [M+NH4]+ is 368.18161, Found: 368.18129 
 
 
 
Synthesis of (4-Methyl-2-oxo-oxazolidin-4-yl)-carbamic acid tert-butyl ester (79): - 
Boc protected Oxazolidine 77 (1.0 g, 2.86 mmol) from the previous step was dissolved in 
anhydrous THF (20 mL) and was cooled to -78 oC. Phase transfer catalyst, BTAH (1.3 
mL of 40% w/v methanolic solution, 3.15 mmol) was added to the above solution drop 
wise, while stirring under argon atmosphere and was allowed to stir for 6 h, and then 
warmed to 40 oC, CH3COOH (1 mL) and distilled H2O (1.5 mL) were added to the 
reaction mixture and stirred for 30 min, after which the organic solvents were evaporated 
to leave behind a white residue that was dissolved in EtOAc (100 mL). Organic layer was 
washed with 10% KHSO4 solution (20 mL) followed by brine (2 x 30 mL), dried over 
anhydrous Na2SO4 and evaporated in vacuo to yield the deprotected oxazolidine 79 (0.21 
g, 23%) as a pure white solid; Rf = 0.26 (1:1 EtOAc/hexane); mp 99 – 102 o C; 1H NMR 
(CDCl3, 400 MHz) δ 1.44 (s, 9H), 1.66 (s, 3H), 4.18-4.20 (d, J = 8 Hz, 1H), 4.41-4.43 (d, 
J = 8.1 Hz, 1H), 5.18 (br s, 1H), 6.15 (br s, 1H); 13C NMR (CDCl3, 100 MHz) 26.8, 28.5, 
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69.3, 75.7, 81.3, 154.4, 158.6 ppm; ESI-TOF Calcd for [M+H]+ is 217.11828, Found: 
217.11801 
 
 
Synthesis of 2,2-Bis-benzyloxycarbonylamino-propionic acid methyl ester (82):- 
To a solution of di-Cbz acid 73 (0.2 g, 0.54 mmol) in dry DMF (1 mL) at -5 oC, 
powdered anhydrous K2CO3 (0.09 g, 0.65 mmol) was added slowly while stirring. To the 
above solution CH3I (40 µL, 0.65 mmol) was added while stirring, then the reaction was 
brought to room temperature and stirred for 1 h. Reaction mixture was washed with 
distilled H2O (5 mL) and then extracted with EtOAc (2 x 5 mL). The combined organic 
layers were washed with brine (2 x 10 mL), dried over anhydrous sodium sulfate and 
evaporated in vacuo to yield methyl ester of di-Cbz acid 82 (0.15 g, 75%) as a pure white 
solid; Rf = 0.72 (1:1 EtOAc/hexane); mp 93 – 96 oC; 1H NMR (CDCl3, 250 MHz) δ 1.81 
(s, 3H), 3.75 (s, 3H), 5.071 (s, 4H), 6.70 (br s, 2H), 7.22-7.32 (m, 10H); 13C NMR 
(CDCl3, 62.5 MHz) 23.6, 53.5, 66.7, 67.4, 127.9, 128.1, 128.4, 136.0, 154.5, 171.1 ppm; 
ESI-TOF Calcd for [M+H]+ is 387.15506, Found: 387.15476 
 
 
 
Synthesis of (1-Benzyloxycarbonylamino-1-methyl-2-oxo-ethyl)-carbamic acid 
benzyl ester (83):- 
A solution of the di-Cbz alcohol 75 (0.1 g, 0.28 mmol) in anhydrous DCM (5 mL) was 
cooled down to -10 oC and then DMP (0.13 g, 0.308 mmol) was added while stirring. 
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After 3 h, the reaction was quenched with equal volume of 10% Na2S2O solution (2 mL) 
and 10% NaHCO3 solution (2 mL). The organic layer was separated and washed with 
brine (10 mL), dried over anhydrous MgSO4 and evaporated in vacuo to yield a crude 
residue. The crude product was subjected to column chromatography (1:1 EtOAc/hexane) 
to yield the pure product as a white solid (0.05 g, 50%) and also unreacted starting 
material (0.03 g, 30%); Rf = 0.82 (1:1 EtOAc/hexane); mp 80 – 83 oC; 1H NMR (CDCl3, 
400 MHz) δ 1.63 (s, 3H), 5.07 (s, 4H), 6.31 (br s, 2H), 7.32-7.36 (m, 10H), 9.26 (s, 1H); 
13C NMR (CDCl3, 100 MHz) 20.9, 67.3, 70.0, 128.3, 128.5, 128.8, 135.9, 155.2, 192.7 
ppm; ESI-TOF Calcd for [M+H]+ is 357.14450, Found: 357.14464 
 
 
 
Synthesis of (1-Benzyloxycarbonylamino-2-hydroxy-1-methyl-3-nitro-propyl)-
carbamic acid benzyl ester (84):- 
Nitromethane (0.2 mL) and DBU (0.4 mL) were stirred at 0 oC for 15 min. After which 
the aldehyde 83 (0.2 gm, 0.56 mmol) in 1 mL of anhydrous THF was added to the above 
solution while stirring vigorously at 0 oC. The reaction mixture was stirred for 12 hr at 
which the temperature was slowly brought to room temperature. Reaction mixture was 
quenched with 2 mL of saturated NaHCO3 solution. The aqueous layer was extracted 
with 10 mL of ethyl acetate, washed with brine, dried over anhydrous Na2SO4 and 
evaporated in vacuo to yield crude product as yellow oil. The crude product was 
subjected to column chromatography (2:5 EtOAc/hexane) to obtain the pure compound 
nitro alcohol 84 as a colorless oil; Rf = 0.36 (1:4 EtOAc/hexane); 1H NMR (CDCl3, 400 
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MHz) δ 1.25 (s, 3H), 4.22 – 4.24 (m, 1H), 4.55 – 4.61 (dd, J = 14.4 Hz, 6.8 Hz, 1H), 4.70 
(br s, 1H), 4.74 – 4.79 (dd, J = 14.4 Hz, 4.4 Hz, 1H), 5.05 (s, 2H), 5.10 (s, 2H), 6.02 (br s, 
1H), 7.30 – 7.38 (m, 10H); 13C NMR (CDCl3, 100 MHz) 21.9, 29.7, 42.9, 66.9, 67.2, 
73.8, 128.1, 128.2, 128.4, 128.5, 128.6, 135.5, 136.2, 154.7 ppm; ESI-TOF Calcd for 
[M+Na]+ is 440.14282, Found: 440.14261 
Synthesis of N-Boc-Triphenyliminophosphorane (102):- 
To a solution of t-butyl carbazate 101 (47.0 g, 0.35 mol) in CH3COOH (145 mL) and 
H2O (290 mL) cooled to 0 oC was added NaNO2 (27.0 g) in portions over 15 min. The 
solution was stirred for 30 min at 0 oC, then extracted with Et2O (3 x 200 mL). The 
combined organic layers were washed with H2O (300 mL), quickly with sat. aq. NaHCO3 
(200 mL), brine (200 mL), and dried over anhydrous Na2SO4. This solution was directly 
used in the next step. CAUTION: To avoid risks of explosion, did not warm the ethereal 
solution of the azide and did not concentrate to dryness! The ether solution of the N-Boc-
azide was cooled to 0 oC, and PPh3 (93.3 g, 0.35 mol) was added in small portions while 
stirring. Strong evolution of nitrogen occurred during the addition of triphenylphosphine. 
The cooling bath was then removed and the reaction stirred for 30 min at r.t. The formed 
white precipitate was filtered, washed with Et2O and dried in vacuo to yield N-Boc-
Triphenyliminophosphorane 102 (109.1 g, 81%); Rf = 0.52 (1:1 EtOAc/hexane); mp 145 
- 148 oC (lit. mpref-2 148 oC); 1H NMR (CDCl3, 400 MHz) δ 1.37 (s, 9H), 7.44-7.48 (m, 
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6H), 7.53-7.58 (m, 3P), 7.71-7.74 (m, 6H); 13C NMR (CDCl3, 100 MHz) 28.5, 128.6, 
128.7, 132.3, 133.2, 133.3 ppm; ESI-TOF Calcd for [M+H]+ is 378.16174, Found: 
378.16161 
 
 
Synthesis of t-Butyl 2,2,2-Trichloro-ethylidenecarbamate (103):-  
A mixture of anhydrous chloral (14.2 mL, 146 mmol) and N-Boc-
Triphenyliminophosphorane 102 (50.0 g, 132.6 mmol) in dry toluene (120 mL) was 
refluxed for 1 h under Ar. After evaporation of toluene in vacuo, Ph3PO was precipitated 
by the addition of dry hexane (100 mL) and filtered off. Evaporation of the filtrate gave 
crude 103 (34 g), which upon vacuum distillation in a Kugelrohr apparatus yielded t-
Butyl 2,2,2-Trichloro-ethylidenecarbamate 103 (31.1 g, 95%) as a pure white solid; mp 
55 – 58 oC (lit. mp 58 oC); 1H NMR (CDCl3, 400 MHz) δ 1.57 (s, 9H), 8.08 (s, 1H); 13C 
NMR (CDCl3, 100 MHz) 27.8, 84.5, 92.9, 159.0, 161.1 ppm; ESI-TOF Calcd for [M+H]+ 
is 245.98499, Found: 245.98529 
 
 
Synthesis of 3-Trichloromethyl-oxaziridine-2-carboxylic acid tert-butyl ester (104):- 
A solution of oxone (70 g) in chilled water (700 mL) was added at 0 oC to a vigorously 
stirred mixture of the pure t-Butyl 2,2,2-Trichloro-ethylidenecarbamate 103 (33.0 g, 
133.9 mmol) in CHCl3 (350 mL), K2CO3 (55 g) and water (400 mL).  After stirring 1 h, 
the aqueous phase was discarded and replaced by fresh solutions of K2CO3 and oxone. A 
total of 8 such cycles was performed. The organic phase was (3 x) washed with water, 
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dried on MgSO4 and concentrated in vacuo (bath temp. < 30 oC) to yield the crude 104 
(34 g). Kugelrohr vacuum distillation of 104 (20 g) gave the pure oxaziridine as a stench 
and colorless oil (15 g, 75%); 1H NMR (CDCl3, 400 MHz) δ 1.55 (s, 9H), 4.95 (s, 1H); 
13C NMR (CDCl3, 100 MHz) 27.7, 81.2, 87.1, 93.8, 158.1 ppm 
 
 
 
t-Butyl 2,2,2-Trichloro-1-hydroxy-ethylcarbamate (105): - 
White solid, mp 151 – 154 oC (lit mp 154 oC); 1H NMR (CDCl3, 400 MHz) δ 1.50 (s, 
9H), 5.48 – 5.50 (d, J = 8Hz, 1H), 5.83 – 5.85 (m, 1H); 13C NMR (CDCl3, 100 MHz) 
28.4, 81.8, 87.4, 99.0, 154.0 ppm 
 
 
Synthesis of Methyl N-(diphenylmethylene)-L-phenylalaninate (110):- 
L-phenylalanine methyl ester HCl salt 108 (0.1 g, 0.46 mmol) and an equimolar quantity 
of benzophenone imine 109 (70 µL, 0.46 mmol) were stirred at room temperature for 24 
h with the exclusion of moisture (CaCl2 tube). The reaction mixture was filtered to 
remove NH4Cl and evaporated to dryness on a rotary evaporator. The residue was taken 
up in 20 mL of ether, filtered, washed with 20 mL of water, dried over anhydrous 
MgSO4, and evaporated in vacuo to yield a crude product. Column chromatography (1:9 
EtOAc/hexane) was performed on the crude to yield Methyl N-(diphenylmethylene)-L-
phenylalaninate 110 (0.14 g, 88%) as a colorless oil; Rf =0.45 (1:9 EtOAc/hexane); IR 
(cm-1) 1732, 1617; 1H NMR (CDCl3, 400 MHz) δ 3.12 – 3.20 (dd, J = 16.0 Hz, 8.0 Hz, 
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1H), 3.24 – 3.30 (dd, J = 16.0 Hz, 8.1 Hz, 1H), 4.22 – 4.28 (q, J = 16.1 Hz, 8.0 Hz, 1H), 
6.55 (br s, 2H), 6.95 – 7.07 (m, 2H), 7.12 – 7.20 (m, 3H), 7.21 – 7.39 (m, 6H), 7.53 – 
7.58 (m, 2H); 13C NMR (CDCl3, 100 MHz) 39.7, 52.2, 67.2, 126.3, 127.5, 127.9, 128.1, 
128.3, 128.7, 129.8, 130.2, 136.0, 137.8, 139.3, 170.8, 172.2 ppm 
 
 
 
Synthesis of (N'-tert-Butoxycarbonyl-N-ethoxycarbonylmethyl-hydrazino)-acetic 
acid ethyl ester (118): - 
To a solution of diethyl iminodiacetate 117 (0.15 g, 0.53 mmol) in anhydrous DCM (5 
mL) at -78 oC was added 3-Trichloromethyl-oxaziridine-2-carboxylic acid tert-butyl ester 
104(0.15 g, 0.58 mmol) and stirred for 24 h during which it was brought to r.t. The 
solvent was evaporated and the crude product was subjected to column chromatography 
(1:1 EtOAc/hexane) to yield the pure (N'-tert-Butoxycarbonyl-N-ethoxycarbonylmethyl-
hydrazino)-acetic acid ethyl ester 118 (0.12 g, 80%) as a colorless oil; Rf = 0.66 (1:1 
EtOAc/hexane); 1H NMR (CDCl3, 400 MHz) δ 1.26 – 1.299 (t, J = 6.8 Hz, 3H), 1.44 (s, 
9H), 3.81 (s, 4H), 4.16 – 4.21 (q, J = 14.4 Hz, 7.2 Hz, 4H), 6.88 (br s, 1H); 13C NMR 
(CDCl3, 100 MHz) 14.3, 28.5, 57.4, 61.2, 66.0, 158.1, 170.1 ppm 
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Synthesis of 2-(Ethoxycarbonylmethyl-amino)-3-phenyl-propionic acid methyl ester 
(120):- 
To a suspension of Phenylalanine methyl ester HCl salt 119 (0.85 g, 3.94 mmol) in 
anhydrous CH3CN (15 mL) was added DIEA (2.6 mL, 15.76 mmol) while stirring under 
argon atmosphere, after the complete addition of the DIEA the suspension becomes clear 
solution. The reaction mixture was allowed to stir for 15 min, after which ethyl 
bromoacetate (0.65 mL, 5.91 mmol) was added drop wise to the above solution, and left 
stirring at room temperature overnight. Reaction mixture was quenched with 50% citric 
acid solution (5 mL) and was extracted with EtOAc (25 mL), separated organic layer was 
washed with brine (2 x 20 mL), dried over anhydrous MgSO4, evaporated in vacuo to 
yield the crude residue. Column chromatography (1:4 EtOAc/hexane) was performed to 
yield 2-(Ethoxycarbonylmethyl-amino)-3-phenyl-propionic acid methyl ester 120 (0.78 g, 
75%) as a colorless oil; Rf = 0.45 (1:4 EtOAc/hexane); 1H NMR (CDCl3, 400 MHz) δ 
1.20 – 1.24 (t, J = 6.8 Hz, 3H), 2.05 (br s, 1H), 2.93 – 3.01 (ddd, J = 13.6 Hz, 7.2 Hz, 
2H), 3.29 – 3.42 (d, J = 16.8 Hz,  2H), 3.57 – 3.61 (t, J = 6.4 Hz, 1H), 3.65 (s, 3H), 4.10 – 
4.15 (q, J = 14.8 Hz, 7.2 Hz, 2H), 7.18 – 7.30 (m, 5H); 13C NMR (CDCl3, 100 MHz) 
14.3, 39.7, 49.3, 52.0, 61.0, 62.3, 127.0, 128.7, 129.4, 137.1, 171.8, 174.2 ppm; ESI-MS  
267.1[M+H]+, 266.1 [M+] 
 
 
 
 
N
Ph
O
O
O
O
NH
Boc
 103
Synthesis of 2-(N'-tert-Butoxycarbonyl-N-ethoxycarbonylmethyl-hydrazino)-3-
phenyl-propionic acid methyl ester (121):- 
To a solution of 2-(Ethoxycarbonylmethyl-amino)-3-phenyl-propionic acid methyl ester 
120 (0.05 g, 0.19 mmol) in anhydrous DCM (5 mL) at -78 oC was added 3-
Trichloromethyl-oxaziridine-2-carboxylic acid tert-butyl ester 104 (0.06 g, 0.23 mmol) 
and stirred for 24 h during which it was brought to r.t. The solvent was evaporated and 
the crude product was subjected to column chromatography (1:1 EtOAc/hexane) to yield 
the pure 2-(N'-tert-Butoxycarbonyl-N-ethoxycarbonylmethyl-hydrazino)-3-phenyl-
propionic acid methyl ester 121 (0.05 g, 78%) as a colorless oil; Rf = 0.78 (1:1 
EtOAc/hexane); 1H NMR (CDCl3, 400 MHz) δ 1H NMR (CDCl3, 400 MHz) δ 1.21 – 
1.25 (t, J = 6.8 Hz, 3H), 1.44 (s, 9H), 2.95 – 3.07 (dd, J = 13.2 Hz, 7.0 Hz, 1H), 3.14-3.18 
(dd, J = 13.0 Hz, 6.8 Hz, 1H), 3.55 (s, 2H), 3.61 – 3.80 (m, 3H), 4.09 – 4.15 (q, J = 13.2 
Hz, 7.6 Hz, 2H), 6.95 (br s, 1H), 7.18 – 7.28 (m, 5H); 13C NMR (CDCl3, 100 MHz) 15.1, 
28.5, 36.6, 51.1, 61.2, 69.5, 127.8, 128.1, 128.9, 137.2, 172.1 ppm; ESI-MS 403.1 
[M+Na]+ 
 
 
Synthesis of 3-tert-Butoxycarbonylamino-4-hydroxy-butyric acid benzyl ester (123):- 
To a solution of N-Boc-L- aspartic acid β-benzyl ester 122 (5.0 g, 15.5 mmol) in 
anhydrous THF (40 mL) at -20 oC was added NMM (6.8 mL, 62 mmol) followed by 
isobutyl chloroformate (2.1 mL, 16.3 mmol) and stirred vigorously for 10 min, after 
which a suspension of NaBH4 (1.0 g, 26.4 mmol) in THF (40 mL) and MeOH (10 mL) 
was added to the above mixture at -78 oC. The reaction mixture was stirred for 2 h at -78 
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oC, and then quenched with 10% HCl solution (20 mL) and further diluted with EtOAc 
(100 mL), washed with sat. NaHCO3 solution (50 mL) and followed by brine (2 x 50 
mL). The organic layers were separated, dried over anhydrous Na2SO4, evaporated in 
vacuo to yield the crude residue. Column chromatography (1:5 EtOAc/hexane) of the 
crude residue yielded 3-tert-Butoxycarbonylamino-4-hydroxy-butyric acid benzyl ester 
123 (3.95 g, 83%) as a white solid; Rf = 0.20 (1:9 EtOAc/hexane); mp 54 – 57 oC; 1H 
NMR (CDCl3, 400 MHz) δ 1.42 (s, 9H), 2.21 (br s, 1H), 2.66 – 2.68 (d, J = 5.6 Hz, 2H), 
3.68 – 3.69 (d, J = 4.4 Hz, 2H), 3.98 – 4.01 (m, 1H), 5.12 (s, 2H), 5.21 (br s, 1H), 7.30 – 
7.38 (m, 5H); 13C NMR (CDCl3, 100 MHz) 28.5, 36.2, 49.6, 64.6, 66.8, 128.4, 128.5, 
128.8, 135.7, 156.0, 171.8 ppm; ESI-TOF Calcd for [M+Na]+ is 332.14684, Found: 
332.14690  
 
 
Synthesis of 3-tert-Butoxycarbonylamino-4-oxo-butyric acid benzyl ester (124):-  
To a solution of oxalyl chloride (2.4 mL, 27.1 mmol) in anhydrous DCM (20 mL) at -78 
oC, dry DMSO (4.0 mL) was added and stirred for 10 min. 3-tert-Butoxycarbonylamino-
4-hydroxy-butyric acid benzyl ester 123 (3.5 g, 11.3 mmol) dissolved in dry DCM (25 
mL) was added to the above solution slowly over a period of 5 min, and stirred 
vigorously for 15 min at -78 oC. TEA (14 mL, 101.7 mmol) was added to the above 
reaction mixture slowly and stirred further for 30 min at the same temperature after which 
the reaction mixture was brought to r.t. and stirred for 2 h. The reaction was quenched 
with 10% citric acid solution (20 mL), the organic layer was separated washed with 
distilled water (50 mL), brine (2 x 50 mL), dried over anhydrous MgSO4, evaporated in 
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vacuo to obtain crude product. The crude product was purified by recrystallization 
(DCM/hexane) to yield 3-tert-Butoxycarbonylamino-4-oxo-butyric acid benzyl ester 124 
(2.4 g, 70%) as a white solid; mp 74 – 77 oC ; 1H NMR (CDCl3, 400 MHz) δ 1.39 (s, 9H), 
2.77 – 2.83 (dd, J = 17.2 Hz, 5.2 Hz, 1H), 2.94 – 2. 98 (dd, J = 17.6 Hz, 5.2 Hz, 1H), 4.28 
– 4.31 (m, 1H), 5.05 (s, 2H). 5.48 – 5.56 (d, J = 8.4 Hz, 1H), 7.25 – 7.31 (m, 5H), 9.57 (s, 
1H); 13C NMR (CDCl3, 100 MHz) 28.4, 34.7, 56.2, 67.2, 80.8, 128.5, 128.7, 128.8, 
135.4, 155.7, 171.3, 199.3 ppm; ESI-TOF Calcd for [M+Na]+ is 330.13119, Found: 
330.13091       
 
 
 
Synthesis of 3-tert-Butoxycarbonylamino-4-hydroxy-5-nitro-pentanoic acid benzyl 
ester (125):- 
To a solution of 1M TBAF solution in THF (0.46 mL, 0.44 mmol) cooled to 0 oC, 2 mL 
of dry THF and nitromethane (0.03 mL, 0.5 mmol) were added and stirred for 5 min. 
After which the aldehyde from the previous step, 3-tert-Butoxycarbonylamino-4-oxo-
butyric acid benzyl ester 124 (0.1 g, 0.33 mmol) dissolved in 3 mL of dry THF was added 
to the above solution while stirring at 0 oC and maintained for 20 min. The reaction 
mixture was poured onto sat. NaHCO3 solution (10 mL) and was extracted with Et2O (3 x 
20 mL). The combined organic layers were washed with brine (2 x 25 mL), dried over 
anhydrous MgSO4, evaporated in vacuo to yield the crude product. Column 
chromatography (2:5 EtOAc/hexane) of the crude to yield 3-tert-Butoxycarbonylamino-
4-hydroxy-5-nitro-pentanoic acid benzyl ester 125 (0.06 g, 50%) as a colorless oil; Rf = 
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0.33 (2:5 EtOAc/hexane); 1H NMR (CDCl3, 400 MHz) δ 1.42 (s, 9H), 2.73 – 2.76 (m, 
1H), 4.02 – 4.16 (m, 1H), 4.45 – 4.49 (m, 2H), 4.69 (s, 2H), 5.13 – 5.14 (d, J = 4.8 Hz, 
2H), 7.34 – 7.37 (m, 5H); 13C NMR (CDCl3, 100 MHz) 28.4, 37.0, 49.6, 65.4, 67.1, 69.7, 
79.0, 127.2, 127.8, 128.6, 128.7, 128.9, 135.5, 156.0, 171.3 ppm;  ESI-TOF Calcd for 
[M+Na]+ is 391.14757, Found: 391.14727  
 
 
Synthesis of (3-Amino-1-benzyloxycarbonylamino-2-hydroxy-1-methyl-propyl)-
carbamic acid benzyl ester (85):- 
To a solution of nitroalcohol 84 (0.03 g, 0.07 mmol) in 1 mL of anhydrous THF, freshly 
activated zinc (0.03 g, 0.4 mmol) and glacial acetic acid (0.5 mL) were added at room 
temperature. The reaction mixture was stirred vigourously under argon atmosphere for 3 
hr, after which the solvents were evaporated. The crude product was subjected to column 
chromatography (9:1 EtOAc/MeOH) to yiled pure amino alcohol 85 (40%) as a colorless 
oil; Rf = 0.1 (9:1 EtOAc/hexane); 1H NMR (CDCl3, 400 MHz) δ 1.25 (s, 3 H), 2.00 (br s, 
4 H), 2.17 (s, 3H), 4.88 (m, 2H), 4.99 (m, 2H), 5.10 (s, 2H), 7.26 – 7.36 (m, 10H); 13C 
NMR (CDCl3, 100 MHz) 29.7, 30.9, 66.5, 67.0, 69.1, 127.8, 128.1, 128.2, 128.4, 128.5, 
136.1, 154.9 ppm. 
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CHAPTER FOUR 
SYNTHESIS, BIOLOGICAL ACTIVITY AND MOLECULAR MODELING OF 
NOVEL 20S PROTEASOME INHIBITORS 
4.1 Introduction 
 Proteins carry out almost all the life’s essential processes. Cellular proteins are in 
a dynamic state of turnover, with the relative rates of protein synthesis and protein 
degradation ultimately determining the amount of protein present at any point of time. 
Breaking down unneeded proteins, a task equal in importance to synthesizing new 
proteins, is accomplished by the orderly action of several multiprotein complexes. 
Usually transcriptional regulation determines the concentrations of specific proteins in 
cells. But some times the amounts of key enzymes and regulatory proteins, such as 
cyclins and transcriptional factors, are controlled via selective protein degradation. In 
addition, abnormal proteins arising from the biosynthetic errors or postsynthetic damage 
must be destroyed to prevent the deleterious consequences of their buildup. Protein 
degradation is also primarily required to supply amino acids for fresh protein synthesis.1 
There are two major intracellular machines that degrade the damaged proteins or the 
excess proteins i) Lysosomes and ii) Proteasomes. Lysosomes primarily deal with the 
extracellular proteins like plasma proteins and membrane bound proteins that are used in 
receptor-mediated endocytosis. Protein degradation in lysosomes is largely nonselective; 
selection occurs only during the endocytosis. Proteasomes on the other hand, deal with 
the degradation of the endogenous proteins like transcriptional factors, cyclins and 
misfolded proteins due to transcriptional errors or encoded by faulty genes.2-5 
Proteasomes are found in eukaryotic as well as in prokaryotic cells. The proteasome is a 
functionally and structurally sophisticated counterpart to the ribosome. Regulation of 
protein levels via degradation is an essential cellular mechanism that is both rapid and 
irreversible.   
4.2 Proteasome structure and ubiquitin-proteasome pathway 
  (a)          (b)  
Figure 4.1:- (a) Crystal structure of the 20S proteasome6 (b) 26S proteasome 
complex 14 
 112
 Proteasomes are large oligomeric structures enclosing a central cavity where 
proteolysis takes place. The 26S proteasome is 2000-kDa ATP-dependent proteolytic 
complex. This large structure contains the central 20S (700 kDa) proteasome, in which 
proteins are degraded, and two 19S complexes, which provide substrate specificity and 
regulation (Figure 4.1).6,7 The 20S proteasome is barrel-shaped and is the most abundant 
particle. It nearly comprises 1% of cellular proteins. The 20S proteasome comprises of 
four stacked rings that enclose the central cavity or chamber where proteolysis occurs. 
The two central β-rings mainly contain a total of six proteolytic active sites that function 
together in protein degradation. These sites differ in their substrate specificity and 
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activity and have been named after enzymes that show similar proteolytic activity or 
specificity. In case of eukaryotic cells two of these sites are chymotrypsin-like, two are 
trypsin-like and two are caspase-like or post-glutamyl peptide hydrolase-like (PGPH). 
Access of polypeptides/proteins to these specific sites is controlled through a 1.3 nm 
opening formed by the outer two α-rings. The functional 26S proteasome consists of the 
core 20S catalytic complex that is capped at each end by the 19S regulatory subunit or 
caps.  
 Ubiquitination is the most common mechanism to label a protein for protein 
degradation in eukaryotes. Ubiquitin is a highly conserved, 76-residue (8.5 kDa) 
polypeptide and is abundant in the cell. The protein substrate is first conjugated to 
multiple molecules of ubiquitin in a reaction involving ubiquitin-activating enzyme (E1), 
ubiquitin carrier protein (E2) and ubiquitin-protein ligase (E3) (Figure 4.2).8-13 E1 
becomes attached via a thioester bond to the C-terminal glycine residue of the ubiquitin 
through ATP-driven formation of an ubiquitin-adenylate intermediate. Ubiquitin is then 
transferred from E1 to an -SH group of E2.  Then E2-S~ubiquitin transfers ubiquitin to 
free amino groups on proteins selected by E3.  Upon binding a protein substrate, E3 
catalyzes the transfer of ubiquitin from E2-S~ubiquitin to free amine groups on the 
protein, usually a Lys ε-NH2. More than one ubiquitin might attach to the protein 
substrate and the tandem linking of the ubiquitin molecules is catalyzed by isopeptidases. 
The 19S complexes contain binding sites for ubiquitinated proteins, enzymes then 
depolymerize the ubiquitin chain and unfold the substrate and facilitates its entry into the 
20S proteasome active cavity. Proteins are degraded by the core particle in a progressive 
manner, generating peptides of 3-25 amino acids in length and are further hydrolyzed to 
amino acids by other peptidases.  
 The catalytic mechanism of the 20S proteasome is highly complex and recent 
studies have revealed the importance of the amino terminal Thr as a nucleophile catalyst. 
Crews et al.12 proposed a mechanism for the proteolysis catalyzed by 20S proteasome via 
Thr-1 and is shown in the figure 4.3. 
Figure 4.2:- Ubiquitin-proteasome pathway for protein degradation14 
Figure 4.3:-Proposed mechanism for the proteolysis catalyzed by the 20S 
proteasome12 
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4.3 Proteasome inhibition: A novel approach to cancer therapy 
 Even though the concept of ubiquitin-proteasome pathway (UPP) as the major 
proteolytic pathway in the nucleus and the cytosol was discovered more than 20 years 
ago, the involvement of the proteasome in apoptosis was demonstrated quite recently.  
Previously, UPP was thought to be merely a disposal system for damaged intracellular 
proteins. But recent studies concluded that UPP is very much necessary for the regulation 
of the various essential proteins that govern an array of cellular functions. Normal 
turnover of cell-cycle regulatory proteins is dependent on the proteasome. Adams et al.15 
and An et al.16 demonstrated that blockade of proteasome function halts cell division. 
However, malignant cells are even more sensitive to the loss of proteasome activity. The 
studies comparing normal and malignant cell lines have shown that proteasome inhibition 
sensitizes malignant cells to apoptosis or programmed cell-death.17 Apoptotic cell death 
is fundamentally important in a wide variety of processes during normal development and 
also considered to be a major factor in anti-cancer therapies.18, 19  
 NF-κB signaling is dependent on the proteasome activity and recent studies had 
proven that interference with NF-κB transcriptional pathway influences tumor cell 
survival.13,14,20 In a normal cell, NF-κB is bound to a specific inhibitor protein IκB in the 
cytoplasm. This makes the NF-κB inactive and prevents transcription of its target genes 
(Figure 4.4). In case of external stress on the cell, IκB is degraded by the proteasome via 
UPP and thus allows NF-κB to translocate to the nucleus. NF-κB then promotes cell 
survival by initiating the transcription of genes encoding stress-response enzymes like 
cyclooxygenase (COX-2), cell-adhesion molecules, pro-inflammatory cytokines like 
tumor necrosis factor (TNF) and interleukins (ILs), and anti-apoptotic proteins such as 
Bcl-2 and cIAP1. In case of tumor cells, NF-κB is very active and promotes the tumor 
cell survival by inhibiting apoptosis and reduces the effectiveness of the anticancer 
therapy. Recent studies by Cusack et al.21 proved that inhibition of the proteasome blocks 
the chemotherapy-induced activation of NF-κB and in turn increases the apoptosis of the 
tumor cells in animal models. 
Figure 4.4:- NF-κB activation pathway13  
4.3.1 Background on the proteasome inhibitors 
 With the information on the proteasome, UPP and the role of proteasome in 
apoptosis, a variety of proteasome inhibitors were developed. Proteasome inhibitors were 
developed as research tools until early 2000, but they grabbed the center stage once their 
potential application in cancer therapy was recognized by Adams et al. Currently the 
classes of proteasome inhibitors can be classified as the following: i) Peptide aldehydes22 
ii) Peptide boronates23 iii) Non-peptide inhibitors like lactacystin24 iv) epoxyketones25 v) 
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Peptide vinyl sulfones26 vi) New natural product inhibitors like EGCG ((-)-
epigallocatechin-3-gallate)27 and its synthetic analogs28, gliotoxin29 etc. Many of these 
compounds have broad specificity, poor metabolic stability and bind irreversibly to the 
proteasome. Although the proteasome has multiple active sites, biological experiments 
proved that the selective inhibition of the Chymotrypsin-like subunit would achieve the 
required inhibition of the proteasome.  
4.3.2 VelcadeTM: Only proteasome inhibitor approved by FDA 
 Julian Adams and his co workers at Millennium pharmaceuticals synthesized a 
dipeptidyl boronic acid bortezomib, which still is the most potent, reversible, and 
selective proteasome inhibitor (Figure 4.5).30,31 In 2003 FDA approved this drug under 
the brand name VelcadeTM for the treatment of multiple myeloma. Multiple myeloma is 
the second most prevalent blood cancer after non-Hodgkin’s lymphoma.32 It is a cancer 
of the plasma cell, an important part of the immune system that produces antibodies to 
help fight infection and disease. There are approximately 45,000 people in the United 
States living with multiple myeloma and an estimated 14,600 new cases of multiple 
myeloma are diagnosed each year. Data showed that Velcade (Ki = 0.6 nM) binds to the 
proteasome with very high affinity and dissociates slowly, conferring stable but 
reversible proteasome inhibition.15  
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Figure 4.5:- Structure of the dipeptidyl boronic acid proteasome inhibitor 
bortezomib 
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4.3.3 Reason for a new proteasome inhibitor 
 The search for new proteasome inhibitors still continues in spite of the recent 
approval of the Velcade because (a) Velcade is highly expensive (3.5 mg = $1000); (b) 
high-toxic profile for Velcade was observed; (c) adverse effects ranging from cardiac 
disorders, thrombocytopenia, GI adverse effects, hypotension, peripheral neuropathy and 
rare cases of acute liver failure; (d) elimination pathways were not fully characterized; (e) 
studies on pediatric and geriatric patients were not conducted; (f) no formal drug 
interactions have been conducted; (g) the field of proteasome inhibition for cancer 
therapy is still juvenile and lot of information is needed. At least some of these reasons 
do warrant a new class of proteasome inhibitors with a less toxic profile.  
4.4 NSC-12155 lead molecule from HTS core 
 High-throughput screening (HTS) Core at the H. Lee Moffitt Cancer Centre & 
Research Institute have conducted an extensive screening on the 2000 NCI chemical 
diversity set of compounds, for proteasome inhibition. They have conducted both virtual 
screening (GLIDE) as well as the enzymatic assays and arrived with a few hit compounds 
in terms of decent activity. Our journey for a novel proteasome inhibitor started with their 
screening and identifying potential targets from the NCI diversity set. NSC-12155 was 
one among the few compounds from their studies which showed IC50 = 1.2 ± 1.0 µM 
(Figure 4.6). 
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Figure 4.6:- NSC-12155, the lead molecule 
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In order to validate the results generated by the HTS core in terms of virtual screening 
(GLIDE) as well as the small scale enzymatic assays, we have to take it to level of lead 
optimization by conducting more biological experiments. For that we have to have a 
greater amount of NSC-12155 and thus we ventured into an in-house synthesis of this 
molecule. 
4.4.1 Background on NSC-12155 (1,3-Bis-(4-amino-2-methyl-quinolin-6-yl)-urea) 
 NSC-12155 is not a new compound as far as synthesis is concerned. The earliest 
literature report of this molecule came in 1937 and was referred to as ‘surfen’ back then. 
‘Surfen’ and its analogs were patented by Jensch33 for their antihelminthic and 
antibacterial properties. The first synthesis of surfen was reported by Jensch34 and it 
remained as the basic route for all the syntheses of 4,6-diaminoquinolines and its analogs 
that later followed over the years (Figure 4.8). The antibacterial property and its low 
toxicity for tissues had prompted many reports for their syntheses.35-37 Most of these 
papers also reported the synthesis of asymmetrical ureas, the analogs for studying the 
structure-activity relationship for the antibacterial activity. But a report by Hunter and 
Hill38 on oncogenic and heparin-neutralizing properties of surfen had suddenly dropped 
the interest of this molecule. But this was not surprising because most of the approved 
drugs today like cisplatin for the treatment of cancer were reported oncogenic earlier.  
 The revival of interest on 4,6-diaminoquinolines and the substituted asymmetrical 
urea analogs appeared “on the scene” because of reported inhibition of C5a receptor 
binding  in human nutrophils.39 C5a is an anaphylatoxin that is implicated in a number of 
inflammatory diseases. It is a highly cationic protein with 13 of 74 amino acids being 
either arginine or lysine. In their study, Lanza39 and coworkers discovered the potential of 
NSC-12155 as one of the potential inhibitor of C5a receptor binding. Shinkai et al.40 
reported 4-aminoquinolines as novel nociceptin antagonists with analgesic activity. 
Panchal et al.41 reported that NSC-12155 is a very good inhibitor of anthrax lethal factor 
(LF) and also published a cocyrstal structure of anthrax LF-NSC12155. This report was 
further supported by Mentecucco et al.42
 Most recently a new synthetic approach for the 4,6-diamino-2-methylquinoline, 
the monomeric unit of the NSC-12155 was reported by Sestili et al.43 (Figure 4.7). They 
also conducted various pharmacological studies on a variety of substituted synthetic 
analogs of 129 as nociceptin receptor (NOP) antagonists. 
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Figure 4.7:- Sestili et al.’s synthesis of 4,6-diamino-2-methylquinoline 129 
Dr. Sebti at Moffitt Cancer Center and his collaborators44 in 2004 identified 15 
compounds from the NCI diversity set of 2000-compound library that would enhance the 
anti-lymphoma activity of the therapeutic monoclonal antibody rituximab. NSC-12155 
was one among these compounds.  
4.5 Results & Discussion 
 The drug discovery team at Moffitt Cancer Center collaborated extensively on the 
current project that is in discussion. Dr. Sebti’s group worked out the biological assays 
for the 20S proteasome inhibition activity. Dr. Wayne Guida’s group supported us with 
the molecular modeling data. We basically followed the synthesis described by Jensch33 
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because of the availability and low cost of the starting materials and the intermediate 
reagents and we intended to use the intermediates 133 and 134 for making libraries. The 
synthesis for NSC-12155 is depicted in the figure 4.8. 
Figure 4.8:- Scheme for the synthesis of NSC-12155 
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We started our synthesis by reacting 4-aminoacetanilide 130 with methylacetoacetate 131 
in methanol at reflux temperature to yield the methyl 3-(4-
acetylaminophenylamino)crotonate 132 in 70% yield. Subsequent cyclization of 
crotonate 132 at 280 oC yielded 6-acetamide-4-hydroxy-2-methylquinoline 133 in 72% 
yield. This method of synthesis of quinoline moiety is known as “Knorr Quinoline 
synthesis”. Methylation of 133 with dimethylsulfate yielded the 4-methoxyquinoline 
derivative 134. The methoxy of 134 was converted to amino group with ammonium 
acetate and the acetyl group was removed by acidic hydrolysis to give 4,6-diamino-2-
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methylquinoline 135 in good yield. Conversion of 135 to NSC-12155 was achieved by 
triphosgene and TEA. We tested our synthesized molecule of NSC-12155 to compare it 
with that of the previous result from the enzymatic assay conducted by the HTS Core. 
The IC50 value matched with the previous result suggesting that we have a lead and the 
biological assay results also demonstrated the selectivity of NSC-12155 towards 
chymotrypsin-like subunit, which is the primary requirement in the proteasome 
inhibition. The molecular docking of NSC-12155 in the chymotrypsin-like subunit of the 
20S proteasome is shown in figure 4.9. The GLIDE molecular modeling software was 
used to obtain the lowest energy docked model and the model with lowest docking scores 
are used for our analysis. 
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Figure 4.9:- Molecular model of NSC-12155 binding to the chymotrypsin-like 
subunit of the 20S Proteasome.   A: The protein surface of the proteasome is shaded 
according to the electrostatic potential. Positively charged areas are in light shade and 
negatively charged areas are shaded dark. For NSC-12155, a wire frame model was 
shown in the binding pocket of the chymotrypsin-like subunit.  B: The hydrogen bonds 
formed between the NSC-12155 and the protein, via Thr1, Thr21 and Gly23 are shown 
schematically but not to scale.  The H bonds are defined with a minimum donor angle of 
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90˚ and minimum acceptor angle of 60˚ and maximum length of 2.5 Å.  C: Surface 
model of the proteasome with space filling model of NSC-12155. 
Based on the molecular modeling data we concluded that the pharmacophore of NSC-
12155 contains a urea moiety and two aryl groups or one aryl group that can be varied 
independently. This prompted us to vary the functional units to maximize the 
chymotrypsin-like activity of the proteasome via focused yet structurally diverse 
compound libraries. 
4.5.1 Synthesis, biological data and molecular modeling of the Library 
 While NSC-12155 is a symmetrical urea, the intermediate 135 can be coupled to 
various aryl or alkyl isocyanates to build asymmetric urea derivatives. With that intention 
we designed a small focused library around the urea moiety. By treating the intermediate 
diamine 135 with the selected isocyanate in acetone with microwave irradiation we were 
able to achieve the desired asymmetric urea as the sole insoluble product (Figure 4.10). 
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Figure 4.10:- Asymmetric urea analogs synthesis 
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The preliminary results of in vitro chymotrypsin-like activity inhibition were reported in 
the figure 4.11. The results are very interesting; they all are as active or nearly active as 
that of the symmetrical urea NSC-12155.  
 
Compounds
NSC-12155
136
137
138
139
140
IC50 (µM)
1.2 ± 1.1
8.4 ± 2.2
7.4 ± 4.0
3.6 ± 1.4
4.3 ± 4.9
1.4 ± 1.0
 
 
 
 
Figure 4.11:- chymotrypsin-like subunit inhibitory activity 
 Molecular modeling of the compounds 137, 138 and 139 clearly shows that the 
4,6-diamino-2-methylquinoline group is critical since it is hydrogen bound to the active 
site Thr 1 hydroxyl group of the enzyme (Figure 4.12). Since no specific hydrogen 
binding interactions are predicted for the other 4,6-diamino-2-methylquinoline of the 
symmetrical urea NSC-12155 (Figure 4.9), our speculation that it can be replaced was 
proven to be correct both by bioassay as well as molecular docking experiments. 
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 Figure 4.12:- Docking of 137, 138 & 139 in the binding pocket  
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We were surprised to observe the binding orientation of 136 because the phenyl moiety 
was shown to be in the binding pocket as opposed to the 4,6-diamino-2-methylquinoline 
group. Even the lowest energy conformation for 136 showed this kind of orientation 
(Figure 4.13). By comparing the most active compound among our series i.e. 140 with 
136 in the binding pocket, the question arises regarding the binding interactions required 
for inhibition. Because it clearly suggests that compound 136’s binding is mainly due to 
hydrophobic interactions as opposed to the hydrogen bonding in case of the rest of the 
compounds. Further studies are needed in order to answer this question. 
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Figure 4.13:- Comparision of 140 vs. 136 binding orientation in the chymotrypsin-
like subunit binding pocket 
 One more study that biologists conducted on NSC-12155 is the Dialysis 
experiment. This experiment was conducted in order to find whether NSC-12155 is a 
reversible or irreversible inhibitor. As mentioned in the introductory section a lot of the 
proteasome inhibitors did not go in to clinical trails because they all irreversibly bind to 
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the chymotrypsin-like subunit of the 20S proteasome. Experiments proved that our lead 
molecule NSC-12155 is a reversible inhibitor of 20S proteasome (Figure 4.14). 
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Figure 4.14:- Dialysis experiment showing the reversible inhibition of NSC-12155 
4.6 Conclusion and future direction 
 In conclusion, we accomplished the synthesis of the lead molecule and a small 
library of molecules that show potential as 20S proteasome inhibitors. There is a lot of 
potential for NSC-12155 as the lead molecule for the proteasome inhibition. Hence we 
can make a variety of molecules around the urea and the quinoline moieties (Figure 4.15). 
Since only one of the two amine protons of the 4-amino group of the 4,6-diamino-2-
methylquinolines are specifically hydrogen bound to the Thr21 backbone carbonyl, 
suggesting that replacement of the 4-amino group with a 4-hydroxy group 141 or with a 
4-(N-methylamino) group 142 could retain that interaction.  The 6-amino-4-hydroxy-2-
methylquinoline derivative 141 needed to test this idea can be prepared from the 
intermediate 132 in the current synthesis of the 4,6-diaminoquinolines and the 
intermediate block 142 can be synthesized from 141 via methylation reaction. 
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Figure 4.15:-Proposed molecules for future syntheses for proteasome inhibition  
4.7 Experimental 
4.7.1 20S proteasome inhibitory assay 
Solutions:- 
(a) 50mM Tris, pH 7.6  
(b) 20S Proteasome Stock Solution (i) 35ng/µl Rabbit 20S Proteasome, Boston 
Biochem#E-350, 25µg/$80.00 (ii) Human 20S Proteasome, Boston Biochem # #-360, 
50µg/$150.00  
(c) Substrate (Chymotrypsin-like; Trypsin-like; or PGPH) (i) CT substrate: Suc-Leu-Leu-
Val-Tyr-AMC (Suc-LLVY-AMC), Boston Biochem, #S-280, 5mg/$85.00 
20S Proteasome Stock Solution:- 
Dilute 20S proteasome stock (50µl) in a total volume of 1428µl (add 1378µl) of 50mM 
Tris, pH 7.6, for a final stock concentration of 35ng/µl.  Aliquot in small volumes and 
store at -80ºC. 
CT substrate (Suc-LLVY-AMC):- 
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a) Dilute CT substrate (Suc-LLVY-AMC) 5mg, in 327µl of DMSO for a 20mM stock 
solution.  Aliquot in small volumes and store at -20ºC.  
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b) Make 2mM working solution of CT substrate (Suc-LLVY-AMC) by diluting 20mM 
stock 1:10 in DMSO. 
Equipment:- 
(a) Clear 96-well ELISA plates  
ing fluorometer with 355nm excitation and 460nm emission filters (b) Plate-read
Protocol:- 
(1) In the wells of 96-well plate, add 96µl of 50mM Tris, pH 7.6, to each well  
(2) Add 2µl of 35ng/µl 20S proteasome (70ng total) to each well.  To the plate blank 
 substrate (20µM final concentration)  
n/emission filters of 355/460nm  
5 mediated proteasome inhibition, 20S 
his 15 µL (225 ng) was used) was 
wells add 99µl of 50mM Tris, pH 7.6  
(3) Add 1µl per well of 100X test sample or vehicle  
(4) Add 1µl per well of the appropriate
(5) Shake plate by hand to mix all reagents  
(6) Cover plates in foil and incubate at 37ºC for 1-4hr  
(7) Read plates on Fluorometer with excitatio
(8) Calculate inhibition based on vehicle control. 
4.7.2 Assay for Reversible Inhibition of NSC-12155 
To measure the effect of dialysis on NSC-1215
prokaryotic proteasome (9 µg in 600 µL solution from t
incubated with 10 µM NSC-12155 or the control solvent DMSO in 50 mM Tris-Hcl, pH 
7.5 for 30 min. This was then incubated at 4 oC with dialysis for different time points 
using a 10,000 MWCO Pierce Slide-A-Lyzer Dialysis Cassette (Rockford, IL) in a 
rotating bath of 50 mM Tris-Hcl, pH 7.5. The proteasomal chymotrypsin-like activity 
was then assayed as previously described.45 
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ynthesis of methyl 3-(4-acet
 solution of 4-aminoacetanilide 130 (20 g, 133.2 mmol) and methyl acetoacetate 131 
 cooling to 0 oC, 
ynthesis of 6-acetamide-4-hydrox 33):- 
m of methyl 3-(4-acetylaminophenylamino)crotonate 132 (10 g, 40.3 
H
N
O
N
H
O
4.7.3 Chemistry 
 MeO
 
S ylaminophenylamino)crotonate (132):- 
A
(17.0 g, 146.5 mmol) in methanol (60 mL) was refluxed for 20 h. After
the precipitate was collected by filtration to give methyl 3-(4-
acetylaminophenylamino)crotonate 132 (23 g, 70%); a colorless solid; mp 134-135 oC; 
1H NMR (CDCl3, 400 MHz) δ 1.92 (s, 3H), 2.15 (s, 3H), 3.67 (s, 3H), 4.67 (br s, 1H), 
6.96-6.98 (d, 2H), 7.44-7.46 (d, 2H), 7.79 (m, 1H), 10.19 (br s, 1H);  13C NMR (CDCl3, 
100 MHz) 20.4, 24.6, 50.5, 85.5, 120.8, 125.5, 135.4, 135.5, 159.6, 168.7, 171.0 ppm 
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S y-2-methylquinoline (1
 The powder for
mmol) was added to Dowtherm A (25 mL) while heating at 280 oC. After heating for 10 
min, the mixture was cooled room temperature. The resulting precipitate was washed 
with ethyl acetate (30 mL) and methanol (10 mL) to give 6-acetamide-4-hydroxy-2-
methylquinoline 133 (6.3 g, 72%) as a deep yellow solid; 1H NMR (CD3OD, 400 MHz) δ 
2.17 (s, 3H), 2.46 (s, 3H), 4.69 (br s, 1H), 4.98 (br s, 1H), 6.21 (s, 1H), 7.54-7.56 (d, 1H), 
7.96-7.99 (dd, 1H), 8.18 (d, 1H); 13C NMR (CD3OD, 100 MHz) 18.7, 22.7, 108.0, 114.5, 
118.6, 124.3, 126.0, 135.0, 137.0, 151.8, 171.2, 178.8 ppm 
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ynthesis of 6-acetamide-4-methox 34):- 
imethyl sulfate (2.5 mL, 23.6 mmol) was added drop wise to a suspension of 133 in 
 to room temperature, 
ynthesis of 4,6-diamin
 mixture of 6-acetamide-4-methoxy-2-methylquinoline 134 (1.3 g, 5.6 mmol) and 
 oC for 4 h. Water (7 mL) and 40% 
N
N
 
 
H
O
OMe
S y-2-methylquinoline (1
D
toluene (20 mL) and the mixture was refluxed for 8 h. After cooling
the precipitate was dissolved in water (40 mL) and the solution was alkalinized with 35% 
aqueous hydroxide solution (3 mL). The resulting precipitate was collected by filtration 
to give 6-acetamide-4-methoxy-2-methylquinoline 134 (1.5 g, 47%) as a brown solid; 1H 
NMR (CD3OD, 400 MHz) δ 2.17 (s, 3H), 2.64 (s, 3H), 4.06 (s, 3H), 6.86 (s, 1H), 7.74-
7.78 (m, 2H), 8.48 (s, 1H); 13C NMR (CD3OD, 100 MHz) 22.6, 23.7, 55.3, 101.1, 110.7, 
120.1, 123.8, 127.0, 135.8, 145.0, 159.5, 162.9, 170.6 ppm 
 
 
S o-2-methylquinoline (135):- 
N
NH2
NH2
A
ammonium acetate (6.6 g, 85 mmol) was heated at 135
sulfuric acid (12 mL) were added to the reaction mixture, which was heated at 90 oC for 5 
h. After cooling to 0 oC, add charcoal (1 g) and stirred for 5 min. After removal of the 
charcoal by filtration, the filtrate was alkalinized with 35% aqueous sodium hydroxide 
while cooling at 0 oC. The resulting precipitate was collected by filtration, washed with 
water (40 mL) an dried under vacuum at 100 oC to give 4, 6-diamino-2-methylquinoline 
135 (0.43g, 45%) as a slightly yellow solid; 1H NMR (d6-DMSO, 400 MHz) δ 2.28 (s, 
3H), 5.02 (br s, 2H), 6.00 (br s, 2H), 6.26 (s, 1H), 6.88 (s, 1H), 6.93- 6.95 (d, 1H), 7.36- 
 131
Synthesis of 1,3-Bis-(4-amino-2-met
o a solution of 6-diamino-2-methylquinoline 6 (0.05 g, 0.30 mmol) in 3 mL of 1,4-
mmol) was 
2-methylquinoline 135 (0.02 g, 0.12 mmol) in dry Acetone 
dded and the 
N
N
H
N
H
N
NH2 NH2
7.38 (d, 1H); 13C NMR (d6-DMSO, 100 MHz) 25.1, 101.7, 102.7, 119.2, 121.1, 129.5, 
142.8, 144.8, 150.0, 153.9 ppm; ESI found 174.1 for [M+H]+  
 
 O
 
hyl-quinolin-6-yl)-urea (NSC-12155) 
T
dioxane, triethylamine (0.12 mL, 0.9 mmol) and triphosgene (0.015 g, 0.05 
added. The reaction was very exothermic and a heavy precipitate was formed. After 
addition of 3 mL of 1,4-dioxane to dilute the mixture, it was heated under reflux for 12 h. 
After cooling, the mixture was poured into 5 mL of ice-H2O and the product was 
collected and washed with H2O. The material was recrystallised from DMF-MeOH to 
provide 3-Bis-(4-amino-2-methyl-quinolin-6-yl)-urea NSC-12155 (0.04 g, 75%) as a 
brown solid; mp 254-256 oC (lit. mp= 255 oC); 1H NMR (CD3OD, 400 MHz) δ 2.46 (s, 
6H), 6.48 (s, 2H), 7.61-7.66 (m, 4H), 8.10 (s, 2H); 13C NMR (CD3OD, 100 MHz) 22.4, 
39.2, 102.5, 109.6, 117.4, 123.8, 126.3, 135.4, 143.2, 153.0, 154.2, 156.6 ppm; ESI-TOF,  
Found: 373.1736  for [M+H]+
General Procedure for the microwave assisted synthesis of the Ureas: -  
To a solution of 4, 6-diamino-
(1 mL) under argon atmosphere the concerned isocyanate (0.12 mmol) was a
reaction vessel was sealed. The reaction mixture was placed in the microwave with a 
previously standardized set of conditions. After the reaction time almost in all the cases a 
precipitate was observed and the precipitate was filtered and dried. The product was 
characterized with out any further purification. 
Microwave conditions:- 
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iscover®
 min  
ynthesis of 1-(4-Amino-2- -phenyl-urea (136):- 
. mp= 226.5-
N
Microwave Type: CEM d
Power: 150 W  
Ramp time: 4:00
Hold time: 20:00 min  
Temperature: 100 oC  
Pressure: 220 psi  
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S methyl-quinolin-6-yl)-3
Product was obtained as pale yellow solid (0.005 g); mp 226-228 oC (lit
227.5 oC); 1H NMR (d6- DMSO, 400 MHz) δ 2.37 (s, 3H), 6.39 (br s, 2H), 6.40 (s, 1H), 
6.95-9.99 (t, 1H), 7.27-7.30 (t, 2H), 7.47-7.49 (d, 2H), 7.61 (s, 1H), 7.62-7.63 (d, 1H), 
7.95-7.96 (d, 1H), 8.65 (br s, 1H), 8.81 (br s, 1H); 13C NMR (d6-DMSO, 100 MHz) 24.5, 
102.2, 109.2117.3, 118.0, 121.6, 122.7, 128.5, 128.6, 128.8, 134.4, 139.7, 144.8, 150.6, 
152.6, 156.3 ppm; ESI-TOF Calcd for [M+H]+ is 293.13969, Found:  293.13976 
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ynthesis of 1-(4-Amino-2-methyl-quinolin-6-yl)-3-p-tolyl-urea (137):- 
t. mp= 260.4-
ynthesis of 1-(4-Amino -(4-chloro-phenyl)-urea (138):- 
6-
 
Synthesis of 1-(4-Amino-2-methyl-quinolin ifluoromethyl-phenyl)-urea 
was obtained as pale yellow flakes (0.05 g); mp 265-266 oC; 1H NMR (d6-
DMSO, 400 MHz) δ 2.38 (s, 3H), 6.41 (br s, 3H), 7.62-7.65 (m, 4H), 7.69-7.71 (d, 2H), 
S
Product was obtained as a pale yellow solid (0.005 g); mp 262-263 oC (li
262.4 oC); 1H NMR (d6-DMSO, 400 MHz) δ 2.24 (s, 3H), 2.37 (s, 3H), 6.38 (br s, 2H), 
6.40 (s, 1H), 7.09- 7.10 (d, 2H), 7.36-7.38 (d, 2H), 7.60 (s, 1H), 7.61 (d, 1H), 7.95 (d, 
1H), 8.65 (br s, 1H), 8.71 (br s, 1H); 13C NMR (d6- DMSO, 100 MHz) 20.2, 24.5, 102.2, 
109.3, 117.4, 118.1, 122.7, 128.5, 129.0, 129.2, 130.4, 134.5, 137.1, 144.7, 150.6, 152.6, 
156.2 ppm; ESI-TOF Calcd for [M+H]+ is 307.15534, Found: 307.15569 
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S -2-methyl-quinolin-6-yl)-3
Product was obtained as a brown solid (0.016 g, 44%); mp 264-265 oC; 1H NMR (d
DMSO, 400 MHz) δ 2.37 (s, 3H), 6.40 (s, 1H), 6.41 (br s, 2H), 7.32-7.34 (d, 2H), 7.51-
7.53 (d, 2H), 7.61 (d, 2H), 7.96 (s, 1H), 8.73 (br s, 1H), 8.97 (br s, 1H); 13C NMR (d6-
DMSO, 100 MHz) 24.5, 102.2, 109.7, 117.3, 119.5, 122.8, 125.1, 128.5, 134.2, 138.7, 
150.6, 152.5, 156.3 ppm; ESI-TOF Calcd for [M+H]+ is 327.10054, Found: 327.10054
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-6-yl)-3-(4-tr
(139):- 
Product 
 134
22.9, 
ynthesis of 1-(4-Amino- lin-6-yl)-3-naphthalen-1-yl-urea (140):- 
roduct was obtained as a brown solid (0.05 g); mp 195-196 oC; 1H NMR (d6- DMSO, 
 (m, 
. L. Trends Cell Biol. 1998, 8, 397 - 403 
ver, A. Cell 1994, 13 – 21.  
Chem. Biol. 1995, 2, 503 – 508. 
 434. 
.; Yasuoka, 
 ID:-1IRU)  
7) Coux, O.; Tanaka, K.; Goldberg, A. L. Annu. Rev. Biochem. 1996, 65, 801 – 847. 
8.00 (br s, 1H); 13C NMR (d6-DMSO, 100 MHz) 24.6, 102.3, 109.9, 117.3, 117.6, 1
125.9, 128.6, 134.1, 145.0, 150.7, 152.4, 156.5 ppm; ESI-TOF Calcd for [M+H]+ is 
361.12707, Found: 361.12738 
 
 
N
NH2
N
H
N
H
O
 
S 2-methyl-quino
P
400 MHz) δ 2.38 (s, 3H), 6.40 (br s, 2H), 6.42 (s, 1H), 7.47-7.51 (t, 1H), 7.55-7.59
2H), 7.61-7.65 (m, 3H), 7.69 (d, 1H), 7.93-7.95 (d, 1H), 8.02-8.03 (d, 1H), 8.06-8.07 (d, 
1H), 8.17-8.19 (d, 1H), 8.96 (br s, 1H), 9.18 (br s, 1H); 13C NMR (d6- DMSO, 100 MHz) 
24.5, 102.3, 109.3, 117.2, 117.4, 121.3, 122.7, 125.5, 125.7, 125.8, 128.6, 133.6, 134.3, 
134.6, 137.8, 142.9, 144.8, 150.6, 153.0, 156.3 ppm; ESI-TOF Calcd for [M+H]+ is 
343.15534, Found: 343.15551 
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CHAPTER 5: APPENDICES 
 
Appendix A: - Selected 1H and 13C NMR spectra 
Appendix A: (Continued) 
 
Spectrum 5.01 
1H NMR (CDCl3, 400 MHz) of 9b
 
13C NMR (CDCl3, 100 MHz) of 9b 
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Appendix A: (Continued) 
 
Spectrum 5.02 
1H NMR (CDCl3, 400 MHz) of 10a
 
 
 
 
13C NMR (CDCl3, 100 MHz) of 10a
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Appendix A: (Continued) 
 
Spectrum 5.03 
1H NMR (CDCl3, 250 MHz) of 10b
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13C NMR (CDCl3, 62.5 MHz) of 10b 
Appendix A: (Continued) 
 
Spectrum 5.04 
1H NMR (CDCl3, 250 MHz) of 10c 
 
 
 
 
 
13C NMR (CDCl3, 62.5 MHz) of 10c 
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Appendix A: (Continued) 
 
Spectrum 5.05 
1H NMR (CDCl3, 250 MHz) of 10d
 
13C NMR (CDCl3, 62.5 MHz) of 10d 
 143
Appendix A: (Continued) 
 
Spectrum 5.06 
1H NMR (CDCl3, 400 MHz) of 11a
 
 
 
13C NMR (CDCl3, 100 MHz) of 11a
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Appendix A: (Continued) 
 
Spectrum 5.07 
1H NMR (CDCl3, 400 MHz) of 11c 
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Appendix A: (Continued) 
 
Spectrum 5.08 
1H NMR (CDCl3, 250 MHz) of 11d
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13C NMR (CDCl3, 100 MHz) of 11d
Appendix A: (Continued) 
 
Spectrum 5.09 
1H NMR (CDCl3, 400 MHz) of 12a
 
 
 
 
13C NMR (CDCl3, 100 MHz) of 12a
 
 
 
 147
 
Appendix A: (Continued) 
 
Spectrum 5.10 
1H NMR (CDCl3, 250 MHz) of 12b
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13C NMR (CDCl3, 62.5 MHz) of 12b 
Appendix A: (Continued) 
 
Spectrum 5.11 
1H NMR (CDCl3, 250 MHz) of 12c 
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13C NMR (CDCl3, 100 MHz) of 12c 
Appendix A: (Continued) 
 
Spectrum 5.12 
1H NMR (CDCl3, 250 MHz) of 12d
 150
 
13C NMR (CDCl3, 62.5 MHz) of 12d 
Appendix A: (Continued) 
 
Spectrum 5.13 
1H NMR (CDCl3, 400 MHz) of 13a
 
 
13C NMR (CDCl3, 100 MHz) of 13a 
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Appendix A: (Continued) 
 
Spectrum 5.14 
1H NMR (CDCl3, 250 MHz) of 13b
 
13C NMR (CDCl3, 62.5 MHz) of 13b 
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Appendix A: (Continued) 
 
Spectrum 5.15 
1H NMR (CDCl3, 250 MHz) of 13c 
 
 
13C NMR (CDCl3, 62.5 MHz) of 13c 
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Appendix A: (Continued) 
 
Spectrum 5.16 
1H NMR (CDCl3, 250 MHz) of 13d
 
13C NMR (CDCl3, 62.5 MHz) of 13d 
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Appendix A: (Continued) 
 
Spectrum 5.17 
1H NMR (CDCl3, 400 MHz) of 14a
 
 
13C NMR (CDCl3, 100 MHz) of 14a
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Appendix A: (Continued) 
 
Spectrum 5.18 
1H NMR (CDCl3, 250 MHz) of 14b
 
13C NMR (CDCl3, 62.5 MHz) of 14b 
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Appendix A: (Continued) 
 
Spectrum 5.19 
1H NMR (CDCl3, 250 MHz) of 14c 
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13C NMR (CDCl3, 62.5 MHz) of 14c 
Appendix A: (Continued) 
 
Spectrum 5.20 
1H NMR (CDCl3, 250 MHz) of 14d
 
13C NMR (CDCl3, 62.5 MHz) of 14d 
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Appendix A: (Continued) 
Spectrum 5.21  
 
1H NMR (CDCl3, 400 MHz) of 15a
 
 
 
 
 
13C NMR (CDCl3, 100 MHz) of 15a
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Appendix A: (Continued) 
 
Spectrum 5.22 
1H NMR (CDCl3, 250 MHz) of 15b
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13C NMR (CDCl3, 62.5 MHz) of 15b 
Appendix A: (Continued) 
 
Spectrum 5.23 
1H NMR (CDCl3, 250 MHz) of 15c 
 
13C NMR (CDCl3, 62.5 MHz) of 15c 
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Appendix A: (Continued) 
 
Spectrum 5.24 
1H NMR (CDCl3, 250 MHz) of 15d
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13C NMR (CDCl3, 62.5 MHz) of 15d 
Appendix A: (Continued) 
 
Spectrum 5.25 
1H NMR (CDCl3, 400 MHz) of 16a
 
 
 
 
 
13C NMR (CDCl3, 100 MHz) of 16a
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Appendix A: (Continued) 
 
Spectrum 5.26 
1H NMR (CDCl3, 400 MHz) of 16b
 
 
 
13C NMR (CDCl3, 62.5 MHz) of 16b 
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Appendix A: (Continued) 
 
Spectrum 5.27 
1H NMR (CDCl3, 250 MHz) of 16c 
 
13C NMR (CDCl3, 62.5 MHz) of 16c 
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Appendix A: (Continued) 
 
Spectrum 5.28 
1H NMR (CDCl3, 250 MHz) of 16d
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13C NMR (CDCl3, 62.5 MHz) of 16d 
Appendix A: (Continued) 
Spectrum 5.29  
 
1H NMR (CDCl3, 400 MHz) of 17a
 
 
 
 
 
13C NMR (CDCl3, 100 MHz) of 17a
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Appendix A: (Continued) 
 
 
Spectrum 5.30 
1H NMR (CDCl3, 400 MHz) of 17b
 
 
 
 
 
13C NMR (CDCl3, 100 MHz) of 17b
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Appendix A: (Continued) 
 
Spectrum 5.31 
1H NMR (CDCl3, 250 MHz) of 17c 
 
13C NMR (CDCl3, 62.5 MHz) of 17c 
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Appendix A: (Continued) 
 
Spectrum 5.32 
1H NMR (CDCl3, 250 MHz) of 17d
 
13C NMR (CDCl3, 62.5 MHz) of 17d 
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Appendix A: (Continued) 
 
Spectrum 5.33 
COOEt
COOEt
N3
H3C
1H NMR (CDCl3, 250 MHz) of 62 
 
 
 
13C NMR (CDCl3, 62.5 MHz) of 62 
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Appendix A: (Continued) 
 
Spectrum 5.34 
N3 COOH
H3C COOEt
1H NMR (CDCl3, 250 MHz) of 63 
X
X
 172
 
13C NMR (CDCl3, 62.5 MHz) of 63 
Appendix A: (Continued) 
 
Spectrum 5.35 
N3 COOEt
H3C CON3
1H NMR (CDCl3, 250 MHz) of 64 
 
13C NMR (CDCl3, 62.5 MHz) of 64 
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Appendix A: (Continued) 
 
Spectrum 5.36 
N3 COOEt
H3C NHBoc
1H NMR (CDCl3, 250 MHz) of 65 
 
13C NMR (CDCl3, 62.5 MHz) of 65 
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Appendix A: (Continued) 
 
Spectrum 5.37 
1H NMR (CDCl3, 250 MHz) of 70 
N3
H3C
O
OEt
NH
O
H3C H
X X
 
13C NMR (CDCl3, 62.5 MHz) of 70 
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Appendix A: (Continued) 
 
Spectrum 5.38 
NHCbzCbzHN
COOHH3C
1H NMR (CD3OD, 250 MHz) of 73 
 
13C NMR (CD3OD, 100 MHz) of 73
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Appendix A: (Continued) 
 
Spectrum 5.39 
NHCbzCbzHN
H3C
O
O
N
O
O
1H NMR (CDCl3, 250 MHz) of 74 
 
 
13C NMR (CDCl3, 100 MHz) of 74 
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Appendix A: (Continued) 
 
1H NMR (CDCl3, 400 MHz) of 75 
NHCbzCbzHN
H3C
OHSpectrum 5.40 
 
 
 
 
 
 
13C NMR (CDCl3, 100 MHz) of 75 
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Appendix A: (Continued) 
 
Spectrum 5.41 
O
H
N
CbzHN
H3C O
1H NMR (CDCl3, 400 MHz) of 76 
 
 
 
 
 
13C NMR (CDCl3, 100 MHz) of 76 
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Appendix A: (Continued) 
 
1H NMR (CDCl3, 400 MHz) of 77 
O
N
CbzHN
H3C O
BocSpectrum 5.42 
 
13C NMR (CDCl3, 100 MHz) of 77 
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Appendix A: (Continued) 
 
Spectrum 5.43 
O
H
N
BocHN
H3C
O
1H NMR (CDCl3, 400 MHz) of 79 
 
13C NMR (CDCl3, 100 MHz) of 79 
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Appendix A: (Continued) 
 
Spectrum 5.44 
NHCbz
COOCH3
CbzHN
H3C
1H NMR (CDCl3, 250 MHz) of 82 
 
13C NMR (CDCl3, 62.5 MHz) of 82 
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Appendix A: (Continued) 
 
Spectrum 5.45 
NHCbz
CHO
CbzHN
H3C
1H NMR (CDCl3, 400 MHz) of 83 
 
 
 
13C NMR (CDCl3, 100 MHz) of 83 
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Appendix A: (Continued) 
 
Spectrum 5.46 
O N
O
P
Ph Ph
Ph
1H NMR (CDCl3, 400 MHz) of 102 
 
13C NMR (CDCl3, 100 MHz) of 102
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Appendix A: (Continued) 
 
Spectrum 5.47 
O N
O
HC Cl
Cl Cl
1H NMR (CDCl3, 400 MHz) of 103 
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Appendix A: (Continued) 
 
Spectrum 5.48 
Cl3C
N
O
Boc
1H NMR (CDCl3, 400 MHz) of 104 
 
 
 
13C NMR (CDCl3, 100 MHz) of 104
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Appendix A: (Continued) 
 
Spectrum 5.49 
Ph
N
COOCH3
Ph
Ph
1H NMR (CDCl3, 400 MHz) of 110 
 
 
 
13C NMR (CDCl3, 100 MHz) of 110
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Appendix A: (Continued) 
 
Spectrum 5.50 
O
O
N
O
ONHBoc
1H NMR (CDCl3, 400 MHz) of 118 
 
 
13C NMR (CDCl3, 100 MHz) of 118
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Appendix A: (Continued) 
 
N
H
Ph
O
O
O
O
Spectrum 5.51 
1H NMR (CDCl3, 400 MHz) of 120 
 
 
 
13C NMR (CDCl3, 100 MHz) of 120
 
 
 
 
 189
 
Appendix A: (Continued) 
 
N
Ph
O
O
O
O
NH
Boc
Spectrum 5.52 
1H NMR (CDCl3, 400 MHz) of 121 
 
 
13C NMR (CDCl3, 100 MHz) of 121
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Appendix A: (Continued) 
 
Spectrum 5.53 
1H NMR (CDCl3, 400 MHz) of 123 
BocHN
O
O
Ph
OH
 
 
 
 
13C NMR (CDCl3, 100 MHz) of 123
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Appendix A: (Continued) 
 
Spectrum 5.54 
BocHN CHO
O
O
Ph
1H NMR (CDCl3, 400 MHz) of 124 
 
13C NMR (CDCl3, 100 MHz) of 124
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Appendix A: (Continued) 
 
BocHN
O
O
Ph
NO2HO
Spectrum 5.55 
1H NMR (CDCl3, 400 MHz) of 125 
 
 
13C NMR (CDCl3, 100 MHz) of 125
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Appendix A: (Continued) 
 
Spectrum 5.56 
1H NMR (CDCl3, 400 MHz) of 84 
NHCbzCbzHN
H3C NO2
OH
 
 
 
 
 
 
13C NMR (CDCl3, 100 MHz) of 84 
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Appendix A: (Continued) 
 
NHCbzCbzHN
H3C NH2
OH
Spectrum 5.57 
1H NMR (CDCl3, 400 MHz) of 85 
 
 
 
13C NMR (CDCl3, 100 MHz) of 85 
 195
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Appendix A: (Continued) 
 
 
 
 
13C NMR (CDCl3, 100 MHz) of 132 
1H NMR (CDCl3, 400 MHz) of 132 
H
N
O
N
H
O
MeO
Spectrum 5.58 
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Appendix A: (Continued) 
 
 
 
 
 
 
13C NMR (CD3OD, 100 MHz) of 133
1H NMR (CD3OD, 400 MHz) of 133 
N
H
N
O
OH
Spectrum 5.59 
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Appendix A: (Continued) 
 
 
 
 
 
13C NMR (CD3OD, 100 MHz) of 134
1H NMR (CD3OD, 400 MHz) of 134 
N
H
N
O
OMe
Spectrum 5.60 
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Appendix A: (Continued) 
 
 
 
 
 
 
13C NMR (d6-DMSO, 100 MHz) of 135
1H NMR (d6-DMSO, 400 MHz) of 135
N
NH2
NH2
Spectrum 5.61 
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Appendix A: (Continued) 
 
 
 
 
13C NMR (CD3OD, 100 MHz) 
of NSC-12155 
1H NMR (CD3OD, 400 MHz) of 
NSC-12155 
N
N
H
N
H
O
N
NH2 NH2
Spectrum 5.62 
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Appendix A: (Continued) 
 
 
 
 
 
13C NMR (d6-DMSO, 100 MHz) of 136
1H NMR (d6-DMSO, 400 MHz) of 136
N
NH2
N
H
N
H
O
Spectrum 5.63 
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Appendix A: (Continued) 
 
 
 
 
 
 
13C NMR (d6-DMSO, 100 MHz) of 137
1H NMR (d6-DMSO, 400 MHz) of 137
N
H2N
N
H
N
H
O
Spectrum 5.64 
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Appendix A: (Continued) 
 
 
 
 
 
13C NMR (d6-DMSO, 100 MHz) of 138
1H NMR (d6-DMSO, 400 MHz) of 138
N
NH2
N
H
N
H
O
Cl
Spectrum 5.65 
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Appendix A: (Continued) 
 
 
 
13C NMR (d6-DMSO, 100 MHz) of 139
1H NMR (d6-DMSO, 400 MHz) of 139
N
NH2
N
H
N
H
O
CF3
Spectrum 5.66 
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Appendix A: (Continued) 
 
 
 
 
 
 
13C NMR (d6-DMSO, 100 MHz) of 140
1H NMR (d6-DMSO, 400 MHz) of 140
N
NH2
N
H
N
H
O
Spectrum 5.67 
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Appendix B: - X-ray crystallographic data 
Appendix B: (Continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Structure of the salt 19, of 2-isobutyl-3-nitropropionic acid (16c) with (1R,2R)-(-)-
pseudoephedrine (18) determined by X-ray structural analysis. 
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Appendix B: (Continued) 
 
 
 
 
 
 
 
 
 
 
 
 
Molecule-1 Crystal Structure (82) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecule-2 Crystal Structure (82) 
 
 
Crystal structures of two molecules of 2,2-Bis-benzyloxycarbonylamino-propionic 
acid methyl ester (82) that are in different orientation. 
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Appendix B: (Continued) 
 
 
 
 
 
Relationship of Molecule-1 with Molecule-2 in the crystal lattice of 2,2-Bis-
benzyloxycarbonylamino-propionic acid methyl ester (82). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 209
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Appendix B: (Continued) 
  Table 1.  Crystal data and structure refinement for 82 
Identification code  mm011 
Empirical formula  C20 H22 N2 O6 
Formula weight  386.40 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 14.7237(15) Å a= 90°. 
 b = 16.0439(16) Å b= 97.260(2)°. 
 c = 16.9361(17) Å g = 90°. 
Volume 3968.7(7) Å3 
Z 8 
Density (calculated) 1.293 Mg/m3 
Absorption coefficient 0.096 mm-1 
F(000) 1632 
Crystal size 0.80 x 0.80 x 0.13 mm3 
Theta range for data collection 1.73 to 22.78°. 
Index ranges -16<=h<=10, -17<=k<=16, -18<=l<=18 
Reflections collected 16744 
Independent reflections 5356 [R(int) = 0.0663] 
Completeness to theta = 22.78° 99.6 %  
Absorption correction None 
Max. and min. transmission 1.000 and 0.802 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5356 / 0 / 509 
Goodness-of-fit on F2 1.153 
Final R indices [I>2sigma(I)] R1 = 0.0689, wR2 = 0.1593 
R indices (all data) R1 = 0.0981, wR2 = 0.1824 
Largest diff. peak and hole 0.426 and -0.324 e.Å-3 
 211
Appendix B: (Continued) 
 Table 2.  Atomic coordinates  (x 104) and equivalent isotropic displacement parameters 
(Å2x 103) for mm011.  U(eq) is defined as one third of  the trace of the orthogonalized 
Uij tensor. 
________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________ 
O(1) 2201(2) 3388(2) 2340(2) 26(1) 
O(2) 2265(2) 2467(2) 3363(2) 24(1) 
O(3) 970(2) 3483(2) 5265(2) 29(1) 
O(4) 151(2) 4073(2) 4184(2) 27(1) 
O(5) -838(2) 3416(2) 2524(2) 25(1) 
O(6) 7124(2) 3530(2) 1378(2) 22(1) 
O(7) 6996(2) 3415(2) 39(2) 22(1) 
O(8) 9343(2) 1811(2) 702(2) 34(1) 
O(9) 8446(2) 1326(2) -401(2) 30(1) 
O(10) 10195(2) 3760(2) 1138(2) 33(1) 
O(11) -1167(2) 2817(2) 3652(2) 28(1) 
O(12) 10472(2) 3210(2) -21(2) 33(1) 
N(1) 657(2) 2737(2) 4162(2) 18(1) 
N(2) 917(2) 3048(2) 2818(2) 21(1) 
N(3) 8387(2) 3550(2) 788(2) 23(1) 
N(4) 8706(2) 2678(2) -294(2) 23(1) 
C(1) 3462(3) 3664(3) 1628(2) 24(1) 
C(2) -622(3) 3021(3) 3117(2) 24(1) 
C(3) 335(3) 2627(2) 3326(2) 20(1) 
C(4) 8772(3) 4173(3) -460(3) 32(1) 
C(5) 5873(3) 3581(3) 2133(2) 25(1) 
C(6) 7462(3) 3491(2) 685(2) 18(1) 
C(7) 1836(3) 2929(2) 2886(2) 20(1) 
C(8) 559(3) 3484(3) 4502(2) 22(1) 
C(9) 8924(3) 3445(3) 134(2) 23(1) 
C(10) 8873(3) 1931(3) 64(3) 26(1) 
C(11) 6126(3) 3478(3) 1315(2) 25(1) 
C(12) 3195(3) 3400(3) 2411(3) 32(1) 
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C(13) 267(3) 1692(2) 3144(2) 27(1) 
C(14) 9930(3) 3471(3) 498(2) 25(1) 
C(15) 5661(3) 2895(3) 2574(3) 31(1) 
C(16) 5833(3) 4367(3) 2460(3) 35(1) 
C(17) 3941(3) 4168(3) 172(3) 38(1) 
C(18) 2201(3) 3703(3) 6640(3) 32(1) 
C(19) 5439(3) 2999(4) 3345(3) 48(2) 
C(20) 3675(3) 3081(3) 1080(3) 31(1) 
C(21) 3912(3) 3326(3) 349(3) 39(1) 
C(22) 3498(3) 4495(3) 1437(2) 28(1) 
C(23) 8557(3) -751(3) -1008(3) 35(1) 
C(24) 1074(4) 4559(3) 7146(3) 37(1) 
C(25) 1395(3) 4160(2) 6513(2) 27(1) 
C(26) 3733(3) 4746(3) 709(3) 33(1) 
C(27) 8539(3) 481(2) -102(3) 35(1) 
C(28) 5411(4) 3806(5) 3647(3) 56(2) 
C(29) 8098(3) -66(3) -758(3) 31(1) 
C(30) 2346(4) 4022(3) 8027(3) 55(2) 
C(31) 8158(4) -1237(3) -1635(3) 43(1) 
C(32) 6849(4) -352(3) -1785(3) 52(2) 
C(33) 5616(4) 4474(4) 3208(3) 53(2) 
C(34) 7244(4) 122(3) -1150(3) 48(1) 
C(35) 7314(4) -1028(3) -2034(3) 45(1) 
C(36) 877(4) 4259(3) 5691(3) 39(1) 
C(37) 1551(4) 4487(3) 7908(3) 53(2) 
C(38) 2664(4) 3643(3) 7394(3) 44(1) 
C(39) 11451(3) 3225(3) 250(3) 36(1) 
C(40) -2063(3) 3236(3) 3540(3) 39(1) 
__________________________________________________________________
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 Table 3.   Bond lengths [Å] and angles [°] for mm011. 
_____________________________________________________  
O(1)-C(7)  1.347(5) 
O(1)-C(12)  1.454(5) 
O(2)-C(7)  1.213(5) 
O(3)-C(8)  1.356(5) 
O(3)-C(36)  1.455(5) 
O(4)-C(8)  1.209(5) 
O(5)-C(2)  1.196(5) 
O(6)-C(6)  1.333(5) 
O(6)-C(11)  1.461(5) 
O(7)-C(6)  1.222(4) 
O(8)-C(10)  1.223(5) 
O(9)-C(10)  1.354(5) 
O(9)-C(27)  1.447(5) 
O(10)-C(14)  1.197(5) 
O(11)-C(2)  1.325(5) 
O(11)-C(40)  1.471(5) 
O(12)-C(14)  1.328(5) 
O(12)-C(39)  1.456(5) 
N(1)-C(8)  1.345(5) 
N(1)-C(3)  1.447(5) 
N(2)-C(7)  1.356(5) 
N(2)-C(3)  1.455(5) 
N(3)-C(6)  1.354(5) 
N(3)-C(9)  1.449(5) 
N(4)-C(10)  1.351(5) 
N(4)-C(9)  1.444(5) 
C(1)-C(22)  1.374(6) 
C(1)-C(20)  1.382(6) 
C(1)-C(12)  1.491(6) 
C(2)-C(3)  1.545(6) 
C(3)-C(13)  1.532(5) 
C(4)-C(9)  1.538(6) 
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C(5)-C(16)  1.381(6) 
C(5)-C(15)  1.387(6) 
C(5)-C(11)  1.490(6) 
C(9)-C(14)  1.531(6) 
C(15)-C(19)  1.396(6) 
C(16)-C(33)  1.355(7) 
C(17)-C(26)  1.360(6) 
C(17)-C(21)  1.386(7) 
C(18)-C(38)  1.373(6) 
C(18)-C(25)  1.389(6) 
C(19)-C(28)  1.394(8) 
C(20)-C(21)  1.384(7) 
C(22)-C(26)  1.383(6) 
C(23)-C(29)  1.384(6) 
C(23)-C(31)  1.388(6) 
C(24)-C(25)  1.382(6) 
C(24)-C(37)  1.394(6) 
C(25)-C(36)  1.509(6) 
C(27)-C(29)  1.498(6) 
C(28)-C(33)  1.361(8) 
C(29)-C(34)  1.379(6) 
C(30)-C(38)  1.366(8) 
C(30)-C(37)  1.381(8) 
C(31)-C(35)  1.379(7) 
C(32)-C(35)  1.376(7) 
C(32)-C(34)  1.385(7) 
C(7)-O(1)-C(12) 115.8(3) 
C(8)-O(3)-C(36) 114.5(3) 
C(6)-O(6)-C(11) 114.6(3) 
C(10)-O(9)-C(27) 116.9(3) 
C(2)-O(11)-C(40) 114.2(3) 
C(14)-O(12)-C(39) 116.1(3) 
C(8)-N(1)-C(3) 119.2(3) 
C(7)-N(2)-C(3) 122.7(3) 
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C(6)-N(3)-C(9) 122.1(3) 
C(10)-N(4)-C(9) 121.0(3) 
C(22)-C(1)-C(20) 118.7(4) 
C(22)-C(1)-C(12) 120.4(4) 
C(20)-C(1)-C(12) 120.9(4) 
O(5)-C(2)-O(11) 125.8(4) 
O(5)-C(2)-C(3) 123.1(4) 
O(11)-C(2)-C(3) 110.9(3) 
N(1)-C(3)-N(2) 112.2(3) 
N(1)-C(3)-C(13) 108.7(3) 
N(2)-C(3)-C(13) 111.4(3) 
N(1)-C(3)-C(2) 110.5(3) 
N(2)-C(3)-C(2) 105.3(3) 
C(13)-C(3)-C(2) 108.7(3) 
C(16)-C(5)-C(15) 119.0(4) 
C(16)-C(5)-C(11) 120.2(4) 
C(15)-C(5)-C(11) 120.8(4) 
O(7)-C(6)-O(6) 124.3(4) 
O(7)-C(6)-N(3) 124.3(4) 
O(6)-C(6)-N(3) 111.4(3) 
O(2)-C(7)-O(1) 124.9(4) 
O(2)-C(7)-N(2) 125.0(4) 
O(1)-C(7)-N(2) 110.2(3) 
O(4)-C(8)-N(1) 125.5(4) 
O(4)-C(8)-O(3) 124.2(4) 
N(1)-C(8)-O(3) 110.3(3) 
N(4)-C(9)-N(3) 111.9(3) 
N(4)-C(9)-C(14) 111.6(3) 
N(3)-C(9)-C(14) 106.4(3) 
N(4)-C(9)-C(4) 108.3(3) 
N(3)-C(9)-C(4) 111.3(3) 
C(14)-C(9)-C(4) 107.2(3) 
O(8)-C(10)-N(4) 126.0(4) 
O(8)-C(10)-O(9) 124.8(4) 
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N(4)-C(10)-O(9) 109.3(3) 
O(6)-C(11)-C(5) 107.1(3) 
O(1)-C(12)-C(1) 107.8(3) 
O(10)-C(14)-O(12) 124.5(4) 
O(10)-C(14)-C(9) 124.3(4) 
O(12)-C(14)-C(9) 110.9(3) 
C(5)-C(15)-C(19) 120.3(5) 
C(33)-C(16)-C(5) 121.2(5) 
C(26)-C(17)-C(21) 120.3(4) 
C(38)-C(18)-C(25) 119.6(5) 
C(28)-C(19)-C(15) 118.4(5) 
C(1)-C(20)-C(21) 120.8(4) 
C(20)-C(21)-C(17) 119.3(4) 
C(1)-C(22)-C(26) 120.9(4) 
C(29)-C(23)-C(31) 120.3(5) 
C(25)-C(24)-C(37) 119.8(5) 
C(24)-C(25)-C(18) 119.7(4) 
C(24)-C(25)-C(36) 119.0(4) 
C(18)-C(25)-C(36) 121.3(4) 
C(17)-C(26)-C(22) 120.0(4) 
O(9)-C(27)-C(29) 106.1(3) 
C(33)-C(28)-C(19) 120.8(5) 
C(34)-C(29)-C(23) 118.5(4) 
C(34)-C(29)-C(27) 120.8(4) 
C(23)-C(29)-C(27) 120.6(4) 
C(38)-C(30)-C(37) 119.6(4) 
C(35)-C(31)-C(23) 120.4(5) 
C(35)-C(32)-C(34) 119.6(5) 
C(16)-C(33)-C(28) 120.3(5) 
C(29)-C(34)-C(32) 121.4(5) 
C(32)-C(35)-C(31) 119.7(5) 
O(3)-C(36)-C(25) 107.5(3) 
C(30)-C(37)-C(24) 119.9(5) 
C(30)-C(38)-C(18) 121.4(5) 
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Table 4.   Anisotropic displacement parameters  (Å2x 103) for mm011.  The anisotropic 
displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
________________________________________________________________________ 
 U11 U22  U33 U23 U13 U12 
________________________________________________________________________ 
O(1) 12(2)  41(2) 23(2)  10(1) 1(1)  0(1) 
O(2) 18(2)  32(2) 22(2)  6(1) -3(1)  3(1) 
O(3) 39(2)  26(2) 18(2)  -4(1) -8(1)  11(1) 
O(4) 29(2)  27(2) 23(2)  0(1) -6(1)  9(1) 
O(5) 22(2)  36(2) 16(2)  3(1) -2(1)  -1(1) 
O(6) 16(2)  36(2) 15(2)  -1(1) 2(1)  -2(1) 
O(7) 19(2)  28(2) 17(2)  2(1) -3(1)  -1(1) 
O(8) 30(2)  41(2) 27(2)  2(1) -7(2)  9(2) 
O(9) 33(2)  25(2) 32(2)  -2(1) -3(2)  4(1) 
O(10) 25(2)  51(2) 23(2)  -4(2) 1(1)  -7(2) 
O(11) 15(2)  42(2) 26(2)  7(1) 3(1)  0(1) 
O(12) 19(2)  53(2) 27(2)  -7(2) 0(1)  2(2) 
N(1) 21(2)  18(2) 15(2)  3(1) -1(2)  4(2) 
N(2) 14(2)  30(2) 18(2)  5(2) -2(2)  0(2) 
N(3) 19(2)  33(2) 16(2)  -4(2) -3(2)  -5(2) 
N(4) 23(2)  26(2) 19(2)  0(2) 0(2)  2(2) 
C(1) 10(2)  37(3) 24(2)  -2(2) -2(2)  0(2) 
C(2) 21(3)  26(2) 23(2)  -6(2) 0(2)  -5(2) 
C(3) 20(3)  23(2) 17(2)  2(2) 2(2)  -2(2) 
C(4) 24(3)  32(3) 40(3)  5(2) 2(2)  -4(2) 
C(5) 9(2)  47(3) 17(2)  0(2) -2(2)  1(2) 
C(6) 18(3)  19(2) 19(2)  0(2) 6(2)  0(2) 
C(7) 20(3)  20(2) 18(2)  -7(2) 1(2)  -2(2) 
C(8) 19(3)  26(3) 19(2)  1(2) 0(2)  2(2) 
C(9) 19(3)  34(3) 15(2)  -7(2) 1(2)  -3(2) 
C(10) 18(3)  34(3) 26(3)  -7(2) 5(2)  5(2) 
C(11) 14(3)  37(3) 24(2)  0(2) -2(2)  -2(2) 
C(12) 17(3)  48(3) 32(3)  6(2) 2(2)  -2(2) 
C(13) 28(3)  27(2) 27(2)  -3(2) 1(2)  -2(2) 
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C(14) 23(3)  32(3) 20(2)  -4(2) 6(2)  -5(2) 
C(15) 15(3)  48(3) 31(3)  3(2) 1(2)  0(2) 
C(16) 26(3)  46(3) 33(3)  -7(2) 5(2)  -1(2) 
C(17) 17(3)  68(4) 28(3)  4(3) 3(2)  -2(2) 
C(18) 30(3)  33(3) 32(3)  7(2) -1(2)  4(2) 
C(19) 18(3)  97(5) 29(3)  19(3) 1(2)  -9(3) 
C(20) 16(3)  32(3) 43(3)  -6(2) -5(2)  0(2) 
C(21) 17(3)  62(4) 36(3)  -19(3) 0(2)  1(2) 
C(22) 23(3)  35(3) 25(2)  -7(2) 2(2)  4(2) 
C(23) 34(3)  31(3) 40(3)  5(2) 6(2)  4(2) 
C(24) 51(4)  26(2) 32(3)  -8(2) -6(2)  9(2) 
C(25) 30(3)  21(2) 28(3)  0(2) -4(2)  2(2) 
C(26) 26(3)  39(3) 33(3)  9(2) 3(2)  2(2) 
C(27) 40(3)  22(2) 40(3)  3(2) 0(2)  3(2) 
C(28) 31(3)  115(6) 23(3)  -23(3) 10(2)  -8(3) 
C(29) 35(3)  25(2) 35(3)  2(2) 8(2)  4(2) 
C(30) 73(5)  47(3) 34(3)  8(3) -33(3)  -14(3) 
C(31) 53(4)  30(3) 48(3)  -3(2) 16(3)  10(3) 
C(32) 34(3)  43(3) 74(4)  -3(3) -8(3)  -3(3) 
C(33) 41(4)  79(4) 41(3)  -27(3) 10(3)  -7(3) 
C(34) 33(3)  40(3) 72(4)  -10(3) 4(3)  10(3) 
C(35) 54(4)  36(3) 46(3)  -3(2) 1(3)  -6(3) 
C(36) 53(4)  31(3) 29(3)  -8(2) -10(2)  20(2) 
C(37) 88(5)  43(3) 24(3)  -10(2) -11(3)  -4(3) 
C(38) 29(3)  46(3) 51(4)  14(3) -19(3)  -5(3) 
C(39) 19(3)  53(3) 36(3)  -1(2) 0(2)  1(2) 
C(40) 19(3)  64(3) 35(3)  5(2) 6(2)  5(2) 
________________________________________________________________
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Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 
3) for mm011. 
________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________ 
  
H(1A) 915 2320 4445 22 
H(2A) 663 3394 2452 25 
H(3A) 8670 3655 1266 28 
H(4D) 8460 2697 -795 28 
H(4A) 9131 4078 -901 49 
H(4B) 8968 4695 -190 49 
H(4C) 8121 4209 -667 49 
H(11A) 5912 2932 1092 31 
H(11B) 5842 3923 961 31 
H(12A) 3443 2839 2553 39 
H(12B) 3443 3796 2832 39 
H(13A) 873 1436 3264 41 
H(13B) 40 1609 2581 41 
H(13C) -157 1432 3473 41 
H(15) 5667 2353 2350 38 
H(16) 5960 4840 2156 42 
H(17) 4107 4343 -326 45 
H(18) 2432 3434 6207 38 
H(19) 5310 2532 3657 58 
H(20) 3659 2504 1206 38 
H(21) 4053 2922 -26 46 
H(22) 3360 4903 1811 33 
H(23) 9148 -888 -749 42 
H(24) 529 4881 7063 45 
H(26) 3750 5323 583 39 
H(27A) 8228 419 380 41 
H(27B) 9193 334 34 41 
H(28) 5247 3890 4166 67 
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H(30) 2669 3965 8547 66 
H(31) 8468 -1717 -1791 51 
H(32) 6260 -213 -2048 62 
H(33) 5608 5019 3426 64 
H(34) 6919 587 -980 58 
H(35) 7055 -1348 -2478 55 
H(36A) 223 4376 5727 47 
H(36B) 1133 4728 5410 47 
H(37) 1331 4759 8345 64 
H(38) 3217 3332 7477 53 
H(39A) 11625 3778 463 54 
H(39B) 11790 3101 -198 54 
H(39C) 11597 2806 668 54 
H(40A) -1974 3841 3569 59 
H(40B) -2424 3059 3958 59 
H(40C) -2389 3088 3018 59 
__________________________________________________________________
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 Table 6.  Torsion angles [°] for mm011. 
________________________________________________________________  
C(40)-O(11)-C(2)-O(5) -9.8(6) 
C(40)-O(11)-C(2)-C(3) 174.2(3) 
C(8)-N(1)-C(3)-N(2) 72.6(5) 
C(8)-N(1)-C(3)-C(13) -163.7(4) 
C(8)-N(1)-C(3)-C(2) -44.5(5) 
C(7)-N(2)-C(3)-N(1) 52.9(5) 
C(7)-N(2)-C(3)-C(13) -69.2(4) 
C(7)-N(2)-C(3)-C(2) 173.2(3) 
O(5)-C(2)-C(3)-N(1) 138.3(4) 
O(11)-C(2)-C(3)-N(1) -45.6(4) 
O(5)-C(2)-C(3)-N(2) 17.0(5) 
O(11)-C(2)-C(3)-N(2) -166.9(3) 
O(5)-C(2)-C(3)-C(13) -102.5(4) 
O(11)-C(2)-C(3)-C(13) 73.6(4) 
C(11)-O(6)-C(6)-O(7) -0.2(5) 
C(11)-O(6)-C(6)-N(3) 179.4(3) 
C(9)-N(3)-C(6)-O(7) -6.2(6) 
C(9)-N(3)-C(6)-O(6) 174.1(3) 
C(12)-O(1)-C(7)-O(2) -8.4(5) 
C(12)-O(1)-C(7)-N(2) 172.5(3) 
C(3)-N(2)-C(7)-O(2) 0.4(6) 
C(3)-N(2)-C(7)-O(1) 179.4(3) 
C(3)-N(1)-C(8)-O(4) 6.3(6) 
C(3)-N(1)-C(8)-O(3) -174.8(3) 
C(36)-O(3)-C(8)-O(4) 0.7(6) 
C(36)-O(3)-C(8)-N(1) -178.3(4) 
C(10)-N(4)-C(9)-N(3) -64.2(5) 
C(10)-N(4)-C(9)-C(14) 54.9(5) 
C(10)-N(4)-C(9)-C(4) 172.7(4) 
C(6)-N(3)-C(9)-N(4) -52.5(5) 
C(6)-N(3)-C(9)-C(14) -174.6(3) 
C(6)-N(3)-C(9)-C(4) 68.9(5) 
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C(9)-N(4)-C(10)-O(8) -13.1(7) 
C(9)-N(4)-C(10)-O(9) 167.7(4) 
C(27)-O(9)-C(10)-O(8) 1.8(7) 
C(27)-O(9)-C(10)-N(4) -179.0(4) 
C(6)-O(6)-C(11)-C(5) -176.8(3) 
C(16)-C(5)-C(11)-O(6) 80.5(5) 
C(15)-C(5)-C(11)-O(6) -100.3(4) 
C(7)-O(1)-C(12)-C(1) 160.1(3) 
C(22)-C(1)-C(12)-O(1) 83.6(5) 
C(20)-C(1)-C(12)-O(1) -96.3(5) 
C(39)-O(12)-C(14)-O(10) 4.9(6) 
C(39)-O(12)-C(14)-C(9) 178.5(3) 
N(4)-C(9)-C(14)-O(10) -141.7(4) 
N(3)-C(9)-C(14)-O(10) -19.3(6) 
C(4)-C(9)-C(14)-O(10) 99.9(5) 
N(4)-C(9)-C(14)-O(12) 44.6(5) 
N(3)-C(9)-C(14)-O(12) 167.0(3) 
C(4)-C(9)-C(14)-O(12) -73.8(4) 
C(16)-C(5)-C(15)-C(19) -1.9(6) 
C(11)-C(5)-C(15)-C(19) 178.9(4) 
C(15)-C(5)-C(16)-C(33) 1.8(7) 
C(11)-C(5)-C(16)-C(33) -179.0(4) 
C(5)-C(15)-C(19)-C(28) 1.8(7) 
C(22)-C(1)-C(20)-C(21) -0.6(6) 
C(12)-C(1)-C(20)-C(21) 179.2(4) 
C(1)-C(20)-C(21)-C(17) 0.5(6) 
C(26)-C(17)-C(21)-C(20) -0.4(7) 
C(20)-C(1)-C(22)-C(26) 0.7(6) 
C(12)-C(1)-C(22)-C(26) -179.2(4) 
C(37)-C(24)-C(25)-C(18) -1.2(7) 
C(37)-C(24)-C(25)-C(36) -178.9(5) 
C(38)-C(18)-C(25)-C(24) 0.9(7) 
C(38)-C(18)-C(25)-C(36) 178.5(4) 
C(21)-C(17)-C(26)-C(22) 0.5(7) 
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C(1)-C(22)-C(26)-C(17) -0.6(7) 
C(10)-O(9)-C(27)-C(29) -173.9(4) 
C(15)-C(19)-C(28)-C(33) -1.5(7) 
C(31)-C(23)-C(29)-C(34) -0.5(7) 
C(31)-C(23)-C(29)-C(27) -177.7(4) 
O(9)-C(27)-C(29)-C(34) -47.8(6) 
O(9)-C(27)-C(29)-C(23) 129.3(4) 
C(29)-C(23)-C(31)-C(35) 2.2(7) 
C(5)-C(16)-C(33)-C(28) -1.6(8) 
C(19)-C(28)-C(33)-C(16) 1.4(8) 
C(23)-C(29)-C(34)-C(32) -0.7(8) 
C(27)-C(29)-C(34)-C(32) 176.5(5) 
C(35)-C(32)-C(34)-C(29) 0.1(8) 
C(34)-C(32)-C(35)-C(31) 1.6(8) 
C(23)-C(31)-C(35)-C(32) -2.8(8) 
C(8)-O(3)-C(36)-C(25) -178.2(4) 
C(24)-C(25)-C(36)-O(3) -146.9(4) 
C(18)-C(25)-C(36)-O(3) 35.5(6) 
C(38)-C(30)-C(37)-C(24) 0.9(8) 
C(25)-C(24)-C(37)-C(30) 0.3(8) 
C(37)-C(30)-C(38)-C(18) -1.2(8) 
C(25)-C(18)-C(38)-C(30) 0.3(7) 
___________________________________________________________ 
Symmetry transformations used to generate equivalent atoms: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix B: (Continued) 
 
 
 
 
 
 
 
Crystal structure of N-Boc-Triphenyliminophosphorane (102). 
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Appendix B: (Continued) 
Crystallographic data for compound 102 
 
 
 225
 
Appendix B: (Continued) 
 
 226
Appendix B: (Continued) 
 
 
 
 227
Appendix B: (Continued) 
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Appendix B: (Continued) 
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Appendix B: (Continued) 
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Appendix B: (Continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Crystal structure of t-Butyl 2,2,2-Trichloro-1-hydroxy-ethylcarbamate (105). 
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Appendix B: (Continued) 
 
Crystallographic data of t-Butyl 2,2,2-Trichloro-1-hydroxy-ethylcarbamate (105) 
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